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The importance of our gut for human health was already recognized by Hippocrates at 
400 B.C. as he wrote “death sits in the bowels” and “bad digestion is the root of all evil” 
(Sekirov, et al., 2010). Research of the past two decades has demonstrated that the microbes 
that live in our gut are important modulators of human health and that several diseases (e.g. 
colorectal cancer, type II diabetes, inflammatory bowel diseases) are correlated with a 
disturbed gut microbiota. The research of the gut microbiota in inflammatory bowel diseases 
has expanded and is evolving to find a strategy of how to modulate the disturbed microbiota 
as therapeutic treatment. 
1.1 Incidence and etiology of inflammatory bowel diseases 
Inflammatory bowel diseases (IBD), with Crohn’s disease (CD) and ulcerative colitis 
(UC) as major pathologies, are characterized by a chronic inflammation of the gastrointestinal 
tract. In both disorders, periods of active disease (relapse) alternate with periods without 
symptoms (remission). Common symptoms in IBD patients are severe abdominal pain, 
persistent (bloody) diarrhoea, fever and weight loss (Hendrickson, et al., 2002). Intestinal 
inflammation in CD is discontinuous and extends to the submucosa; it may occur anywhere 
along the gastrointestinal tract – with the highest incidence in terminal ileum (ICD) and colon 
(CCD). In UC, inflammation is continuous, it involves only the mucosa and it is limited to the 
colon. Among CD, complications such as fistulas, abscesses and strictures are common 
(Baumgart & Sandborn, 2007). The prevalence of IBD has risen considerably the last 
decades with the highest prevalence values reported in Europe (UC: 505 per 100 000 persons; 
CD 322 per 100 000 persons) and North America (UC: 249 per 100 000 persons; CD 319 per 
100 000 persons) (Molodecky, et al., 2012). Peak onset age is between 15-30 years but lately 
a rise in incidence of paediatric IBD is observed (primarily due to a rise in paediatric CD) 
(Benchimol, et al., 2011). 
IBD is a multifactorial disease and the etiology is not fully understood. However, 
research indicated that an inappropriate immune response in genetically susceptible 
individuals together with the complex interaction between environmental factors, intestinal 
microbiota and the intestinal immune system are involved in the pathogenesis of IBD (Figure 
1.1) (Danese & Fiocchi, 2006, Zhang & Li, 2014).  





Figure 1.1 Multifactorial etiology of IBD. Figure derived from (Dalal & Chang, 2014) 
Genome-wide association studies (GWAS) were capable to identify 163 gene variants 
associated with IBD (23 UC specific; 30 CD specific) (Jostins, et al., 2012). Nevertheless, 
these 163 susceptibility genes account only for 13.6 % disease variance in CD and 7.5 % in 
UC and is therefore not the only cause of onset of IBD. The rest can be explained by other 
factors (environment, gene-gene interactions, gene-environment interactions) (Fiocchi, 2015). 
Noteworthy, 70% of the IBD associated genes are common with other complex immune-
mediated disorders (e.g. coeliac disease, rheumatoid arthritis, ankylosing spondylitis, 
psoriasis) (Lees & Zhernakova, 2013).  
The observed increase in IBD prevalence has occurred too rapidly to be solely attributed 
to genetic factors. Moreover, there is an increase in occurrence of IBD among immigrants 
from developing countries to high incidence areas (Ko, et al., 2014). A wide variety of 
environmental factors are linked to the pathogenesis in IBD but large epidemiologic studies 
are lacking. Only for smoking, appendectomy and diet (Western, high fat, high sugar, high 
calorie) reliable epidemiological evidence as risk factor for IBD is available (Fiocchi, 2015). 
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The GWAS emphasized the importance of the intestinal microbiota in the pathogenesis 
of IBD because a substantial number of IBD loci are involved in host-microbe interaction 
processes such as, barrier function, wound healing, autophagy, immune balance, and stress 
responses (Jostins, et al., 2012, Dalal & Chang, 2014, McCole, 2014). The first microbial 
studies in IBD searched for a single pathogenic species that was present in IBD and absent in 
healthy individuals (Kirsner, 2001). Although up to now no single species has been proven to 
cause IBD in all patients, there are a few pathogens associated with the disease and its 
etiology (Dalal & Chang, 2014). The first pathogen associated with IBD is  Mycobacterium 
avium subspecies paratuberculosis (MAP) that causes Johne’s diseas (chronic ileitis) in cattle 
and sheep. MAP is more detected in samples of CD patients compared to samples of healthy 
individuals and UC patients (Feller, et al., 2007). Adherent invasive Escherichia coli (AIEC) 
are a second and more important group of pathogens associated with (ileal) CD (Martinez-
Medina, et al., 2009). AIEC are able to invade the epithelial cells and replicate within 
macrophages and are detected at higher levels in granulomas from CD compared to non-CD 
granulomas (Glasser, et al., 2001, Ryan, et al., 2004). However, AIEC infection is not the 
primary cause of CD because CD-associated AIEC have only been detected in approximately 
20% to 50% of CD patients (Darfeuille-Michaud, et al., 2004, Martinez-Medina, et al., 2009). 
Overall changes in the composition and function of the intestinal microbiota are more likely 
as microbial factor in IBD. It is now generally accepted that the microbial dysbiosis – an 
imbalance in structural and functional properties of the gut microbiota that can disrupt host-
microbe homeostasis – is part of the pathogenesis of IBD (Dalal & Chang, 2014)(More details 
in 1.3.1).  
Current IBD therapy aims to control the impaired host immune response and includes 
anti-inflammatory, intestinal immune-suppressive and immune-modulating agents such as 
corticosteroids, 5-Aminosalicylates, thiopurines and so-called biological agents (anti-TNF) 
(Bernstein, 2015). Although successful in treatment of several IBD conditions, these agents 
can cause severe side-effects and are not effective to induce remission in all patients (Sales-
Campos, et al., 2015). With the increasing knowledge of the microbial dysbiosis in IBD 
(more details in 1.3.1) and to improve current IBD therapy, it is suggested that future IBD 
therapy should also focus on manipulating the gut microbiota to counterbalance the microbial 
dysbiosis (D'Haens, et al., 2014, Kostic, et al., 2014, Hansen & Sartor, 2015). 
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1.2 The human gut microbiota 
1.2.1 Composition of the human gut microbiota 
The gastrointestinal tract harbours the most dense and complex microbial community, 
which consists primarily of bacteria but also contains archaea, fungi, viruses and protozoa 
(Walter & Ley, 2011). The intestinal bacteria among human individuals consist of 500-1000 
species belonging to only a few of the 55 described bacterial phyla. Firmicutes and 
Bacteroidetes are the most prominent bacterial phyla while the other species belong to the 
phyla Actinobacteria, Proteobacteria, Verrucomicrobia, Fusobacteria and Cyanobacteria 
(Arumugam, et al., 2011, Huttenhower, et al., 2012). The microbial community composition 
and functionality varies along the longitudinal (stomach to colon) and axial (mucosa to 
lumen) gradients of the gastrointestinal tract (Backhed, et al., 2012) (Figure 1.2). This 
variation can be explained by the fact that gut microbes are exposed to fluctuating 
environmental factors such as pH, oxygen concentration, motility and luminal flow, mucus 
composition and secretion of antimicrobial compounds (e.g. bile acids and peptides) (Simrén, 




Figure 1.2 Longitudinal (A) and axial (B) variation of human gastrointestinal microbiota due to 
fluctuating environmental factors. Figure adapted from (Walter & Ley, 2011, Koropatkin, et al., 2012, 
Mowat & Agace, 2014)  
1.2.1.1 Longitudinal variation of the gut microbiota: stomach to colon  
The density and diversity of the gastrointestinal microbial community increases from 
the stomach to the colon (Marteau, et al., 2001, Sekirov, et al., 2010). 
The microbial density in the stomach is low (101-103 cells/mL), which is due to the 
acidic pH (pH 2-5), strong peristalsis and thick mucus layer (Walter & Ley, 2011). Only a few 
bacterial species can reside in the stomach and Helicobacter pylori is the major one that under 
certain conditions is also able to persist (Walter & Ley, 2011). Whether other common 
detected bacterial genera (Prevotella, Streptococcus, Veillonella, Rothia and Haemophilus) 
are able to colonize the gastric mucosa or are just part of the transient microbiota is not yet 
clear (Nardone & Compare, 2015).  
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The microbial density in small intestine increases from 103 cells/mL in duodenum to 
108 cells/mL in ileum (Walter & Ley, 2011). Several host factors have a strong selective 
pressure on the small intestinal microbiota. First of all, bactericidal digestive enzymes and 
bile are secreted in the duodenum when food passes. Next, the transit time is short as the 
intestinal content passes from the duodenum to ileum in one to four hours (Leser & Molbak, 
2009). Almost all bile acids (95%) are reabsorbed when the intestinal content enters the ileum 
(Begley, et al., 2005). This, together with a slower luminal flow, explains the increase in 
bacterial density in the ileum. Final host factor that has an influence on the small intestinal 
microbiota is the presence of specialized epithelial cells (Paneth cells), which produce 
antimicrobial peptides, and the presence of Peyer’s patches, which consist of large number of 
immune cells (Mowat & Agace, 2014). Small intestinal microbiota studies in healthy 
individuals are rare due to its limited accessibility. Therefore, most information about the 
microbial composition is based on analysis of ileostoma effluent, which resembles that of 
jejunal and proximal-ileum content of healthy individuals (Zoetendal, et al., 2012). Large 
fluctuations in the individual small intestinal microbiota were observed over a period of 
several days, and even between morning and afternoon samples (Booijink, et al., 2010). 
Despite these fluctuations and interindividual differences, Streptococcus and Veillonella 
species could be identified as core members of the ileal microbial community (El Aidy, et al., 
2015).  
In the large intestine or colon microbial densities reach up to 1011 cells/mL, the highest 
among all environmental niches (Walter & Ley, 2011). In fact, conditions for bacterial growth 
and activity are optimal in the colon as the pH is less acidic (pH 5- pH 7), the bile acid 
concentration is low, the volume is larger, the retention time is longer and the immune system 
tolerates more bacteria in comparison to the upper gastrointestinal tract (Walter & Ley, 2011). 
Due to low oxygen concentration (0.1-1 mmHg) and redox potential (~ -200 mV) in the large 
intestinal lumen, obligate anaerobic bacteria are most dominant (> 99 %) (Blaut, 2013, Espey, 
2013). Colon microbial composition is mostly based on analysis of fecal samples and thus 
represent a mix of mucus-associated and luminal colon microbiota (Eckburg, et al., 2005, 
Ley, et al., 2006, Yasuda, et al., 2015). These studies show that the colon microbiota are 
members of only five bacterial phyla (Firmicutes, Bacteroidetes, Actinobacteria, 
Verrucomicrobia and Proteobacteria), but is characterized by a high species richness.  
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1.2.1.2 Axial variation of the gut microbiota: mucosa to lumen 
The healthy gastrointestinal epithelium is covered with a mucus layer that lubricates and 
protects the epithelial cells against microbial invasion. The mucus composition and thickness 
varies along the length of the gastrointestinal tract, and the mucus layer is continuously 
renewed (Figure 1.2B) (Matsuo, et al., 1997, Koropatkin, et al., 2012). Several intrinsic 
factors characterize the mucosal microenvironment that differentiate it from the lumen, 
including presence of host defence molecules and an oxygen gradient (Figure 1.2B) (Van den 
Abbeele, et al., 2011). Bacteria, which are able to reside and colonize the mucus layer 
developed strategies to deal with these factors. 
Bacteria are predominantly detected in the mucus layer of the colon (Johansson, et al., 
2008). The colon mucus layer consists of two layers: in inner, firmly attached mucus layer of 
several 100 µm thick that is primarily devoid of bacteria, and an outer, looser mucus layer of 
3 to 4 times the volume of the inner mucus layer that is colonized by 105– 106 microbes/mL 
mucus (Van den Abbeele, et al., 2011, Johansson, et al., 2013). As the mucosa-associated 
microbial community (MAMC) resides close to the epithelium, they are considered to be 
important modulators of human health. The composition of the colon MAMC was 
characterized by the analysis of biopsy samples and compared with the fecal microbial 
composition (mix of mucus and lumen).  
There is an axial gradient of increased microbial diversity and density observed from 
the colon mucosa to lumen (Van den Abbeele, et al., 2011, Sommer & Backhed, 2013). 
Several studies detected a clear difference in composition between MAMC and fecal 
microbiota (Zoetendal, et al., 2002, Eckburg, et al., 2005, Lepage, et al., 2005, Aguirre de 
Carcer, et al., 2011, Hong, et al., 2011, Ringel, et al., 2015). MAMC are characterized by 
higher levels of Firmicutes bacteria and more specifically of Lachnospiraceae and 
Ruminococcaceae (Nava, et al., 2011). 
The physicochemical conditions vary along the colon and this influences the 
composition and activity of the MAMC. The longitudinal gradient of the MAMC was long 
not detected as it was obscured behind large inter-individual differences in mucosal 
microbiota (Zoetendal, et al., 2002, Eckburg, et al., 2005, Lepage, et al., 2005) (Zhang, et al., 
2014). However, a few recent studies in matched biopsy samples taken from different colon 
regions observed a clear spatial heterogeneity of the mucosal microbiota along the human 
colon (Aguirre de Carcer, et al., 2011, Nava, et al., 2012, Zhang, et al., 2014). 
Introduction 
9 
1.2.1.3 Intra- and interindividual variation of the gut microbiota 
Within one individual, the intestinal microbial community is relatively stable over time 
and follows a natural fluctuation with age (Figure 1.3)(Costello, et al., 2009, Huttenhower, et 
al., 2012, Faith, et al., 2013, Rajilic-Stojanovic, et al., 2013). However, several factors can 
cause significant changes in the intestinal microbial structure, such as antibiotics, diet, 
xenobiotics, pollutants and others (Figure 1.3) (Betts, 2011, Backhed, et al., 2012). Some of 
these factors can introduce perturbations in the microbiome that may cause microbial 
dysbiosis (Kostic, et al., 2014).  
 
Figure 1.3 Factors influencing the human gut microbiome in health and disease. Figure derived from 
(Kostic, et al., 2014). 
The concept that all humans have a core microbiome was addressed during the Human 
Microbiome Project Consortium and suggested that all individuals share some of the same 
microbes (Qin, et al., 2010, Huttenhower, et al., 2012). However, a phylogenetic core could 
not be detected in all studies, as the gut microbiota varies greatly between individuals in 
abundance and composition (Figure 1.4) (Eckburg, et al., 2005, Huttenhower, et al., 2012).  
Despite large inter-individual differences in composition, intestinal microbiota are 
largely functionally equivalent (Turnbaugh, et al., 2009, Huttenhower, et al., 2012). This is 
demonstrated in Figure 1.4. Microbial composition (16S rRNA gene analysis) in stool 
samples of 242 individuals showed tremendous abundance diversity whereas the functional 
profiles in the same samples (shotgun metagenomic analysis) are very similar. Therefore, it is 




Figure 1.4 Microbial composition in fecal samples varies while functional profiles remain stable 
within a healthy population (n= 242). Figure derived from (Huttenhower, et al., 2012). 
1.2.2 Functions of the human gut microbiota 
The human gut microbiota possess a tremendous functional capacity. The gut 
microbiome, the collective genomes of the gut microbiota, consists of 3.3 million microbial 
genes and is approximately 150 times larger than the human genome (Qin, et al., 2010). In 
addition, the gut microbiome has a metabolic capacity that equals that of the liver and can be 
considered as ‘a virtual organ within an organ’ (Gill, et al., 2006). The human gut microbiota 
exert both adverse and beneficial functions that affect the host health. Aim of microbial 
targeted therapy is manipulating the gut microbiota to enhance the beneficial functions and to 
minimize the adverse functions. Adverse effects include, infection, production of toxins and 
formation of detrimental metabolites (Louis, et al., 2014). Beneficial microbial functions 
include, short-chain fatty acid (SCFA) production, vitamin production, immune system 
development and epithelial barrier fortification (O'Hara & Shanahan, 2006). Figure 1.5 gives 
an overview of the different beneficial functions of the human gut microbiota, which can be 
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categorized under metabolic, structural and protective functions. Relevant metabolic functions 
for this thesis will be described more in detail. 
 
Figure 1.5 Beneficial functions of the human gut microbiota. Figure modified from (O'Hara & 
Shanahan, 2006, Prakash, et al., 2011) 
The major metabolic microbial process in the colon that drives microbial growth and 
activity is fermentation of diet-, host- or microbe-derived substrates (Cummings & Englyst, 
1987). Dietary substrates can be undigested complex carbohydrates and proteins. Host-
derived substrates consist of body secretions like pancreatic enzymes, mucins and sloughed 
epithelial cells. Microbial substrates can be damaged or dead microbes or microbial polymers 
(Falony & De Vuyst, 2009). In addition to serving as an energy- and carbon-source for 
microbial growth, microbial fermentation can have direct and indirect health-effects. Three 
fermentative processes that contribute to overall gut health are discussed below. Carbohydrate 
fermentation is beneficial as it results in the formation of health-promoting SCFA such as 
butyrate (more details in 1.4.1). Microbial protein fermentation is detrimental because toxic 
and carcinogenic agents are produced (Louis, et al., 2014). Mucus fermentation/degradation is 
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associated with both health and disease and it is not yet clear if it is beneficial or detrimental 
for the host (Tailford, et al., 2015). 
1.2.2.1 Carbohydrate fermentation 
Carbohydrate fermentation by saccharolytic bacteria mainly occurs in the proximal 
colon, as the carbohydrate availability is high and the majority of the colon bacteria prefer 
carbohydrates as energy source (Macfarlane, et al., 1992). In addition, metagenomic studies 
showed that the gut microbiome is enriched in genes involved in carbohydrate breakdown 
(Gill, et al., 2006, Morgan, et al., 2013).  
Dietary fibers form the major substrate for carbohydrate fermentation and include: 
resistant starch (5-40 g/day), non-starch polysaccharides (10-20 g/day) (cellulose, 
hemicellulose, pectin, inulin) and oligosaccharides (2-9 g/day) (Kovatcheva-Datchary, et al., 
2013). Most saccharolytic colon bacteria (e.g. Bacteroides spp., Bifidobacterium spp., 
Firmicutes of clostridial clusters IV and XIVa) appear to be generalists as they can degrade a 
wide range of complex carbohydrates (Walter & Ley, 2011). This phenomenon is known as 
functional redundancy and helps the colon microbiota to cope with quantitative and 
qualitative changes in diet composition, which leads to  a stable community function (Louis, 
et al., 2007, Falony & De Vuyst, 2009). However, some colon bacteria (e.g. Ruminococcus 
bromii, Eubacterium rectale and Roseburia spp.) show specialization for specific substrates 
and a high inter-individual variability in community changes after specific substrate 
intervention was noted (Martínez, et al., 2010, Walker, et al., 2011). In addition, substrate 
competition between related strains can drive niche specialization and support diversity 
(Walter & Ley, 2011).  
End products of carbohydrate fermentation are gases (H2, CO2 and CH4) and SCFA 
with acetate, propionate and butyrate as the main products (Figure 1.6) (Macfarlane & 
Macfarlane, 2003, Falony & De Vuyst, 2009). The fermentation occurs in several steps with 
formation of intermediates such as formate, lactate, succinate and ethanol. During 
carbohydrate fermentation cross-feeding occurs, primary degraders provide breakdown 





Figure 1.6 Schematic overview of carbohydrate fermentation by colonic bacteria. PEP, 
phosphoenolpyruvate. Figure derived from (Falony & De Vuyst, 2009). 
Depending on the diet and composition and activity of the gut microbiota, SCFA 
production can vary between individuals and between different time points. In vivo SCFA 
concentrations are difficult to determine as SCFA are rapidly absorbed and only 5-10% of the 
produced SCFA is excreted in the feces (Wong, et al., 2006). As an indication, SCFA 
concentration in autopsy samples from six sudden death victims varied from 137 – 197 mmol 
(kg gut content)-1 in proximal colon and 86-97 mmol (kg gut content) – 1 in distal colon.; the 
acetate:propionate:butyrate ratio was similar in the different colon regions and about 57:22:21 
(Cummings, et al., 1987). 
1.2.2.2 Protein fermentation 
When carbohydrates are depleted, proteins and amino acids become the main energy 
source for gut microbiota. Therefore, protein degradation increases towards the distal part of 
the colon (Macfarlane, et al., 1992). It is estimated that per day 3-12 g dietary protein and 4-6 
g host enzymes enter the colon and serve as substrate during microbial protein fermentation 
(Blaut, 2013). Several species of intestinal bacterial genera produce proteases (Bacteroides, 
Clostridium, Propionibacterium, Fusobacterium, Streptococcus and Lactobacillus) and 
hydrolyze proteins to oligopeptides and amino acids that serve as carbon-, nitrogen- and 
energy- source for other bacteria (Kovatcheva-Datchary, et al., 2013). End products of 
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intestinal protein fermentation are SCFA, ammonia, branched-chain fatty acids (isovalerate 
and isobutyrate), amines, H2S, thiols, phenols and indols.  
1.2.2.3 Degradation of host-derived glycoproteins 
Intestinal mucins are the major source of glycoproteins in the gastrointestinal tract and 
are derived from the mucus layer covering the epithelial cells. Mucins are secreted by surface 
mucus cells in the stomach or goblet cells in the small and large intestine. Glycoproteins 
consist of a polypeptide backbone with a large number of covalently linked oligosaccharide 
chains. The oligosaccharide chains are responsible for 80% of the molecular weight of 
glycoproteins and bind water, which gives mucus its gel-like properties (Sheng, et al., 2012, 
Johansson, 2014). Despite their high complexity and diversity, intestinal mucins, can be 
degraded by a variety of human gut bacteria that produce proteases, sulfatases and glycoside 
hydrolases. Mucin-degrading bacteria in the human gut belong to several phyla: Bacteroidetes 
(B. thetaiotaomicron, B. fragilis, B. vulgatus), Firmicutes (Ruminococcus torques, R. gnavus), 
Actinobacteria (Bifidobacterium bifidum, B. longum, B. breve) and Verrucomicrobia 
(Akkermansia muciniphila) (Tailford, et al., 2015). During mucin degradation, SCFA are 
produced and oligosaccharides are released. Mucin-degrading bacteria have been proposed to 
be key players in cross-feeding interactions as their metabolic products (e.g. acetate and 
oligosaccharides) serve as substrate for other (beneficial) bacteria (e.g. butyrate-producing 
bacteria) (Belzer & de Vos, 2012).  
1.3 Microbial and epithelial dysfunction in IBD 
1.3.1 Microbial dysbiosis in IBD 
1.3.1.1 Phylogenetic shifts in IBD microbiota 
In the last decade, the composition of gut bacteria of IBD patients was studied with high 
throughput molecular techniques such as bacterial 16S rRNA gene sequencing. This allowed 
researchers to define the microbial dysbiosis in fecal and mucus-associated (biopsy) IBD 
microbiota on phylogenetic level. However, one should be careful when comparing findings 
among the different studies since some studies used a mix of UC and CD samples and 
location of biopsy sampling varied. In addition, the definition of the control group varied from 
healthy individuals to unaffected relatives to individuals with non-inflammatory conditions to 
samples from unaffected gut regions of the IBD patients. An overview of the most consistent 




Figure 1.7 Microbial dysbiosis in IBD: Most consistent outcomes of gut microbiome analyses. Figure 
modified from (Sheehan, et al., 2015)  
Overall, microbial dysbiosis in IBD can be defined by a decrease in diversity and 
temporal stability of the fecal as well as the MAMC (Ott, et al., 2004, Manichanh, et al., 
2006, Martinez, et al., 2008, Andrews, et al., 2011, Walker, et al., 2011). Furthermore, there 
is a decrease in the abundance of bacterial species belonging to the Firmicutes phylum, and 
often in Bacteroidetes as well; an increase in Proteobacteria and Actinobacteria species in 
IBD samples is often noted (Frank, et al., 2007, Willing, et al., 2010). The most common 
finding in defining the microbial dysbiosis in IBD, especially in CD, is the decreased 
abundance of species belonging to Clostridial cluster IV and XIVa, which include many 
important butyrate-producing bacteria (Kostic, et al., 2014, Matsuoka & Kanai, 2015).      
The microbial dysbiosis is different between: ICD, CCD and UC patients; active and 
remissive patients; sites with and without inflammation; fecal and mucus-associated 
microbiota (Rausch, et al., 2011, Walker, et al., 2011, Morgan, et al., 2012, Gevers, et al., 
2014). The largest IBD-related microbiome study to date with treatment-naive samples of 
paediatric CD demonstrated that mucosal samples are superior to detect dysbiosis (Gevers, et 
al., 2014).  
A drawback and reason of variability in results between phylogenetic microbiome 
studies in IBD, is the large inter- and intra-individual differences in microbial composition, 
which can outrange the differences between control and diseased group (Gruber & Haller, 
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2015). Characterizing the dysbiosis in IBD on functional level may have higher potential to 
reveal microbial functionality defects. 
1.3.1.2 Functional shifts in IBD microbiome 
To study the putative functionality of the intestinal microbiota one can use metagenomics – 
what genes are present – or metatranscriptomics – what genes are expressed – while 
metaproteomics – what proteins are expressed – and metabolomics – what metabolites are 
present – can be used to study the exerted microbial activity. These techniques enabled to 
detect changes in microbial functionality in IBD samples (stool, intestinal tissue, fecal water) 
(Gruber & Haller, 2015). For example, CD microbiomes were shown to express less 
microbial genes and produce less proteins compared to controls (2% vs. 8%) (Erickson, et al., 
2012). A metagenomic study demonstrated that the fecal samples of UC and CD contained on 
average 25% fewer genes than the non-IBD controls (Qin, et al., 2010).  
More specifically, IBD microbiomes were found to have a decreased amino acid metabolism 
(Morgan, et al., 2012), an increased propensity for managing oxidative stress (Morgan, et al., 
2012), and an increased prevalence of bacterial genes with virulence-related functions 
(Erickson, et al., 2012). In addition, the concentration of SCFA, especially butyrate, is lower 
in fecal water of CD patients, and to a lesser extent of UC patients, compared to healthy 
persons (Marchesi, et al., 2007). This can be explained by findings of studies using 
metagenomics as well as proteomics as it was demonstrated that pathways for carbohydrate 
metabolism and SCFA production were underrepresented in ICD (Erickson, et al., 2012, 
Morgan, et al., 2012). Moreover, metagenomic reads of F. prausnitzii and Roseburia, 
important butyrate-producers, and their proteins were significantly reduced in ICD. Finally, 
the IBD microbiome is enriched in genes involved in metabolism of the sulfur-containing 
amino acid cysteine and there is an increased sulfate transport in both UC and CD (Morgan, et 
al., 2012). This is linked with the observed increase in abundance of sulfate-reducing bacteria 
and elevated levels of hydrogen sulfide (Pitcher, et al., 2000). The latter is toxic for intestinal 
epithelial cells and inhibits butyrate metabolism in colonocytes (De Preter, et al., 2012). 
1.3.2 Disturbed host-microbe interactions in IBD 
The onset of chronic inflammation in IBD is linked to a loss in intestinal immune 
homeostasis, i.e. the balance between immune tolerance against commensal microbes and 
defense against pathogens. IBD patients do not have the ability to mount an appropriate 
response towards changes in the gut microbiota. A substantial number of IBD associated 
genes are involved in mechanisms of the fine-balanced interactions between microbes and 
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host; e.g. barrier function, primary defence mechanisms and adaptive immunity. Here, 
important mechanisms involved in barrier function will be discussed in detail. 
Patient studies demonstrated that there is an increased intestinal permeability in both 
active and quiescent IBD (Teshima, et al., 2012). Several mechanisms in the host epithelium 
can cause a decreased barrier function in IBD. First, a dysregulation of the differentiation of 
stem cells to specialized epithelial cells was found to be part of the IBD pathogenesis (Koch 
& Nusrat, 2012). Secondly, the barrier integrity and paracellular permeability of the intestinal 
epithelium - mediated by the formation of tight junctions (TJs) that seal the space between the 
intestinal epithelial cells – is compromised. The composition, structure and permeability of 
TJs are regulated by physiological and pathophysiological stimuli including inflammatory 
regulators (Hering, et al., 2012). For example, pro-inflammatory cytokines TNF-α, IFN γ and 
IL-13, which are increased in IBD, induce barrier defects by increasing TJ permeability 
(Coskun, 2014). In addition, several IBD susceptible genes play a critical role in TJ- assembly 
and regulation (McCole, 2014). Thirdly, there are several factors in IBD that lead to an 
aberrant mucus layer. For example, IBD susceptible genes, ECM1, MUC3A and MUC19 
are involved in mucus and glycoprotein regulation. The mucus layer of IBD patients showed 
differences in structure and composition and is more permeable to bacteria (Boltin, et al., 
2013, Johansson, et al., 2014). The mucus layer also helps in intestinal defense by retaining 
antimicrobial peptides and proteins (AMP), which are produced by Paneth cells in the 
epithelium of the small intestine. Next to AMP production, Paneth cells sense and sequester 
luminal bacteria/antigens. In IBD, Paneth cell dysfunction has been linked to the IBD 
susceptibility genes NOD2 and ATG16L1 (Ogura, et al., 2001{Cadwell, 2008 #1445, 
Cadwell, et al., 2008). NOD2 is an intracellular receptor for bacterial cell wall components 
and induces the NF-κB pathway and autophagy. In the small intestine, NOD2 is 
predominantly present in Paneth cells (Ogura, et al., 2003).  The ATG16L1 protein is 
selectively important for the biology of Paneth cells (Cadwell, et al., 2008). Polymorphisms in 
NOD2 and ATG16L1 have been linked to abnormalities in Paneth cells with reduced sensing 
and autophage of bacteria, as well as reduced expression of the AMP α-defensin (Wehkamp, 
et al., 2004{Cadwell, 2008 #1445, Cadwell, et al., 2008).    
Next to host factors, there are also microbial factors that can cause a disruption of the 
epithelial barrier in IBD. Microbiota can modulate the gut epithelial barrier directly through 
the release of metabolites, toxins or cellular structural components or indirectly through 
effects on host immune cells and release of cytokines (Camilleri, et al., 2012).  For example, 
CHAPTER 1 
18 
the microbial metabolite butyrate enhances the gut epithelial barrier function (more described 
in detail in 1.4.1) (Plöger, et al., 2012). A decreased level of butyrate together with an 
increased number of bacteria that trigger the host cells to produce cytokines that reduce the 
barrier function (e.g. TNFα, IFNγ), may trigger epithelial barrier dysfunction in IBD. 
1.3.3 Microbial dysbiosis as target in IBD therapy: Pre- and probiotics  
Microbiome and genome studies in IBD demonstrated that microbial dysbiosis and 
disturbed host response to the microbiota are important in IBD pathogenesis. Therefore, 
manipulating the microbiota with prebiotics or probiotics to restore gut homeostasis and 
induce or maintain remission can be of interest. There is a large collection of in vitro and 
animal studies demonstrating the effect of potential prebiotics and probiotics for IBD. This 
literature review will primarily focus on pre- and probiotic studies from clinical trials with 
IBD patients.  
Prebiotics are defined as “selectively fermented ingredients that allow specific changes, 
both in the composition and/or activity in the gastrointestinal microbiota that confers benefits 
upon host well-being and health” (Gibson, et al., 2004). Common prebiotics for human 
consumption are inulin, lactulose, and fructo- and oligosaccharides (FOS) (Gruber & Haller, 
2015). Efficacy of prebiotics is typically studied in vitro and in IBD animal models. 
Randomized controlled trials with prebiotics in human IBD patients are scarce. There are a 
few small trials in UC or CD with FOS (Lindsay, et al., 2006), lactulose (Hafer, et al., 2007) 
and germinated barley (Kanauchi, et al., 2003, Hanai, et al., 2004) and one large randomized, 
double-blind, placebo-controlled study in CD with FOS (Benjamin, et al., 2011). Germinated 
barley showed the most consistent positive outcome (reduced disease activity) among the 
different trials in UC (Kanauchi, et al., 2003, Hanai, et al., 2004, Faghfoori, et al., 2011, 
Faghfoori, et al., 2014). Results of trials with the other prebiotics in UC or CD could not be 
repeated. For example, consumption of FOS resulted in a significant increase of fecal 
bifidobacteria concentration and reduced disease activity in a small open label trial in patients 
with active ileocolonic CD (n=10). Yet, this could not be confirmed in a large randomized, 
double-blind, placebo-controlled study in active CD (n=103) (Lindsay, et al., 2006, Benjamin, 
et al., 2011). As beneficial bacteria are often decreased in IBD, a combination of prebiotics 
with probiotic bacteria (= synbiotic) may have better efficacy as microbial therapy in IBD.  
 
According to the FAO/WHO a probiotic is defined as, “live microorganisms that, when 
administered in adequate amounts, confer a health benefit on the host” (FAO/WHO, 2002). 
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Both bacteria and yeasts are associated with probiotic activity and Lactobacillus, 
Bifidobacterium and Saccharomyces are the most common probiotic genera. There are a 
number of other species with described probiotic properties (e.g. Bacillus, Bacteroides, 
Enterococcus) and several in vitro and in vivo animal studies demonstrated their mechanisms 
of suppressing inflammation (Haag & Siegmund, 2014). Other mechanisms of probiotics that 
could be of interest for IBD include modulation of barrier function, alteration of gut microbial 
diversity and modulation of innate and adaptive immune response (Madsen, et al., 2001, 
Round & Mazmanian, 2009, Haller, et al., 2010). 
Although the large number of studies demonstrating the potential of probiotics in IBD, 
the number of randomized placebo-controlled trials in IBD patients successfully using 
probiotics are scarce. Comparison of different probiotic trials in IBD is challenging due to the 
variety of probiotic strains or combinations used, different outcomes and diverse types of 
cohorts. Meta-analysis of similar trials could demonstrate probiotic efficacy in UC for 
maintenance of remission rather than induction of remission or treatment of active disease 
(Sang, et al., 2010). Probiotics which showed efficacy in UC in human trials are 
Bifidobacterium-fermented milk, E. coli Nissle 1917 and probiotic mixture VSL#3 (four 
Lactobacilli strains, three Bifidobacteria strains and one Streptococcus strain) (Ishikawa, et 
al., 2003, Kruis, et al., 2004, Bibiloni, et al., 2005). Outcome of trials in CD patients were 
disappointing as none showed effectiveness of the tested bacterial probiotics (VSL#3, E. coli 
Nissle 1917 and a few Lactobacilli strains) (Rahimi, et al., 2008, Pagnini, et al., 2013). 
Although three small randomized controlled trials with the yeast probiotic Saccharomyces 
boulardii in CD patients showed significant clinical benefit (Plein & Hotz, 1993, Guslandi, et 
al., 2000, Garcia Vilela, et al., 2008), a larger randomised controlled trial in 165 CD patients 
did not observe positive effects of S. boulardii (Bourreille, et al., 2013).   
Until now, no relevant safety concerns were raised in the published studies with prebiotics 
and probiotics in IBD (Haag & Siegmund, 2014). However, adverse effects of probiotics have 
been reported in severe immunocompromised and critically ill patients (Sanders, et al., 2010). 
Risks of administrating high doses of bacteria to these patients include, infection, bacterial 
translocation and sepsis. Thus, administration of probiotics to severe ill IBD patients could 
have an increased risk and caution is warranted. 
Due to their lack of efficacy of current probiotic formulations, there is a need for novel 
probiotic species with known mechanisms, especially for CD. Butyrate-producing bacteria are 
a promising group of next generation probiotics for IBD. 
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1.4 Butyrate-producing bacteria as next generation probiotics in IBD 
1.4.1 Butyrate is important to maintain gut health 
Butyrate is the preferred energy source for colonocytes (i.e. colon epithelial cells) and 
after absorption it is rapidly oxidized into CO2 with generation of ATP (Sakata & Engelhardt, 
1983). In case of active IBD, there is a lower in situ production and impaired uptake of 
butyrate and a disturbed capacity of the colonocytes to oxidize butyrate (De Preter, et al., 
2012, De Preter, et al., 2013). This leads to decreased cellular ATP levels and nutritional 
deficiency of epithelium resulting in a shorter life of colonocytes. Butyrate has multiple 
beneficial effects (e.g. anticarcinogenic, anti-inflammatory, neuroprotective): the next 
paragraphs focus on the mechanisms with therapeutic potential for IBD. 
1.4.1.1 Improvement of intestinal barrier 
Butyrate has been shown to improve intestinal barrier functioning in several ways, supporting 
its therapeutic potential for IBD. Experimental studies (in vitro and ex vivo) demonstrated that 
butyrate increases MUC2 gene expression and mucin synthesis (Finnie, et al., 1995, 
Hatayama, et al., 2007). Next, butyrate increases expression of tight junction proteins and 
facilitate their assembly by acceleration of the relocation of TJ proteins ZO-1 and occludin, 
which results in an increased barrier integrity (Peng, et al., 2007, Peng, et al., 2009). Repair of 
intestinal wounds and ulcers is important to re-establish the epithelial barrier. Butyrate 
increases the rate of cell migration and restored transglutaminase levels, an enzyme involved 
in intestinal mucosal healing (D'Argenio, et al., 1996, Wilson & Gibson, 1997). Another 
target of butyrate may be oxidative stress, which is induced during colon inflammation due to 
high levels of reactive oxygen species (ROS), thereby compromising the epithelial barrier. 
Several in vitro and ex vivo studies demonstrated an antioxidant effect of butyrate (Leonel & 
Alvarez-Leite, 2012). For example, in a study in biopsies of colonic mucosa from CD patients 
and healthy controls, butyrate was able to restore the intracellular ROS balance and attenuated 
lipopolysaccharide induced inflammation (Russo, et al., 2012). Finally, butyrate enhances 
proliferation and differentiation of intestinal epithelial cells (Guilloteau, et al., 2010).  
1.4.1.2 Anti-inflammatory functions 
Butyrate has potential to modulate chronic inflammation as it possesses several anti-
inflammatory functions. It reduced the expression and production of pro-inflammatory 
mediators ex vivo (TNFα, IL-1β, IL-6) in intestinal biopsies of CD patients (Segain, et al., 
2000). Moreover, in antigen-stimulated human monocytes, butyrate strongly reduced 
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production of pro-inflammatory cytokine IL-12, which is involved in IBD, and up-regulated 
secretion of anti-inflammatory cytokine IL-10 (Säemann, et al., 2000). Butyrate also 
modifies the inflammatory response by inhibiting activation of nuclear factor kappa B (NF-
κB) which controls the expression of a wide variety of genes involved in inflammatory 
processes (e.g. pro-inflammatory cytokines, adhesion molecules, growth factors, immune 
receptors) (Hamer, et al., 2008). This was demonstrated in a trial with UC patients where the 
activated NF-κB levels were reduced by butyrate and resulted in a decreased disease activity 
and mucosal inflammation (Lührs, et al., 2002). Finally, butyrate induces differentiation of 
colonic regulatory T cells (Treg), which have a central role in suppression of inflammatory 
responses: the luminal concentration of butyrate is thus found to positively correlate with the 
number of colonic Treg cells (Furusawa, et al., 2013). 
1.4.2 Taxonomy of butyrate-producing bacteria in the human gut 
Butyrate-producing bacteria within the human intestinal microbiota form one functional 
group but are diverse on phylogenetic level. They are Gram-positive anaerobic bacteria 
belonging to different classes within the Firmicutes phylum. The two most important 
phylogenetic families containing butyrate-producers are (1) the Ruminococcaceae – 
clostridial cluster IV (or Clostridium leptum group) – with Faecalibacterium prausnitzii as the 
most abundant member and (2) the Lachnospiraceae – clostridial cluster XIVa (or 
Clostridium coccoides group) – with Eubacterium rectale and Roseburia spp. as abundant 
members (Louis & Flint, 2009). Their abundance in human fecal samples varies from 13-25 
% for clostridial cluster IV and 25-58 % for clostridial cluster XIVa (Lay, et al., 2005, 
Gosalbes, et al., 2011, Kolmeder, et al., 2012). Important to mention, both families include 
also non-butyrate-producing species since butyrate production is not a common feature of 
these phylogenetic groups (Pryde, et al., 2002, Louis, et al., 2010). Therefore, a classification 
based on the functional gene for butyrate-production instead of 16S rRNA gene would be a 
better approach to describe human intestinal butyrate-producing bacteria. This was recently 
performed by Vital and co-workers who screened sequenced bacterial genomes (derived from 
The Human Microbiome Project) for known individual genes of butyrate-producing 
pathways. In addition to the previously described Firmicutes families, members of 
Bacteroidetes, Fusobacteria and Spirochaetes were also identified with a potential to produce 
butyrate in the human gastrointestinal tract (Vital, et al., 2014).  
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1.4.3 Metabolic pathways for microbial butyrate production 
Bacteria can produce butyrate through four known pathways: (1) the acetyl-CoA, (2) the 
glutarate, (3) the lysine and (4) the 4-aminobutyrate pathway (Figure 1.8). In the human gut, 
the acetyl-CoA pathway is the main pathway (80% of butyrate-producing pathways), 
followed by the lysine pathway (11 %) (Vital, et al., 2014).  
 
Figure 1.8 Four different pathways for butyrate synthesis and corresponding genes (protein names) 
are displayed. Figure derived from (Vital, et al., 2014). 
During microbial substrate fermentation in the colon, through the Embden-Meyerhof-
Parnas pathway, glucose is converted into pyruvate, which is converted into acetyl-CoA. 
Following the acetyl-CoA pathway, two molecules of acetyl-CoA are assembled to form 
butyryl-CoA. Then, butyryl-CoA is converted to butyrate by either (1) butyryl-CoA:acetate 
CoA-transferase (but pathway) or by (2) butyrate kinase (buk pathway) (after 
phosphorylation of butyryl-CoA). The but pathway is the dominating pathway for butyrate 
production in the human colon (Louis & Flint, 2009, Vital, et al., 2013). In case of the but 
pathway, acetate is used as co-substrate and the supply of exogenous acetate is important to 
maintain butyrate production (Duncan, et al., 2004). Some butyrate-producing human colon 
bacteria (e.g. Anaerostipes spp. and Eubacterium hallii) can convert acetate and lactate into 
butyrate (via pyruvate) (Duncan, et al., 2004).  
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1.4.4 Variation in butyrate production in the human gut 
The butyrogenic potential of the intestinal microbiota varies between individuals. A 
metagenome study in 15 stool samples detected that 3 to 39 % (median 19 %) of the genes of 
the microbiome were involved in one of the butyrate-producing pathways (Vital, et al., 2014). 
However, detection of butyrate-producing genes does not imply production of butyrate 
because several environmental factors determine the gene expression and functioning 
pathway. 
 Diet and substrate availability are amongst the major factors influencing the growth 
and activity of butyrate-producing bacteria. Especially the supply of polysaccharides is 
important for maintaining a well-functioning butyrate-producing community. For example, a 
high-protein, low-carbohydrate diet resulted in a decreased abundance of Lachnospiraceae 
and a drop of fecal butyrate levels (Duncan, et al., 2007). Butyrate-producing bacteria can 
utilize a wide range of substrates (e.g. starch, xylan, inulin) and certain substrates can enhance 
butyrate production either by direct stimulation or by metabolic cross feeding with acetate- 
and lactate-producing species (Louis & Flint, 2009). The pH also influences the butyrate 
production: it was demonstrated that incubation of fecal microbiota at pH 5.5 resulted in 
higher butyrate concentrations compared to incubations at pH 6.5 (Walker, et al., 2005). 
Other factors that negatively influence the abundance of butyrate-producers and butyrate 
production are high oxygen concentrations, the use of antibiotics and a deficiency in iron 
(Willing, et al., 2011, Dostal, et al., 2012, Khan, et al., 2012). The latter suggests that 
administration with dietary iron supplements may enhance butyrate-producing bacteria and 
increase butyrate production. However, iron supplementation to rats after an iron-deficient 
diet did not restore the Roseburia spp./Eubacterium rectale numbers (Dostal, et al., 2012).  
1.4.5 Butyrate-producing bacteria with probiotic potential for IBD 
Human studies were performed in UC patients to assess the therapeutic potential of pure 
butyrate by means of butyrate-containing tablets or rectal enemas. These trials have not 
always been successful due to problems to deliver butyrate in the colon, short and 
discontinuous exposure of butyrate and poor compliance of the patients with the treatment 
(Hamer, et al., 2008). Therefore, an elegant alternative could be the consumption of butyrate-
producing bacteria that increase the in situ butyrate production where it is needed. Although 
no clinical trials have been performed, a number of in vitro and in vivo studies support the 
therapeutic potential of butyrate-producing bacteria for IBD and two potential probiotic 
candidates will be discussed below. 
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1.4.5.1 Faecalibacterium prausnitzii 
F. prausnitzii is the most abundant butyrate-producing member of the clostridial 
cluster IV and its overall abundance in total fecal microbiota of healthy individuals varies 
between 5 and 15 % of total fecal microbiota (Lay, et al., 2005). In IBD, its abundance is 
decreased (Sokol, et al., 2009). Moreover, there is a correlation between F. prausnitzii levels 
and maintenance of remission in UC and CD (Sokol, et al., 2008, Varela, et al., 2013).  
In different rodent colitis models F. prausnitzii and its culture supernatant were shown 
to reduce the severity of chemically induced colitis (Sokol, et al., 2008, Rosique, et al., 2012, 
Martín, et al., 2014). The anti-inflammatory effect of F. prausnitzii and its culture supernatant 
could be explained by several mechanisms: up regulation of anti-inflammatory cytokine and 
Treg cell production (Qiu, et al., 2013), improvement of intestinal barrier integrity by affecting 
paracellular permeability (Carlsson, et al., 2013, Laval, et al., 2014), and down-regulation of 
pro-inflammatory cytokine production (Martín, et al., 2014). In vitro studies could further 
elucidate the anti-inflammatory mechanisms of F. prausnitzii as it increased IL-10 levels and 
decreased IL-12 levels produced by peripheral blood monocytes. F. prausnitzii supernatant 
reduced IL-1β induced NF-κβ activation and secretion of IL-8 in caco-2 cells (Sokol, et al., 
2008). 
Next to butyrate, a combination of different factors and secreted bioactive compounds 
of F. prausnitzii can contribute to its protective effect during inflammation. For example, 
Rossi and co-workers demonstrated that isolated and purified extracellular polymeric matric 
(EPM) of F. prausnitzii HTF-F reduced the transcription and production of pro-inflammatory 
cytokine IL-12 in inflammatory stimulated dendritic cells. Moreover, the EPM producing F. 
prausnitzii strain resulted in a stronger protection to DSS-induced colitis in mice compared to 
the type strain F. prausnitzii A2-165 (Rossi, et al., 2015). Recently, a microbial anti-
inflammatory molecule (MAM) protein of 15 kDa produced by F. prausnitzii A2-165 was 
identified and isolated (Quévrain, et al., 2015). These studies indicate that butyrate-producing 
bacteria have additional beneficial properties to their butyrate production. 
1.4.5.2 Butyricicoccus pullicaecorum 
The genus Butyricicoccus is part of clostridial cluster IV and was described for the first 
time in 2008 by Eeckhaut and co-workers after isolation of its type strain B. pullicaecorum 
25-3T from the caecum of chicken (Eeckhaut, et al., 2008).  
Butyricicoccus spp. are detected in the gastrointestinal tract of mice (Nava, et al., 2011, 
Galley, et al., 2014), cattle (Li, et al., 2012), pigs (Kim, et al., 2012), seals (Nelson, 2012), 
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wild carnivores: snow leopards (Zhang, et al., 2014), non-human primates: red-tailed guenons  
(Yildirim, et al., 2010), howler monkeys (Amato, et al., 2013) and in humans (Frank, et al., 
2011, Nava & Stappenbeck, 2011, Claesson, et al., 2012, Durbán, et al., 2012, Harrell, et al., 
2012, Morgan, et al., 2012, Papa, et al., 2012, Ng, et al., 2013, Schloss, et al., 2014, Schnorr, 
et al., 2014). The abundance in human fecal samples is low: 0.05% to 0.4% of total fecal 
microbiota (Claesson, et al., 2012, Schnorr, et al., 2014). 
The presence and abundance of Butyricicoccus spp. is associated with different 
conditions with a microbial dysbiosis. Abundance of Butyricicoccus spp. was decreased in 
IBD patients (both in active and remission) (Eeckhaut, et al., 2012, Papa, et al., 2012); in 
antibiotic treated IBD patients (Morgan, et al., 2012), in irritable bowel syndrome patients 
(Durbán, et al., 2012) and in hospitalized elderly people (Claesson, et al., 2012).  
B. pullicaecorum 25-3T attenuated chemically-induced colitis in a rodent IBD model 
and its culture supernatant preserved epithelial barrier function and down-regulated IL-8 
production in TNFα and IFNγ stimulated Caco-2 cells (Eeckhaut, et al., 2012). It is therefore 
suggested that B. pullicaecorum may contribute to restore gastrointestinal health in IBD but 




1.5 Objectives and outline of this research 
The microbial dysbiosis plays an important role in the pathogenesis of IBD. Current 
therapy in IBD aims to restore the immune homeostasis and focusses only on the host 
response. However, correcting both facets of the pathogenesis (host and microbiota) may 
increase efficacy of IBD therapy. Butyrate-producing bacteria are identified as future 
probiotics with the potency to counterbalance the dysbiosis in IBD and restore gut 
homeostasis. However, before administrating butyrate-producing bacteria to IBD patients, 
more knowledge of their behavior under gastrointestinal conditions is required. The objective 
of this PhD research was to answer following research questions by using in vitro intestinal 
technology and with the focus on B. pullicaecorum 25-3T. 
- How can we administer oxygen-sensitive butyrate-producers and deliver high 
concentrations of viable and active probiotic cells into the gut? 
- What is their intrinsic tolerance to the harsh environment of the stomach and small 
intestine? 
- What is their capacity to increase butyrate levels in (dysbiosed) human microbiota? 
- What is their colonization potential after administration to (dysbiosed) human 
microbiota? 
- Does administration of butyrate-producing bacteria to dysbiosed human microbiota 
result in an increased epithelial barrier function? 
Before developing a stable formulation of B. pullicaecorum for oral administration, in 
chapter 2 its intrinsic tolerance to the conditions of stomach and small intestine was 
evaluated using in vitro batch experiments. The cultivability and viability during exposure to 
stomach conditions at different pH levels and subsequent small intestinal conditions was 
monitored. We also evaluated whether the tolerance was influenced by the suspension 
medium of B. pullicaecorum and whether milk had a protective effect. To assess the 
metabolic potency after stomach and small conditions, B. pullicaecorum that had been 
subjected to gastrointestinal conditions was further incubated and short chain fatty acid 
production was monitored. 
To evaluate the future use of B. pullicaecorum as probiotic, we developed a strategy in 
chapter 3 to protect this butyrate-producer from acid stress and deliver it into the gut. A 
stable formulation with freeze-dried B. pullicaecorum for oral consumption was developed. 
Furthermore, the protective effect of an enteric coating with cellulose acetate phthalate (CAP) 
on the cultivability and viability during gastric and small intestine conditions was assessed. 
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Finally, the potential to produce butyrate during colon incubations in the absence and 
presence of colonic bacteria was evaluated. 
Little is known about the abundance of B. pullicaecorum in the colon microbiota and its 
butyrogenic properties after administration. In chapter 4, we used the M-SHIME® to assess 
the colonization potential of B. pullicaecorum 25-3T and to analyze its impact on butyrate 
production by the microbiota of different individuals (healthy volunteers and CD patients in 
remission) after B. pullicaecorum 25-3T administration. We applied a single dose of B. 
pullicaecorum 25-3T to monitor its growth or wash-out from the microbial communities 
during the 10 day follow-up period and effect of composition of receiving microbial 
community.  
In chapter 5, we studied the difference between two B. pullicaecorum strains, F. 
prausnitzii A2-165 and a mix of six butyrate-producing bacteria in their capacity to increase 
butyrate production of and colonize the microbiota of active and remissive CD patients. 
Furthermore, we assessed the effect on epithelial barrier function of supplementation of B. 
pullicaecorum 25-3T and a mix of butyrate-producing bacteria to CD microbiota. In this 
study, an in vitro approach was used combining microbial and epithelial models to study the 
different interactions. 
In chapter 6, an overview of the obtained research outcomes is given in combination 
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Butyrate has several beneficial properties that are essential to maintain gastrointestinal 
health. Therefore butyrate-producing bacteria are seen as the next generation of probiotics. 
The butyrate-producing bacterium Butyricicoccus pullicaecorum (a clostridial cluster IV 
strain) is such a promising probiotic candidate for people suffering from inflammatory bowel 
disease. To exert its beneficial properties, it is crucial that B. pullicaecorum survives the harsh 
conditions of the upper gastrointestinal tract to arrive in the colon in a viable and 
metabolically active state. Before developing a stable formulation of B. pullicaecorum for oral 
administration, it is important to know its intrinsic acid and bile tolerance. We monitored the 
survival during and short chain fatty acid production after incubation in conditions simulating 
the stomach and small intestine using in vitro batch experiments.  
In case of acid conditions (pH 2 and pH 3), B. pullicaecorum was viable and active but 
not cultivable. Cultivability was restored during subsequent small intestine conditions. 
Importantly, bile and pancreatic juice had no lethal effect. Milk, as suspension medium, only 
had a protective effect on the cultivability during the first hour at pH 2. B. pullicaecorum was 
still metabolically active after upper gastrointestinal conditions and produced short chain fatty 
acids, but a shift from butyrate to acetate production was observed. Although the butyrate-
producing anaerobe B. pullicaecorum showed good intrinsic acid and bile tolerance in terms 
of viability and metabolic activity, colonization efficiency and butyrate production under 
colon conditions is needed to further evaluate its probiotic potential. 
 
2 CHAPTER 2 
Butyricicoccus pullicaecorum, a butyrate producer with 
probiotic potential, is intrinsically tolerant to stomach 
and small intestine conditions 
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2.1 Introduction 
Butyrate has several beneficial properties that help to maintain gastrointestinal health: it 
is the main energy source of the colonocytes, inhibits pro-inflammatory pathways, reduces the 
oxidative stress in the colon and maintains gut barrier function (Roediger, 1982, Hamer, et al., 
2008, Hamer, et al., 2009). Several strategies are proposed to increase the concentration of 
butyrate in the gut. A direct strategy is the administration of pure butyrate by means of 
butyrate containing tablets or rectal enemas (Hamer, et al., 2008). An elegant alternative 
could be the consumption of butyrate-producing bacteria as an indirect strategy to increase the 
in situ butyrate production in the gut. Therefore, butyrate-producing bacteria are seen as the 
next generation probiotics to improve treatments of intestinal disorders like Inflammatory 
Bowel Disease (IBD) (Van Immerseel, et al., 2010, Marteau, 2013, Walker & Lawley, 2013). 
Butyrate-producing bacteria present in the human gut are obligate anaerobic Gram-positive 
bacteria, originating from two important groups: the Clostridium leptum (or clostridial cluster 
IV) cluster and the Clostridium coccoides (or clostridial cluster XIVa) cluster (Louis & Flint, 
2009). 
A good probiotic candidate could be derived from the genus Butyricicoccus (clostridial 
cluster IV) (Papa, et al., 2012), as fecal samples of IBD patients display lower numbers of 
Butyricicoccus bacteria (Eeckhaut, et al., 2012). Recently, a novel butyrate-producing species, 
Butyricicoccus pullicaecorum, was isolated from caecal content of broiler chickens and 
showed high in vitro butyrate production (18 mM overnight in its growth medium) (Eeckhaut, 
et al., 2008). In addition, this isolate showed promising probiotic properties in a study with 
rats and Caco-2 epithelial cells (Eeckhaut, et al., 2012). In the rat study a less severe colitis 
developed after chemically induced inflammation in rats treated with B. pullicaecorum 
through intra gastric gavage compared to the control group (Eeckhaut, et al., 2012).  
To exert its beneficial properties, it is crucial that B. pullicaecorum arrives in the ileum 
and colon in a viable and metabolically active state. Therefore it needs to survive the harsh 
conditions of the upper gastrointestinal tract (UGIT): low pH in the stomach and presence of 
bile salts and pancreatic enzymes in the small intestine.  
There is a lack of information on the intrinsic gastric and bile salt tolerance of butyrate-
producing bacteria. If these are not able to withstand the harsh conditions of the UGIT, a 
suitable protection strategy (e.g. encapsulation with enteric coating) will be necessary.   
During this study the intrinsic tolerance of B. pullicaecorum to the conditions of 
stomach and small intestine was evaluated using in vitro batch experiments. The cultivability 
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and viability during exposure to stomach conditions at different pH levels and subsequent 
small intestinal conditions was monitored. We also evaluated whether the tolerance was 
influenced by the suspension medium of B. pullicaecorum and whether milk had a protective 
effect. To assess the metabolic potency after UGIT conditions, B. pullicaecorum that had been 
subjected to gastrointestinal conditions was further incubated and short chain fatty acid 
production was monitored. 
2.2 Materials and methods 
2.2.1 Bacterial strain and growth conditions 
Butyricicoccus pullicaecorum 25-3T (LMG 24109T) was grown in anaerobic M2GSC 
medium at pH 6 prepared as described by Miyazaki et al. (Miyazaki, et al., 1997) using 15 % 
(v/v) of clarified rumen fluid instead of 30 % (v/v). M2GSC (1.5 % w/v) agar plates were 
incubated at 37° C in an anaerobic (8 % CO2, 8 % H2 and 84 % N2) workstation (Ruskinn 
Technology, Bridgend, UK) for 20 h. Before use in each experiment, a B. pullicaecorum 
colony was transferred into 10 mL of anaerobic M2GSC broth and incubated overnight at 37° 
C. Subsequently, the culture was subcultured (10 % v/v) once in anaerobic M2GSC broth and 
incubated for 20h at 37°C. 
Continuous anaerobic growth curves of B. pullicaecorum 25-3T were recorded in a 96 
well-plate based on the method described by Eini et al. (Eini, et al., 2013). M2GSC medium 
was prepared using sterile, anaerobic techniques in Hungate tubes and inoculated with 10 % 
(v/v) of a pre-culture grown in static conditions at 37° C for 20 h. A 96 well-plate 
(transparent, flat bottom) was prepared in an anaerobic (10 % CO2, 90 % N2) workstation 
(GP-Campus, Jacomex, TCPS NV, Rotselaar, Belgium). Each well was filled with 200 µL of 
inoculated broth, ensuring at least triplicate wells of each replicate (n=2). The lid was sealed 
on the well-plate with commercially available petroleum jelly. Growth at 37° C was 
subsequently monitored by hourly measurements of optical density (OD) at 600 nm with a 
well-plate reader (Tecan Infinite M200 Pro, Grödig, Austria) outside the anaerobic 
workstation. Comparison of the residual liquid in the Hungate tubes with the well-plate 
showed comparable results after incubation (data not shown). No growth was observed in 
uninoculated wells/tubes, indicating aseptic conditions (Figure 1). Growth rate was calculated 
as the average rate of six wells by using µ= (LnOD2-LnOD1)/(t2-t1), where OD and t are the 
values obtained from the linear model of the exponential growth phase. Generation time was 
calculated by using td = (ln 2)/µ. 
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2.2.2 Simulation of gastrointestinal conditions 
During batch experiments with a 2 h gastric phase and 4 h small intestine phase the 
upper gastrointestinal conditions were simulated. Transit times, composition of nutritional 
medium and concentration of enzymes (pepsin, pancreatin) and bile extract were based on 
previous reported in vitro simulation studies for upper gastrointestinal tract (Jacobsen, et al., 
1999, Oomen, et al., 2003, Verthe, et al., 2004). Experiments were performed in 
quadruplicate in sterile penicillin flasks flushed with nitrogen gas to obtain anaerobic 
conditions. All manipulations were done in the Ruskinn anaerobic workstation. At the start of 
simulation, 3 mL of a stationary (20h incubation; Figure 2.1) B. pullicaecorum culture was 
added to 27 mL of sterile anaerobic gastric simulation medium set to different pH levels (pH 
2, pH 3, pH 4 and pH 6) with 5 M HCl or 5 M NaOH. The composition of the gastric 
simulation medium was the following (per liter): 1 g arabinogalactan, 2 g pectin, 1 g xylan, 3 
g potato starch, 0.4 g glucose, 3 g yeast extract, 1 g peptone, 4 g mucin, 0.5 g cysteine, 1 g 
pepsin (Sigma). After a 2 h gastric incubation at 37° C under gentle shaking (100 rpm), 15 
mL of pancreatic and bile fluid was added consisting of (per liter): 3 g pancreatin (Sigma), 8 g 
dehydrated bile extract (Oxgall; Difco) and NaHCO3. The NaHCO3 was added to the 
pancreatic and bile fluid to increase the pH of the gastric suspension to pH 6.5. Depending on 
the pH of the gastric suspension  following concentrations (g/L) of NaHCO3 were used: 12.5 
(gastric pH 2), 10 (gastric pH 3), 7.5 (gastric pH 4) and 2.5 (gastric pH 6). Flasks were 
incubated for another 4 h (100 rpm; 37°C). A second batch experiment was performed to 
evaluate the survival under fed and fasted gastrointestinal conditions. For fasted conditions, 3 
mL of an overnight culture was added to 27 mL of anaerobic gastric fluid at pH 2 which 
contained (per liter): 4 g NaCl, 4 g mucin and 1 g pepsin. After incubation of 2 h, 15 mL 
pancreatic fluid was added with lower concentrations of bile and pancreatin compared to fed 
simulation and consisted of (per liter): 12.5 g NaHCO3, 2 g pancreatin (Sigma) and 2.5 g bile 
(Oxgall; Difco). For fed conditions, 3 mL of the same overnight culture was added to 27 mL 
of anaerobic feed with pH 2 and the experiment was continued as described earlier. 
To determine whether the suspension medium of the inoculum had a protective effect 
towards the cultivability of B. pullicaecorum during stomach conditions at pH 2 and small 
intestine conditions at pH 6.5, the pellet (centrifugation for 10 min. at 1500 g) of a stationary 
culture was resuspended in different matrices. Suspension media used were; fresh M2GSC 
medium (FM), depleted M2GSC medium (DM), semi skimmed (1.5 % fat) UHT milk and 
PBSS (10.2 g KH2PO4/L, 13.2 g K2HPO4/L, 8.0 g NaCl/L and 1.0 g cysteine-HCl/L). The 
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milk matrix was used for its previous described protective effect towards probiotic survival 
during gastric conditions (Lo Curto, et al., 2011, Martinez, et al., 2011). The sterility of the 
milk was evaluated by plating on Luria Bertani agar (Oxoid) and incubation under aerobic an 
anaerobic conditions at 37° C for 48 h. DM was the filter sterilized supernatant collected of a 
stationary (20 h incubation) culture of B. pullicaecorum after centrifugation for 10 min at 
1500 g.  
The metabolic potency in terms of short chain fatty acid (SCFA) production of B. 
pullicaecorum that had been subjected to gastrointestinal conditions was assessed by further 
incubation for another 18 h under more optimal growth conditions. Therefore the bottles after 
stomach (pH 2, pH 3, pH 4 and pH 6) and small intestine conditions were supplemented with 
M2GSC medium (50 % v/v). As a control, SCFA production of B. pullicaecorum was 
determined in 24 h incubation in UGIT simulation medium without pepsin, bile salts and 
pancreatin supplemented with M2GSC medium (50 % v/v). 
2.2.3 Bacterial viability 
Cultivability of B. pullicaecorum, expressed in colony forming units (CFU), was 
determined by plating serial dilutions in anaerobic PBSS on M2GSC agar plates with the 6 x 
6 drop plate method (Chen, et al., 2003). M2GSC agar plates were incubated for 20 h at 37° C 
in the Ruskinn anaerobic worstation. The concentration of B. pullicaecorum (CFU/mL) in the 
inoculum and at different time points during upper gastrointestinal passage (1 h, 2 h, 4 h and 6 
h) was determined.  
Viability of B. pullicaecorum was determined by a live/dead analysis with flow 
cytometry (CyAn_ ADP LX flow cytometer, Dakocytomation, Heverlee, Belgium) as 
described previously (De Roy, et al., 2012). In brief, samples at different time points during 
the upper gastrointestinal passage were diluted in filter sterile mineral water (Evian) to obtain 
an optimal cell density (104 – 106 cells/mL) for flow cytometry analysis. The cells were 
stained with a live/dead staining which was a combination of two DNA binding fluorescent 
stains: SYBR® Green I and propidium iodide (PI). The former penetrates all cells and results 
in a green fluorescence, the latter penetrates only cells with a damaged cell membrane 
resulting in a red fluorescence. Based on this principle, the amount of cells with an intact cell 
membrane – viable cells – was determined in each sample. 
2.2.4 Short Chain FattyAcid (SCFA) analysis 
The SCFAs in the samples taken upon upper gastrointestinal tract simulation were 
extracted with diethyl ether and analysed using a gas chromatograph as described by De 
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Weirdt et al. (De Weirdt, et al., 2010). The concentration of acetate, propionate, butyrate, 
isobutyrate, valerate, isovalerate, caproate and isocaproate was determined in each sample. 
2.2.5 Statistical analysis 
SPSS Statistics 20 software was used to perform all statistical analysis. Significance 
level was set at 0.05. Means were compared using the nonparametric Wilcoxon test in case of 
dependent samples. 
2.3 Results 
2.3.1 Growth rate of B. pullicaecorum in M2GSC medium 
A continuous anaerobic growth curve of B. pullicaecorum in M2GSC medium was 
recorded to assess the growth rate and characteristics under standard cultivation conditions. A 
triplicate OD measurement of two biological replicates showed an average growth rate of 0.19 
± 0.01 h-1, equivalent to a generation time of 3.6 ± 0.2 h or 216 ± 14 min (Figure 2.1). 
 
Figure 2.1 Continuous anaerobic growth curve of B. pullicaecorum in M2GSC medium. Mean OD 
(600 nm) values ± standard deviation (n=6) of B. pullicaecorum in M2GSC medium () and 
uninoculated, sterile M2GSC medium (▲). 
2.3.2 Cultivability of B. pullicaecorum depends on pH during stomach conditions 
The ability of a stationary culture of B. pullicaecorum (7.7 ± 0.2 log CFU/mL) to 
survive or grow under gastrointestinal circumstances was assessed during a 2 hour stomach 
incubation at pH 2, pH 3, pH 4 and pH 6 followed by a 4 h small intestine incubation. Both 
upon stomach incubation at pH 2 and pH 3 the Butyricicoccus concentration decreased under 
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the limit of detection (2 log CFU/mL), while incubation at pH 4 and 6 did not affect 
Butyricicoccus survival (Figure 2.2). After 2 h of incubation, pancreatic and bile fluid were 
supplemented to the gastric digest to initiate the small intestine incubation (at pH 6.5). Small 
intestine incubation of 4 h of Butyricicoccus that had been acid stressed (pH 2 and pH 3 
during stomach phase) resulted in Butyricicoccus levels of 3.4 ± 0.7 and 4.5 ± 0.5 log 
CFU/mL, respectively (Figure 2.2). B. pullicaecorum that had been subjected to pH 4 or pH 6 
during gastric incubation were unaffected during small intestine incubation, displaying levels 
of 7.1 ± 0.5 and 8.1 ± 0.4 log CFU/mL, respectively after 6 h. 
 
Figure 2.2 Cultivability of B. pullicaecorum is dependent on pH during stomach conditions. 
Cultivability is expressed as mean log CFU/mL ± standard deviation (n=4) of B. pullicaecorum 
during stomach conditions (0-2 h) at pH 2 (), pH 3 (), pH 4 (▲) and pH 6 (●) followed by small 
intestine conditions (indicated by the dashed vertical line;---) (2-6 h) at pH 6.5. Limit of detection 
(LOD) is indicated (dashed horizontal line; ---). 
B. pullicaecorum that had been subjected to fasted gastric and small intestine incubation 
resulted in higher (p = 0.05) cultivable bacteria compared to fed gastric and small intestine 
incubation (Figure 2.3). Levels of B. pullicaecorum after fasted and fed simulation of 6 h 
were 4.5 ± 0.1 and 3.2 ± 0.3 log CFU/mL, respectively. 
Intrinsic tolerance of B. pullicaecorum 25-3T to stomach and small intestine conditions 
37 
 
Figure 2.3 Cultivability of B. pullicaecorum during fed versus fasted stomach-small intestine conditions. 
Cultivability is expressed as mean log CFU/mL ± standard deviation (n=3) of B. pullicaecorum during stomach 
conditions (0-2 h) at pH 2 followed by small intestine conditions (indicated by the dashed vertical line;---) (2-6 
h) at pH 6.5. Limit of detection (LOD) is indicated (dashed horizontal line; ---) 
2.3.3 Different suspension media had no protective effect during stomach-small 
intestine simulation 
Different suspension media were used to assess their protective effect during upper 
gastrointestinal simulation. After 1h of stomach conditions at pH 2, B. pullicaecorum was no 
longer detected in case of FM, DM and PBSS but presence of a milk matrix resulted in 6.0 ± 
0.8 log CFU/mL (Figure 2.4). The protective effect of the milk matrix disappeared after 2 h of 
stomach incubation at pH 2. Overall, there was no difference in cultivability of B. 
pullicaecorum in the different matrices upon stomach and small intestine conditions after 6 h 





Figure 2.4 Cultivability in mean log CFU/mL ± standard deviation (n=3) of B. pullicaecorum during 
stomach conditions (0-2 h) at pH 2 followed by small intestine conditions (indicated by the dashed 
vertical line; …) (2-6 h) at pH 6.5. Different inoculum matrices were used: 1.5% fat UHT milk (), 
Phosphate Buffered Saline Solution (PBSS) (), depleted cultivation medium (DM) (▲) and fresh 
cultivation medium (FM) (●). Limit of detection (LOD) is indicated (dashed horizontal line; ---). 
2.3.4 Cultivability versus viability of B. pullicaecorum during stomach-small intestine 
conditions   
The findings above demonstrated that the exposure of acid stressed cells (pH 2 and pH 
3 during stomach simulation) to more optimal pH conditions (pH 6.5) in the subsequent small 
intestine simulation restored their cultivability. To assess viability of B. pullicaecorum during 
stomach incubation at pH 2, as opposed to its cultivability, another UGIT incubation was 
carried out. Viability of B. pullicaecorum was determined through a live/dead staining 
followed by flow cytometry. The concentration of viable (intact) cells in the inoculum was 9.9 
± 0.6 log viable cells/mL and differed 2 log units from the CFU concentration (7.8 ± 0.2 log 
CFU/mL) as determination of cultivability (Figure 2.5). The number of viable cells did not 
significantly change (p = 0.13) after 2 h gastric incubation at pH 2 (8.8 ± 0.3 log viable 
cells/mL). This is in sharp contrast with the undetectable levels of cultivable Butyricicoccus 
upon a 2 h gastric incubation at pH 2. Also after exposure to small intestinal conditions at pH 
6.5, the concentration of viable cells remained high (8.9 ± 0.5 log viable cells/mL). Overall, 
during stomach and small intestine simulation the number of viable cells was always higher 
than the number of cultivable cells. The number of dead (permeable) cells remained constant 
throughout the experiment (9.9 ± 0.6 log dead cells/mL). 
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Figure 2.5 Cultivability versus viability of B. pullicaecorum during stomach (0-2 h) and small 
intestine conditions (indicated by the dashed vertical line; …) (2-6 h). Cultivability of B. 
pullicaecorum in mean log CFU/mL ± standard deviation (n=3) (). Viability of B. pullicaecorum in 
mean log viable cells/mL ± standard deviation (n=3) (). Limit of detection (LOD) of plate counts is 
indicated (---). 
2.3.5 B. pullicaecorum is metabolically active after treatment under upper 
gastrointestinal conditions 
During the 18 h incubation following UGIT conditions, butyrate and acetate were the 
only SCFA detected. After non UGIT conditions (control) B. pullicaecorum consumed 3.0 ± 
0.1 mM acetate and produced 5.4 ± 0.3 mM butyrate (Figure 5). There was a shift from 
acetate consumption to acetate production for B. pullicaecorum cells that had gone through 
the stomach-small intestine incubation. Net acetate production in all UGIT treated cells was 
higher than 5.8 +/- 1.7 mM and higher than the net production of butyrate. Net butyrate 
production after exposure to stomach conditions at pH 2 was low (0.10 ± 0.07 mM) compared 
to production after exposure at pH 3 (1.8 ± 1.0 mM), pH 4 (2.9 ± 1.0 mM) and pH 6 (2.4 ± 
0.5 mM). Concentration of cultivable B. pullicaecorum bacteria after 18 h incubation 
following UGIT conditions with gastric phase at pH 2, pH 3, pH 4 and pH 6 were 3.8 ± 0.6, 




Figure 2.6 B. pullicaecorum is metabolically active after upper gastrointestinal conditions. Net short 
chain fatty acid production 18h after stomach conditions (0-2 h) at pH 2, pH 3, pH 4 and pH 6 
followed by small intestine conditions (2-6 h) at pH 6.5. Control is medium only at pH 6.5, no acid 
stress nor bile salts added. Concentrations of acetate and butyrate in mM ± standard deviation (n=4).  
 
Figure 2.7 Cultivability of B. pullicaecorum during incubation following UGIT conditions with gastric phase at 
pH 2 (), pH 3 (), pH 4 (▲) and pH 6 (●) followed by small intestine conditions at pH 6.5. Cultivability is 
expressed as mean log CFU/mL ± standard deviation (n=4) of B. pullicaecorum. Limit of detection (LOD) is 
indicated (dashed horizontal line; ---). 
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2.4 Discussion 
In this study we assessed the intrinsic tolerance of the obligate anaerobic butyrate-
producing bacterium Butyricicoccus pullicaecorum 25-3T to the harsh conditions of the 
stomach and small intestine.  
Our results demonstrate that during acidic conditions (pH 2 and pH 3) B. pullicaecorum 
lost cultivability, but still remained viable and active. These findings indicate that 
Butyricicoccus enters a viable but noncultivable (VBNC) state in response to acid stress. 
Many other bacteria are known to enter a VBNC state when harsh environmental conditions 
are introduced such as osmotic stress, pH stress and starvation (Oliver, 2005). The VBNC 
state in B. pullicaecorum was not only induced by acid stress but also during starvation 
because there were also VBNC bacteria present in the stationary culture used as an inoculum 
during the experiments. The VBNC state is seen as a survival strategy and once the stress 
factor disappears, the bacteria resuscitate and become cultivable again (Oliver, 2005). This 
was also the case for B. pullicaecorum as the cultivability was restored during small intestinal 
simulation when the pH conditions were more optimal. The concentration of cultivable B. 
pullicaecorum at low gastric pH (2 and 3) was below the detection limit and subsequently 
increased in 2 h of small intestinal conditions to 3.1 log CFU/mL (gastric pH 2) and 3.8 log 
CFU/mL (gastric pH 3). If this increase was due to regrowing of a few cultivable cells under 
the detection limit, this would indicate a generation time of ca. 34 min in case of gastric pH 2 
and ca. 20 min in case of gastric pH 3. As the generation time of B. pullicaecorum is typically 
216 ± 14 min (Figure 1), we conclude that there was a resuscitation of VBNC cells during 
small intestine incubation. 
Bile salts and pancreatic enzymes are factors to which B. pullicaecorum is subjected 
during small intestinal conditions. This environment had no inhibitory effect on B. 
pullicaecorum because the concentration of cells did not decrease during small intestinal 
simulation. The final concentration of bile extract used in this study was 0.3 % (w/v) oxgall 
and corresponds with a concentration of 3.7 mM bile salts which is at the lower limit of the in 
vivo concentrations found in the small intestine (varies from 2 - 15 mM) (Northfield & 
McColl, 1973, Kalantzi, et al., 2006). However this concentration is used in several other 
tolerance studies with probiotics (Noh & Gilliland, 1993, Jacobsen, et al., 1999, Kheadr, et 
al., 2007) as it is considered a critical concentration to screen for bile resistant strains 
(Gilliland, et al., 1984). Bacterial bile acid tolerance is strain-specific and may not be 
generalized between species (Begley, et al., 2005). Butyrate-producing bacteria also showed a 
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difference in bile tolerance: isolates of Faecalibacterium prausnitzii showed an average 
growth inhibition of 76% and 95 % to bile salt concentrations of 0.1 % respectively 0.25 % 
(w/v) and an Enterococcus durans isolate was only able to grow in 0.05 % (w/v) bile salts 
(Raz, et al., 2007, Lopez-Siles, et al., 2012). From the presented results it can be concluded 
that B. pullicaecorum is able to withstand conditions that prevail in the small intestine. 
B. pullicaecorum was still metabolically active upon upper gastrointestinal conditions 
but there was a lower butyrate production and a shift to acetate production. This indicates that 
certain stress factors, affecting bacterial metabolism and SCFA production, are still 
prevailing. It is possible that the bile salts and pancreatic enzymes, which had not been 
removed from the culture when metabolic activity was assessed, negatively affected butyrate 
production. It was previously shown that chenodeoxycholic acid (CDC), one of the primary 
bile acids, affected glucose fermentation by Clostridium absonum. Similar to our findings, the 
presence of 0.4 mM CDC resulted in a decreased butyrate to acetate ratio (Warchol, et al., 
2003). Butyrate production by B. pullicaecorum may be restored once the microorganisms 
reach more favorable conditions of the colon (optimal substrate availability, pH and redox 
potential) and this needs future evaluation.  
In conclusion, this study showed that the butyrate-producing anaerobe Butyricicoccus 
pullicaecorum is viable and metabolically active after treatment simulating the harsh 
conditions of the upper gastrointestinal tract. However cultivability decreased in case of low 
pH and there was a shift from butyrate to acetate production after treatment with stomach and 
small intestine conditions. This is one of the first studies of an anaerobic butyrate-producing 
bacterium that assesses the intrinsic acid and bile tolerance in terms of metabolic activity. One 
of the future challenges will be to find a stable formulation for oral administration of B. 
pullicaecorum. The evaluation of the colonization efficiency and butyrate production under 
colon conditions will allow us to further evaluate the probiotic capacities of B. pullicaecorum. 
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Probiotic products for oral consumption are usually formulated as capsules containing 
freeze-dried probiotic bacteria. During their production and storage, probiotic bacteria are 
exposed to harsh conditions. Producing a stable probiotic product with oxygen sensitive 
butyrate-producing bacteria and delivering a sufficient amount of viable bacteria into the gut 
will be a challenge. As shown in chapter 2, Butyricicoccus pullicaecorum 25-3T is 
intrinsically tolerant to upper gastrointestinal conditions but loses cultivability during acid 
gastric conditions. To evaluate its future use as probiotic, more knowledge of possible 
strategies to protect this butyrate-producer from acid stress and deliver it into the gut is 
required. Therefore, the aim of this study was to develop of a stable formulation with freeze-
dried B. pullicaecorum for oral consumption. Furthermore, the protective effect of an enteric 
coating with cellulose acetate phthalate (CAP) on the cultivability and viability during gastric 
and small intestine conditions was assessed. Finally, the potential to produce butyrate during 
colon incubations in the absence and presence of colonic bacteria was evaluated. 
CAP enteric coated HPMC capsules containing freeze-dried B. pullicaecorum protected 
the bacteria from acid gastric conditions and delivered more cultivable bacteria into the colon 
as compared to uncoated capsules. Butyrate production by B. pullicaecorum during 
subsequent colon incubation was highly variable, especially in presence of a colon microbial 
community. However, CAP-enteric coated capsules resulted in higher butyrate production in 
sterile colon suspension compared to uncoated capsules. To conclude, CAP-enteric coated 
HPMC capsules are effective in delivering high amounts of viable oxygen- and acid- sensitive 
probiotic bacteria, such as B. pullicaecorum, into the gut. 
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3.1 Introduction 
Butyrate-producing bacteria are important to maintain gut health as certain species 
possess anti-inflammatory properties and butyrate serves as energy source for colonocytes 
and improves epithelial barrier function (Sokol, et al., 2008, Guilloteau, et al., 2010). 
Therefore, it has been suggested to use butyrate-producing bacteria as probiotics to restore 
homeostasis and health in gastrointestinal disorders such as colorectal cancer and 
inflammatory bowel diseases (Van Immerseel, et al., 2010, Tirandaz & Mohammadi, 2013). 
However, producing a stable probiotic product and delivering a sufficient amount of viable 
bacteria into the gut is normally a challenge as all butyrate-producers are obligate anaerobes. 
According to the FAO/WHO a probiotic is defined as, “live microorganisms that, when 
administered in adequate amounts, confer a health benefit on the host” (FAO/WHO, 2002). 
Although the adequate amount is not defined in the guideline, there is a consensus to follow 
regulatory approaches of Canada and Italy where a probiotic dose is defined as 1x109 colony 
forming units (CFU) per serving (Health Canada) or per day (Italian Ministry of Health) (Hill, 
et al., 2014). Both regulatory doses define the concentration of live bacteria in the product and 
not the amount reaching the target sites (ileum or colon). However, the French Food Safety 
Agency (AFSSA) acknowledged the importance to obtain high concentrations of probiotic 
bacteria in the different parts of the gastrointestinal tract. In their report they state: “It is often 
said that probiotic concentrations must be greater than or equal to 1x106 CFU/mL in the small 
intestine (ileum) and 1x108 CFU/g in the colon, but the scientific basis for these statements is 
relatively weak.” (AFSSA, 2005). Hence, it is important that probiotic bacteria survive the 
harsh conditions during production, storage and passage of the stomach and small intestine. 
Additionally, during production and storage of the probiotic product several environmental 
factors such as O2, nutrient and salt concentration, stage of growth, preservation method, have 
an influence on the probiotic activity and efficacy (Marco & Tachon, 2013). Probiotics for 
oral consumption are available as functional foods, such as yoghurt, or as nutraceuticals in, 
capsules, tablets and sachets (Burgain, et al., 2011).  
To protect probiotic cells from the adverse environment during production and storage 
of the probiotic product, free cells can be dehydrated by lyophilization followed by 
encapsulation. Lyophilization or freeze-drying is a commonly used technique to produce 
stable and viable probiotic cells which can be added to food carriers or capsules. However, 
during lyophilization cells are exposed to severe stress which can cause cell membrane and 
DNA damage with, as a result, loss in functionality (Meng, et al., 2008). To minimize 
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probiotic cell damage during freeze-drying, lyoprotectant agents as non-fat milk solids, 
serum, sucrose, trehalose, lactose and polymers such as dextran are used but their protective 
effect is strain specific (Morgan, et al., 2006, Peiren, et al., 2015). 
Acid-sensitive probiotics do not survive the gastric conditions. Therefore, gastro-
resistant polymers like cellulose acetate phthalate (CAP) are widely used as enteric coating to 
deliver probiotics to the intestine. CAP is insoluble at pH < 5 and becomes soluble at pH > 6, 
is approved for oral administration and safe for human ingestion (Riaz & Masud, 2011).  
Most probiotic formulations contain lactic acid bacteria such as lactobacilli or 
bifidobacteria, which are described as facultative anaerobes (Holzapfel, et al., 2001, 
Andriantsoanirina, et al., 2013). On the contrary, butyrate-producing bacteria are highly 
oxygen-sensitive and only a few products with these types of species are available on the 
market. For example, MIYA-BM and Bio-three are probiotic products which contain 
Clostridium butyricum - a spore-forming butyrate producer - as spores (MIYA-BM) or as 
lyophilized bacteria together with two other probiotic species (Bio-three) (Seki, et al., 2003, 
Tsuda, et al., 2007, Hua, et al., 2010). The advantage of using spores is that these are resistant 
to detrimental environmental conditions during storage and upper gastrointestinal passage 
(Hong, et al., 2005). However, not much is known about the actual germination of C. 
butyricum spores and the viability and activity of their vegetative cells after gastric passage. 
We previously showed that another butyrate-producer, Butyricicoccus pullicaecorum, is 
intrinsically tolerant to upper gastrointestinal conditions but loses cultivability during gastric 
conditions at pH 2 and pH 3 (Geirnaert, et al., 2014) (Chapter 2). More knowledge of possible 
strategies to deliver this non-sporulating butyrate-producer is required to evaluate its future 
use as probiotic.  
Therefore, the aim of this study was to develop of a stable formulation with freeze-dried 
B. pullicaecorum for oral consumption. Furthermore, the protective effect of a CAP-enteric 
coating on the cultivability and viability during gastric and small intestine conditions was 
assessed. Finally, the potential to produce butyrate during colon incubations in the absence 
and presence of colonic bacteria was evaluated. 
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3.2 Materials and methods 
3.2.1 Bacterial strain and capsules 
Butyricicoccus pullicaecorum 25-3T (LMG 24109T) was grown in anaerobic M2GSC 
medium at pH 6 prepared as described by (Miyazaki, et al., 1997) but with 15% (v/v) of 
clarified rumen fluid instead of 30% (v/v). After overnight incubation, two times 100 mL 
bacterial culture was centrifuged at 2900 g for 15 min at 37°C and the pellet was resuspended 
in 30 mL of lyoprotectants consisting of either 10% skim milk + 7.5% trehalose or horse 
serum + 7.5% trehalose. All manipulations were performed under anaerobic (84% N2, 8% 
CO2, 8% H2) conditions. The suspensions were freeze-dried overnight using the standard 
operation conditions with the Alpha 1-2 LDplus (Christ, Osterode Germany). Furthermore, the 
effect of the bacterial growth stage at time of freeze drying as well as the concentration at 
time of resuspension of the bacteria in the lyoprotectants was evaluated. Therefore bacteria 
were grown either 8 or 20 hours before they were centrifuged and resuspended in horse serum 
+ 7.5% trehalose while concentrating 7.7 or 30.8 times.  
Hydroxypropyl methylcellulose (HPMC) size 0 capsules were manually filled with 400 
mg lyophilized B. pullicaecorum 25-3T. Part of the HPMC capsules was coated with the 
enteric polymer cellulose acetate phthalate (CAP) and diethyl phthalate as plasticizer by SEPS 
Pharma NV (Ghent, Belgium). Capsules were stored in heat sealed aluminum bags at 2-8°C 
until further use. 
3.2.2 Simulation of gastrointestinal conditions 
Survival of B. pullicaecorum 25-3T in HPMC and enteric coated HPMC capsules during 
upper gastrointestinal conditions was monitored through batch experiments with a 2 h gastric 
phase and 4 h small intestine phase. Transit times, composition of nutritional medium and 
concentration of enzymes (pepsin, pancreatin) and bile extract were based on previous 
reported in vitro simulation studies for upper gastrointestinal tract (Jacobsen, et al., 1999, 
Oomen, et al., 2003, Verthe, et al., 2004, Marzorati, et al., 2015). Experiments were 
performed in triplicate in sterile penicillin flasks flushed with nitrogen gas to obtain anaerobic 
conditions. All manipulations were done in an anaerobic (10% CO2, 90% N2) workstation 
(GP-Campus, Jacomex, TCPS NV, Rotselaar, Belgium). At the start of each simulation, one 
capsule was added to 27 mL of sterile anaerobic gastric simulation medium at pH 2. The 
composition of the gastric simulation medium was the following (per liter): 1 g 
arabinogalactan, 2 g pectin, 1 g xylan, 3 g potato starch, 0.4 g glucose, 3 g yeast extract, 1 g 
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peptone, 4 g mucin, 0.5 g cysteine, 1g pepsin (Sigma, Bornem, Belgium). After a 2 h gastric 
incubation at 37°C under gentle shaking (100 rpm), 15 mL of pancreatic and bile fluid was 
added consisting of (per liter): 3 g pancreatin (Sigma, Bornem, Belgium), 8 g dehydrated bile 
extract (Oxgall, Difco, Bierbeek, Belgium), 12.5 g NaHCO3. The latter was added to increase 
the pH of the gastric suspension from pH 2 to pH 6.5 (small intestine pH). To assess whether 
there was a bile acid effect on cultivability and viability of B. pullicaecorum 25-3T, we 
included also small intestine simulations without adding bile extract. Flasks were incubated 
for another 4 h on a shaker (100 rpm) at 37°C. In case the capsule was not dissolved at time of 
sampling, the capsule was taken out of the simulation medium, opened and its contents 
dissolved in phosphate-buffered saline (PBS) (6.8 g KH2PO4/L, 8.8 g K2HPO4/L, 8.0 g 
NaCl/L and 1.0 g cysteine-HCl/L). 
After upper gastrointestinal incubation, the metabolic activity of B. pullicaecorum (i.e. 
butyrate production) was assessed during a subsequent incubation under colon conditions for 
another 20 h at 37°C. We supplemented 1.5 mL of each of the four different upper 
gastrointestinal suspensions (coated with and without bile acids ; uncoated with and without 
bile acids ) with 3.5 mL of colon suspension with or without colonic bacteria. As colon 
suspension we used a sample of the ascending colon compartment of the Simulator of the 
Human Intestinal Microbial Ecosystem (SHIME®), which is a dynamic in vitro model of the 
gastrointestinal tract (Molly, et al., 1993, Possemiers, et al., 2004). This colon suspension 
contained colonic bacteria and their metabolites. The colon suspension without colonic 
bacteria was prepared by removing the bacteria by centrifugation (10 min, 1500 g) and 
autoclaving the supernatant. Anaerobic conditions were maintained during sampling of the 
SHIME and preparing of the colon incubation by use of standard techniques for cultivation of 
anaerobic bacteria and Hungate tubes flushed with nitrogen gas (DSMZ). Colon incubations 
were performed in triplicate with three different SHIME samples taken from colon ascendens 
vessel on three consecutive days and, for each time, the upper gastrointestinal suspension 
without B. pullicaecorum was used as negative control. 
3.2.3 Bacterial cultivability and viability 
Cultivability of B. pullicaecorum, expressed in colony forming units (CFU), was 
determined by plating serial dilutions in anaerobic PBSS on M2GSC agar plates with the 6x6 
drop plate method (Chen, et al., 2003). M2GSC agar plates were incubated for 20h at 37°C in 
the anaerobic work station. The concentration of B. pullicaecorum (CFU/mL) was determined 
at different time points during upper gastrointestinal passage (0 h, 2 h, 4 h and 6 h).  
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Viability of B. pullicaecorum was determined by a live/dead analysis with flow 
cytometry (Accuri C6, BD Biosciences) according to Van Nevel et al. (Van Nevel, et al., 
2013). The staining procedure was adjusted to 4 µM propidium iodide and 13 min incubation 
at 37°C. In brief, samples at different time points during the upper gastrointestinal passage 
were diluted in filter-sterile PBS solution to obtain an optimal cell density (104 – 106 
cells/mL) for flow cytometry analysis. The cells were stained with a live/dead staining which 
was a combination of the two DNA binding fluorescent stains: SYBR® Green I and 
propidium iodide (PI). The former penetrates all cells and results in a green fluorescence, the 
latter penetrates only cells with a damaged cell membrane resulting in a red fluorescence. 
Based on this principle, the amount of cells with an intact cell membrane – viable cells – was 
determined in each sample. 
3.2.4 Short-Chain Fatty Acid analysis 
Butyrate in the samples taken before and after the colon simulation was extracted with 
diethyl ether and analysed using  gas chromatograph as described by (De Weirdt, et al., 
2010). The concentration of butyrate was determined in each sample and expressed as 
percentage increase compared to the negative control. 
3.2.5 Statistical analysis 
SPSS Statistics 21 software was used to perform all statistical analysis. Significance 
level was set at 0.05. Means were compared using the nonparametric Mann-Whitney U test 





3.3.1 Optimal lyophilization conditions 
Only 16.6% B. pullicaecorum bacteria survived the lyophilizing process when skim milk was 
used as lyoprotectants compared to 62% when using horse serum (data not shown). Freeze-
drying of an 8 hour old culture resulted in more cultivable cells compared to a 20 hour old 
culture (8.25 log CFU/mL vs. 7.55 log CFU/mL) and also concentration beneficially 
influenced cultivability (Table 3.1). Therefore, CAP-enteric coated HPMC capsules were 
produced with B. pullicaecorum bacteria which were harvested after 8 hours of incubation 
and up-concentrated for 30.8 times in lyoprotectant medium with horse serum before 
lyophilization.  
Table 3.1 The number of B. pullicaecorum expressed as log 10 cfu/ml surviving the freeze-drying 
process. 
 7.7 up concentration 
(log CFU/ml) 
30.8 up concentration 
(log CFU/ml) 
8h old culture 8.25 9.51 ± 0.06 
20h old culture 7.55 ± 0.11 8.45 ± 0.36 
3.3.2 Stability of freeze-dried B. pullicaecorum in CAP-enteric coated HPMC capsules 
The initial concentration of B. pullicaecorum bacteria in the capsules was 7.7 ± 0.1 log 
CFU/capsule and 10.0 ± 0.2 log of viable B. pullicaecorum bacteria/capsule. Eight months 
after production, we evaluated the cultivability and viability of freeze-dried B. pullicaecorum 
bacteria in enteric coated HPMC capsules. Plating on M2GSC agar showed a concentration of 
6.7 ± 0.7 log CFU/capsule and live-dead flow cytometer analysis showed a concentration of 
10.2 ± 0.3 log of viable B. pullicaecorum bacteria/capsule. 
3.3.3 CAP-enteric coated HPMC capsules protect B. pullicaecorum during acid 
stomach conditions  
CAP-enteric coated capsules remained intact during the 2 h stomach simulation while 
uncoated capsules opened immediately and dissolved completely within 15 min in stomach 
suspension at pH 2. Overall, concentration of viable (intact) and cultivable B. pullicaecorum 
bacteria was higher in case of enteric coated capsules compared to uncoated capsules (Figure 
3.1). After stomach simulation, the concentration of viable bacteria decreased from 10.2 ± 0.3 
to 7.4 ± 0.3 log viable cells/uncoated capsule. The acid conditions during stomach simulation 
had a higher impact on cultivability of B. pullicaecorum as there were no cultivable bacteria 
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detected in case of uncoated capsules and B. pullicaecorum levels decreased from 6.9 ± 0.7 to 
4.8 ± 0.7 log CFU in enteric coated capsules.  
 
Figure 3.1 Cultivability and viability of B. pullicaecorum during stomach (0-2h) at pH 2 followed by 
small intestine conditions (2-6 h) with addition of bile acids (A) or without bile acids (B) at pH 6.5. 
Cultivability of B. pullicaecorum in mean log CFU/capsule ± standard deviation (n=3) for CAP-
enteric coated capsules (●, full line) and uncoated capsules (●, dashed line). Viability of B. 
pullicaecorum in mean log viable cells/capsule ± standard deviation (n=3) for CAP-enteric coated 
capsules (▲, full line) and uncoated capsules (▲, dashed line). Limit of detection (LOD) is indicated 
(
….. 






- for cultivable cells). Significant 
differences between coated and uncoated samples are indicated (* for FCM and * for CFU values) 
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3.3.4 CAP-Enteric coated HPMC capsules result in more cultivable B. pullicaecorum 
bacteria after small intestine conditions 
After 2 h of stomach simulation, the pancreatic fluid with or without bile acids was 
supplemented to start the small intestine simulation at pH 6.5. The intact CAP-enteric coated 
capsules opened and dissolved completely within 30 min after the start of the small intestine 
simulation. After 4 h, cultivable and viable (intact) levels of B. pullicaecorum in enteric 
coated and uncoated capsules were determined Overall, enteric coating of the capsules 
resulted in higher levels of B. pullicaecorum bacteria at the end of upper gastrointestinal 
simulation (Figure 3.1). 
When there was only an acid stress (gastric phase) applied (i.e.pancreatic fluid without bile 
acids ) B. pullicaecorum levels in case of enteric coated capsules restored after 4 h upper 
gastrointestinal conditions to the initial levels (7.3 ± 0.3 log CFU/coated capsule and 9.9 ± 0.3 
log viable cells/coated capsule). In case of uncoated capsules, B. pullicaecorum bacteria 
became again cultivable during small intestine conditions but the concentration at the end of 
incubation (3.95 ± 0.2 log CFU/uncoated capsule) was lower compared to the initial 
concentration (7.0 ± 0.7 log CFU/uncoated capsule). The level of viable B. pullicaecorum in 
case of uncoated capsules was slightly higher after small intestine conditions (8.3 ± 0.4 log 
viable cells/uncoated capsule) compared to levels after stomach incubation (7.4 ± 0.3 log 
viable cells/uncoated capsule).  
When there was an acid stress applied followed by a bile stress (i.e pancreatic fluid with bile 
acids), there was a decrease in viable and cultivable B. pullicaecorum concentrations in case 
of both enteric coated and uncoated capsules compared to the initial concentrations. In 
contrast to the incubation without bile acids , the level of viable B. pullicaecorum in case of 
enteric coated capsules decreased during small intestine conditions to the same level as in 
uncoated capsules (8.6 ± 0.3 log viable cells/coated capsule and 8.3 ± 04 log viable 
cells/uncoated capsule). Again, the concentration of cultivable bacteria was higher in case of 
enteric coated capsules as compared to uncoated capsules at the end of small intestine 
simulation with bile acids. 
B. pullicaecorum bacteria of enteric coated capsules showed a bile acids sensitivity since 
levels of viable and cultivable bacteria were lower after incubation in small intestine 
conditions with bile acids compared to levels without bile acids (Table 3.2). In contrast, 
concentration of viable and cultivable B. pullicaecorum of uncoated capsules did not differ 
between incubation with or without bile acids.   
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Table 3.2 Effect of bile acids on viability and cultivability after stomach and small intestine conditions 
(T6). Difference in mean value between incubation with and without bile acids was evaluated (p-
value) 
 Viability (Log cells/capsule) Cultivability (Log CFU/capsule) 
 + Bile - Bile p-value + Bile - Bile p-value 
Coated 8.56 ± 0.27 9.94 ± 0.26 0.05 5.64 ± 0.09 7.33 ± 0.31 0.05 
Uncoated 8.29 ± 0.42 8.26 ± 0.47 0.82 3.72 ± 0.11 3.95 ± 0.22 0.25 
 
3.3.5 Butyrate production during subsequent colon incubation is highly variable 
After upper gastrointestinal conditions, the simulation continued under colon conditions 
to evaluate butyrate production as compared to the negative control (upper gastrointestinal 
suspension without B. pullicaecorum capsule). Since the results of the three independent 
colon incubations with different colon suspensions were highly variable, we included the 
results as separate data points instead of average values (Table 3.3). 
After incubation in intestinal suspension without colonic bacteria there was an increase 
in butyrate production in all cases. This was most clear in case of CAP enteric coated capsules 
where no bile acids  were added during small intestine incubation, the increase in butyrate 
production compared to negative control (no addition of B. pullicaecorum) ranged between 
161% and 308%. In all other cases the increase in butyrate production ranged between 2% 
and 51%.  
There were also colon incubations performed with colonic bacteria to simulate bacterial 
competition occurring in the human colon. The change in butyrate production of the colon 
microbiota in the presence of B. pullicaecorum compared to the negative control was highly 
variable as it ranged between -4% and 45%. Furthermore, there was no difference observed 
between coated and uncoated capsules.   
Table 3.3 Change in butyrate concentration (%) during colon conditions(intestinal suspension ) in the 
absence and presence of colonic bacteria. % = ((mM butyrate sample – mM butyrate negative 
control)/ mM butyrate negative control)*100 
 Without colonic bacteria With colonic bacteria 
 A B C A B C 
Coated + Bile 16 2 51 9 1 4 
Uncoated + Bile 18 10 43 7 6 2 
Coated  308 161 286 0 33 -3 




Enteric coating of HPMC capsules with CAP protected freeze-dried B. pullicaecorum 
bacteria from acidic conditions, as indicated by the viability and cultivability of the strain. 
This is in agreement with previous studies with lactobacilli sp. and bifidobacteria sp. where 
CAP was also successful in improving the survival after acid conditions (Rao, et al., 1989, 
Albertini, et al., 2010, Silva, et al., 2013).  
In chapter 2 it was described that B. pullicaecorum enters a viable but non cultivable 
(VBNC) state during acid conditions (Geirnaert, et al., 2014). During this study the VBNC 
state was confirmed for B. pullicaecorum bacteria in non-enteric coated capsules after gastric 
conditions and there followed a resuscitation during small intestine conditions. Although B. 
pullicaecorum bacteria derived from uncoated capsules were viable and cultivable after upper 
gastrointestinal conditions, the concentration of cultivable cells was higher in case of CAP 
enteric coated capsules. It is expected that cultivable bacteria will show a higher metabolic 
activity when reaching the colon as VBNC bacteria typically have low levels of metabolic 
activity (Oliver, 2005). This hypothesis was partially confirmed as there was a clear increase 
in butyrate production during incubation of B. pullicaecorum bacteria from coated capsules in 
intestinal suspension. However, when colon bacteria were present, the increase in butyrate 
production was much more variable, indicating that the substrate competition during 
fermentation was challenging for B. pullicaecorum. Of course, it is possible that butyrate 
production is not the only beneficial characteristic of B. pullicaecorum. In fact, an in vitro 
study demonstrated anti-inflammatory effects of Faecalibacterium prausnitzii, an important 
butyrate-producer in human gut, in a way independent of butyrate (Sokol, et al., 2008, 
Quévrain, et al., 2015). 
During eight months of storage the concentration of cultivable B. pullicaecorum 
bacteria decreased with one log unit but the concentration of viable bacteria remained the 
same. Both the enteric CAP coating and HPMC capsules used in this study are permeable to 
oxygen. Under the current storage conditions (ambient air, dark, 2-8°C) oxygen may have 
induced the decrease in cultivable cells. Current formulation can be improved by adding anti-
oxidants riboflavin or cystein as described by Khan and colleagues or by using capsules that 
have a lower oxygen permeability compared to HPMC capsules such as pullulan capsules 
(Kathpalia, et al., 2014, Khan, et al., 2014).  
The presence of bile acids had an inhibitory effect on B. pullicaecorum bacteria from 
CAP-enteric coated capsules, whereas B. pullicaecorum bacteria exposed to acid conditions 
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(i.e. uncoated capsules opened during gastric phase) did not show bile acids sensitivity. This 
indicates that the acid stressed bacteria were more resistant to bile acids stress which is a 
mechanism earlier described for other types of stresses and bacteria and known as multiple 
adaptive response or ‘cross-protection’ (Rodriguez-Romo & Yousef, 2005). For example, 
acid-adapted Salmonella enterica bacteria were more resistant to subsequent low acid and 
cold stresses (Xu, et al., 2008). To protect freeze-dried B. pullicaecorum bacteria from BA we 
could apply an extra coating with the bile acids adsorbent resin cholestyramine. This strategy 
showed full protection against 4% bile for a bile acids -sensitive bacterial strain (mouse 
plague vaccine strain SL3261/pAH34L) since 4200-fold more bacteria recovered from 
cholestyramine treated capsules compared to untreated capsules (Edwards, et al., 2010).  
In this study we demonstrated that a CAP-enteric coated HPMC capsule containing 
freeze-dried strictly anaerobic butyrate-producing bacteria is a stable oral formulation that 
successfully protects the bacteria from acid gastric conditions and delivers more cultivable 
bacteria into the colon as compared to uncoated capsules. Butyrate production by B. 
pullicaecorum during subsequent colon incubation was highly variable, especially in presence 
of a colon microbial community. CAP-enteric coated capsules however resulted in higher 
butyrate production in sterile colon suspension compared to uncoated capsules. To our 
knowledge this is the first study assessing the survival and activity of a capsule containing a 
non-sporulating anaerobic butyrate-producer after upper gastrointestinal conditions. These 
results may stimulate the production of probiotic formulations with other oxygen- and acid- 
sensitive future probiotic candidates.  
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Butyrate-producing bacteria are promising probiotic candidates to target microbial dysbiosis 
in gastrointestinal disorders like Inflammatory Bowel Diseases. Butyricicoccus pullicaecorum 
25-3T, a butyrate-producing clostridial cluster IV strain, is such a candidate. Little is known 
about its abundance in the colon microbiota and its butyrogenic properties. We used the M-
SHIME®, an in vitro simulator for the human intestinal microbial ecosystem, to study the 
effect of supplementing a single dose of B. pullicaecorum 25-3T on lumen- and mucus-
associated microbiota of eight individuals.  
B. pullicaecorum was more abundant in mucus-associated microbiota compared with lumen 
microbiota. Supplementation with a single dose of B. pullicaecorum 25-3T resulted in a 
temporary increase in B. pullicaecorum bacteria in lumen compartment of all individuals. In 
two cases, the responders, an increased butyrate production was observed as compared with 
the control. 16S rRNA gene amplicon sequencing revealed the microbiota of responders to be 
different as compared to non-responder microbiota. We can conclude that B. pullicaecorum 
25-3T is a mucus-associated bacterium whose potency to stimulate butyrate production is 
characterized by a large interindividual variability in terms of composition of the receiving 
microbial community. 
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4.1 Introduction 
The human gastrointestinal tract contains up to 100 trillion (1014) microbes which live 
in homeostatic symbiosis with their host and contribute to its health (Bäckhed, et al., 2005). 
Microbial dysbiosis is defined as a shift of the microbial composition and activity from a 
normal, beneficial state to one that could influence human health and contribute to disease 
(Frank, et al., 2011, Walker & Lawley, 2013). The onset and duration of several intestinal and 
systemic disorders have been linked to microbial dysbiosis (Alonso & Guarner, 2013, Walker 
& Lawley, 2013). This is also the case for Inflammatory Bowel Diseases (IBD), including 
Crohn’s Disease (CD) and Ulcerative Colitis (UC), which are characterized by a chronic, 
relapsing inflammation of the gastrointestinal tract. Microbial dysbiosis in IBD can be 
described by a loss in diversity of the dominant bacterial phyla (particularly Firmicutes), 
increased numbers of Proteobacteria and Actinobacteria and reduced numbers of anaerobic 
Firmicutes bacteria (Manichanh, et al., 2006, Frank, et al., 2007, Willing, et al., 2010, 
Lepage, et al., 2011). The reduction in Firmicutes bacteria can be explained by the observed  
loss in butyrate-producing Firmicutes bacteria from clostridial cluster IV and XIVa. Butyrate 
is important to maintain gastrointestinal health, because it serves as the main energy source 
for colonocytes, enhances epithelial barrier integrity and inhibits inflammation (Hamer, et al., 
2008). Therefore, it has been suggested to target microbial dysbiosis by supplementing 
butyrate-producing bacteria to restore homeostasis and health in IBD (Van Immerseel, et al., 
2010).  
Butyricicoccus pullicaecorum 25-3T is a butyrate-producing strain of the family 
Ruminococcaceae (clostridial cluster IV) with potential probiotic characteristics (Eeckhaut, et 
al., 2008). While the genus Butyricicoccus is decreased in abundance in stool samples of IBD 
patients, B. pullicaecorum 25-3T is able to attenuate chemically induced colitis in a rodent 
IBD model (Eeckhaut, et al., 2012). In an in vitro study, we demonstrated a good intrinsic 
tolerance of B. pullicaecorum 25-3T to stomach and small intestinal conditions which makes it 
suitable for probiotic application (Geirnaert, et al., 2014).  
To further assess the probiotic use of B. pullicaecorum 25-3T, it is important to know its 
behavior in the presence of a complex microbial community under colon conditions. In vitro 
models which simulate the human microbiota are a good tool to study the change in 
composition and metabolic activity after treatment with a probiotic, prebiotic, or other 
compound without the influence of the host (Venema & van den Abbeele, 2013). The M-
SHIME® is such a model, which simulates the mucus and lumen human intestinal microbial 
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ecosystem (Van den Abbeele, et al., 2012). The advantages of the M-SHIME® over other 
common in vitro models are the incorporation of a mucus environment, conservation of 
butyrate-producing bacteria, and maintenance of interindividual differences in composition 
and activity of the microbiota in vitro (Van den Abbeele, et al., 2013). It has previously been 
used to study the colonization of microbiota of UC patients (Vermeiren, et al., 2012, 
Vigsnaes, et al., 2013) . 
Here, we use the M-SHIME® to assess the colonization potential of B. pullicaecorum 
25-3T and to analyze its impact on butyrate production by the microbiota of different 
individuals (healthy volunteers and CD patients in remission) after B. pullicaecorum 25-3T 
administration. We applied a single dose of B. pullicaecorum 25-3T to monitor its growth or 
wash-out from the microbial communities during the 10 day follow-up period and effect of 
composition of receiving microbial community.  
4.2 Materials and methods 
4.2.1 Bacterial strain, growth conditions and preparation treatment 
Butyricicoccus pullicaecorum 25-3T (LMG 24109T) was grown in anaerobic M2GSC 
medium at pH 6 prepared as described by Miyazaki et al. (Miyazaki, et al., 1997) but with 
15% (v/v) of clarified rumen fluid instead of 30% (v/v). M2GSC agar (1.5% w/v) plates were 
incubated at 37°C in an anaerobic (10% CO2, 90% N2) workstation (GP-Campus, Jacomex, 
TCPS NV, Rotselaar, Belgium) for 20h. Before use in each experiment, a B. pullicaecorum 
colony was transferred into 10 mL of anaerobic M2GSC broth and incubated overnight at 
37°C. Subsequently, the culture was subcultured (10% v/v) once in 500 mL anaerobic 
M2GSC broth and incubated for 20h at 37°C. The B. pullicaecorum culture was concentrated 
from 500 mL to 10 mL by centrifugation (10 min, 1500 g). The supernatant was removed and 
the pellet was resuspended in 10 mL anaerobic phosphate buffered saline (PBS per L: 8.8g 
K2HPO4, 6.8g KH2PO4, 8 g NaCl, 1 g cysteine-HCl) to supplement to M-SHIME colon 
vessels. This suspension contained 9.9 log B. pullicaecorum copies/mL.  Growth requirements 
of B. pullicaecorum 25-3T are the presence of fermentable sugars and yeast extract; butyrate 
production is stimulated by exogenous acetate. All of these compounds were present in the 
suspension from M-SHIME colon vessels. 
4.2.2 Fecal bacteria from human volunteers 
Fecal bacteria of 3 healthy individuals (HV 1 – HV 3, aged 23-37) and 5 CD patients in 
remission (no  active inflammation) for more than 12 months (CD 1 – CD 5, aged 24-41) 
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were prepared to inoculate M-SHIME. The study was approved by the Ethics Committee of 
the University Hospital Ghent (permit numbers EC UZG 2006/377 & EC UZG 2012/415), 
and all volunteers received and signed an informed consent form. None of the donors had 
received antibiotics or probiotics for at least 3 months before fecal sample donation. CD 1 – 
CD 3 received maintenance treatment with azathioprine (immunosuppressive drug) and CD 4 
and CD 5 had not taken any medication since 8 months before sample donation. CD 2, CD 4, 
and CD 5 had a history of ileitis, CD 1 and CD 3 had a history of ileocolitis. 
Fecal samples were collected in airtight containers together with one AnaeroGen sachet 
(Oxoid) to maintain anoxic conditions until start of incubation. Time between fecal sample 
donation and start of incubation was maximum 2h. A 20% (m/v) fecal suspension was 
prepared by homogenizing the fecal sample with 0.1 M anaerobic phosphate buffer (per L: 
8.8g K2HPO4, 6.8g KH2PO4 and 1g C2H3O2Sna, pH 6.8) in a stomacher for 2 min. After 
removing particulate material by centrifugation (2 min. at 500g) the suspension was used as 
inoculum for incubation.  
4.2.3 Simulation of lumen- and mucus-associated microbiota – M-SHIME® 
The behavior of B. pullicaecorum was studied in the M-SHIME®, a dynamic in vitro 
model which simulates the lumen- and mucus-associated human intestinal microbial 
ecosystem (ProDigest-Ghent University, Ghent, Belgium) (Van den Abbeele, et al., 2012, 
Van den Abbeele, et al., 2013). This model consists of pH controlled, stirred (200 rpm), 
airtight, double-jacketed glass vessels kept on 37°C and under anaerobic conditions by daily 
flushing with N2 (15 min). The setup used in this study consisted of a stomach and a small 
intestine vessel and two colon vessels (control and treatment) in parallel for each studied 










Figure 4.1 Overview of experimental set-up of simulation mucosal and luminal microbiota in M-
SHIME
®
. In total 8 simulations of 17 days were performed starting with fecal microbiota of 8 different 




The system was operated and simulation media were prepared as described earlier (Van 
den Abbeele, et al., 2013). The colon vessels were inoculated at the start with 40 mL fecal 
suspension in 500 mL sterile nutritional medium (per L: 3 g yeast extract, 1 g special peptone 
(Oxoid), 4 g commercial porcin gastric mucin (Sigma) and 0.5 g L-cystein). After an initial 
static incubation of 18 h, 140 mL sterile nutritional medium at pH 2 per colon vessel was 
supplemented to the stomach vessel: this procedure was conducted three times a day. Stomach 
digest suspension was pumped into the small intestine vessel together with 60 mL pancreatic 
juice (per L: 12.5 g NaHCO3, 6 g dehydrated bile extract (Oxgall, Difco) and 0.9 g pancreatin 
(Sigma)) per colon vessel. Small intestinal digest suspension was distributed over the different 
proximal colon vessels, which contained simulated colon microbiota. To simulate colon 
conditions, the residence time in the colon vessels was 20 h and pH was controlled at pH 
6.15- 6.40 which are both in the range of in vivo observations (Metcalf, et al., 1987, Nugent, 
et al., 2001). Mucus microbiota were simulated by adding carriers coated with agar containing 
commercial available porcine gastric mucin (Sigma, Bornem, Belgium) which is a crude 
stomach extract containing mucin types MUC5AC & MUC6. The mucin type in colon mucus 
is mainly MUC2 but is not commercial available. The mucin-agar beads serve as a 
glycoprotein contact surface, which results in a better simulation of the colon microbiota. To 
each colon vessel, 60 mucin agar-covered microcosms in a polyethylene netting were added. 
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Mucin agar consisted of 5% (m/v) commercial pig gastric mucin and 1% (m/v) agar. Every 
two to three days 2/3 of the mucin agar-covered microcosms were replaced by fresh sterile 
ones under a flow of N2 to prevent disruption of anaerobic conditions. Seven days after 
inoculation, colon vessels were inoculated with 10 mL B. pullicaecorum culture (109 
bacteria/mL) (treatment vessels) or 10 mL sterile anaerobic PBSS (control vessels). After 
treatment there was a follow-up period of 10 days. Lumen samples were taken every day, 
mucin agar samples were taken every two to three days. Mucin agar-covered microcosms 
were washed with sterile PBSS to remove lumen bacteria. Mucin agar was removed from 
microcosms, homogenized and stored immediately at -20°C until further analysis.  
Previous studies showed a good reproducibility of the SHIME (Van den Abbeele, et al., 
2010). To validate the reproducibility during this study with an M-SHIME, we used the fecal 
slurry of 2 individuals (CD 5 and HV 3) to inoculate each two identical M-SHIME colon 
vessels. SCFA concentrations in lumen samples of replicates were similar during the 
experiment of 17 days and confirmed reproducibility (Supplementary Figure 4.1). 
4.2.4 Short-Chain Fatty Acid (SCFA) analysis 
The SCFA in the lumen samples of the M-SHIME® were extracted with diethyl ether 
and analyzed using a gas chromatograph as described by De Weirdt et al. (De Weirdt, et al., 
2010). The concentration in mM of acetate, propionate, butyrate, isobutyrate, valerate, 
isovalerate, caproate and isocaproate was determined in each sample. The concentration of 
acetate and butyrate was expressed as mol% which is the ratio of the concentration of acetate 
or butyrate (mM) and the total SCFA concentration (mM) multiplied by 100 in the sample. 
4.2.5 DNA extraction  
Liquid samples (1 mL fecal suspension and 1 mL lumen M-SHIME®) for total DNA 
extraction were centrifuged for 10 min at maximum speed, supernatant was removed and 
pellet was stored immediately at -20°C until further analysis.  
Total DNA was extracted from pellet of 1 mL liquid samples and 0.5 g mucin agar 
following a protocol adapted from Vilchez-Vargas et al. (Vilchez-Vargas, et al., 2013). Cells 
were lysed with 1 mL lysis buffer (100 mM Tris/HCl pH 8.0, 100 mM EDTA pH 8, 100 mM 
NaCl, 1% (m/v) polyvinylpyrrolidone and 2% (m/v) sodium docecyl sulphate) and 200 mg 
glass beads (0.11 mm, Sartorius) in a FastPrep®-96 instrument (MP Biomedicals, Santa Ana, 
USA) for two times 40 s (1600 rpm). After removing glass beads by centrifugation (5 min at 
maximum speed), DNA was extracted from supernatant following a phenol-chloroform 
extraction. DNA was precipitated with 1 volume ice-cold isopropyl alcohol and 0.1 volume 3 
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M sodium acetate for at least 1 h at -20°C. After removal of isopropyl alcohol by 
centrifugation (30 min, maximum speed) the DNA pellet was dried and resuspended in 100 
µL (fecal sample) or 30 µL (M-SHIME® sample) 1x TE (10 mM Tris, 1 mM EDTA) buffer. 
After finishing the extraction protocol, DNA samples were immediately stored at -20°C until 
further analysis.  
Quality of DNA samples was analyzed by 1% (w/v) agarose (Life technologiesTM, 
Madrid, Spain) gel electrophoresis. DNA was quantified by a fluorescence assay with the 
QuantiFluor® dsDNA kit (Promega, Madison, USA) and Glomax®-Multi+ system (Promega, 
Madison, USA). 
4.2.6 qPCR 
Total bacterial 16S rRNA gene and species specific 16S rRNA gene of B. 
pullicaecorum was quantified with qPCR in 100-fold diluted DNA extracts of fecal and M-
SHIME® samples. All qPCR assays were performed on a StepOnePlusTM Real-Time PCR 
system (Applied Biosystems, Carlsbad, CA). The amplification reactions were carried out in 
triplicate in a volume of 25 µL which contained 20 µL of in-house prepared mastermix and 5 
µL of DNA template. The in-house prepared mastermix was comprised of 1x Colorless 
GoTaq® reaction buffer (Promega), 1.5 mM MgCl2 , 200 nM dNTP mix, 200 nM of each 
forward and reverse primer, 0.625 U GoTaq® HotStart polymerase (Promega) and 0.1x 
SYBR® Green I (InvitrogenTM, provided at 10 000x, stock solutions of 20x were prepared in 
DMSO). Primers for total Bacteria (PRBA 338f and 518r) amplified a 180 bp amplicon of V3 
region of the 16S rRNA gene (Ovreas, et al., 1997). Cycling program for total bacteria was as 
follows: 3 min at 95°C followed by 40 cycles of 1 min at 95°C, 40 s at 56°C and 40 s at 72°C. 
Species specific primers were designed and synthesized by PrimerDesign Ltd. (Southampton, 
UK) and amplified a 126 bp amplicon of the 16S rRNA gene of B. pullicaecorum. Primer 
sequences of forward primer was 5’- GAGGCAGCAGTGGGGAA and reverse primer 5’- 
TCTTCAGGTACCGTCATTTGTT. Program was as follows: 3 min at 95°C followed by 40 
cycles of 1 min at 95°C, 40 s at 54.5°C and 40 s at 72°C. The annealing temperature of the 
species-specific primers of 54.5°C was determined for specificity by using target DNA and 
non-target DNA (phylogenetic related butyrate-producing bacteria) as template in parallel 
gradient PCR reactions with annealing ranging from 51°C to 56°C. Primer specificity and 
verification of presence of desired amplicon was determined by melting curve analysis and 
gel electrophoresis. Samples with a difference in melting temperature (Tm) of > 1°C compared 
to Tm of B. pullicaecorum standard were excluded. In a preliminary test, species-specific 
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primers were evaluated by analysis of B. pullicaecorum concentration in DNA of a fecal 
sample spiked with high concentration of B. pullicaecorum 25-3T. B. pullicaecorum 
concentration in spiked fecal sample and inoculum of B. pullicaecorum was the same. For 
each qPCR assay, standard curves were created by a 10-fold dilution series of DNA of 
plasmid containing the 16S rRNA gene fragment of B. pullicaecorum 25-3T. PCR efficiency 
(%) was calculated from the slope of the standard curve of each qPCR assay (10(-1/slope) – 1). 
Assays with an efficiency of 90%- 110% (slope of 3,2 – 3,58) were included in data analysis.  
4.2.7 Illumina 
The V3-V4 region of the 16S rRNA gene was amplified with primer pair 341F and 
785R, with dual multiplex identifier (MID) and adaptors as described by (Kozich, et al., 
2013). Sequencing was performed using Illumina MiSeq sequencer and sequencing kit MiSeq 
V3 to produce 300 bp pair-end reads. After de-multiplexing, fastq sequences were merged 
using FLASH (Magoč & Salzberg, 2011) software with default parameters, and successfully 
combined reads were filtered based on quality (>90% of nucleotides must have quality score 
30 or higher for every read) using Fastx tool kit (http://hannonlab.cshl.edu/fastx_toolkit/). A 
minimum of 3,000 reads was obtained for each sample included in the study. Chimeras were 
removed using UCHIME (Edgar, 2013) and each sample was standardized to 3,000 reads 
using random selection of reads. The taxonomy of reads was determined using RDP classifier 
(Wang, et al., 2007) and species-level OTUs (taxonomical bins of sequences with >97% 
similarities) was created using USEARCH pipeline (Edgar, 2013), and genus/OTU tables 
were created using Perl scripts. Detailed information on microbiome analysis results can be 
found in supplementary info. 
4.2.8 Statistical analysis 
All statistical analyses were performed in R. Bray-Curtis dissimilarity was the major 
beta-diversity measure used in this study and was calculated using package “vegan” (Dixon, 
2003); alpha diversity measures included Chao1 richness measurement, observed number of 
genera/OTUs and Shannon evenness, all calculated in “vegan” as well. “adonis” (analysis of 
dissimilarity, multidimensional ANOVA of distance matrices) was used to determine the 
variation explained by different factors tested in the study, as well as the significances. 
Constrained analysis of principal coordinates (‘capscale’, (Anderson & Willis, 2003)) was 
used to perform coordination of samples according to the variable being tested and determine 




4.3.1 Relative B. pullicaecorum abundance increased in the mucus-associated 




Colon vessels of the M-SHIME® were inoculated with fecal suspensions of one 
individual and in total eight incubations were performed with fecal suspensions of eight 
different individuals (CD1-5; HV1-3). During a period of seven days, fecal bacteria were able 
to colonize the lumen and/or mucus environment of the in vitro model. The concentration of 
bacteria (total 16S rRNA gene) and indigenous B. pullicaecorum (species-specific 16S rRNA 
gene assay) was determined by qPCR to determine the initial levels of B. pullicaecorum 
before supplementation. Fecal concentrations of total bacteria ranged from 7.9 to 10.1 log 
copies/mL with a median at 9.9 copies/mL. Lumen concentrations of total bacteria on day 7 
ranged from 7.6 to 9.0 log copies/mL with a median at 8.5 log copies/mL while mucus 
concentrations ranged from 8.9 to 9.9 log copies/g with a median of 9.4 log copies/g. Fecal 
concentrations of B. pullicaecorum ranged from 5.2 to 8.0 log copies/mL with a median at 6.6 
log copies/mL. Lumen concentrations of B. pullicaecorum varied from 4.3 to 6.2 log 
copies/mL with a median at 5.5 log copies/mL while mucus concentrations ranged from 6.3 to 
7.8 log copies/mL with a median at 7.2 log copies/mL. Overall, there was no difference in 
concentration of total and B. pullicaecorum bacteria between CD and HV microbiota in the 
M-SHIME (data not shown). The ratio of B. pullicaecorum 16S rRNA gene copies to total 
16S rRNA gene copies was used to calculate the relative abundance of B. pullicaecorum in 
the lumen- versus mucus-associated microbiome. B. pullicaecorum was relatively more 
abundant (p<0.0001) in mucus microbial community (0.85 ± 0.14 %) than the lumen 
microbial community (0.16 ± 0.03 %) (Figure 4.2.A). 
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Figure 4.2 qPCR analysis of mucosal and luminal communities in M-SHIME
®
. A) Boxplot of relative 
abundance of B. pullicaecorum (16S rRNA gene copy number B. pullicaecorum/ Total 16S rRNA 
gene) in lumen samples (n = 16) and mucus samples (n = 16) after 7 days in M-SHIME
®
 and before 
treatment. Black lines within boxplot represent median values and whiskers indicate minimum and 
maximum value. Means +/- standard error are shown above each boxplot. B) Concentration of B. 
pullicaecorum (log copies/mL or /g) in lumen and mucus samples of control (C) and treatment (T) 
vessels before treatment (B1), three days after treatment (B2) and ten days after treatment (B3). Each 
data point represents an individual M- SHIME
® 
sample. Triangles indicate HV samples and circles 
indicate CD samples. Limit of detection (LOD) is indicated by grey horizontal line. Significant 
differences are indicated by asterisks with ** = p<0.001; *** = p<0.0001  and ns = non-significant.  
4.3.2 Treatment of microbial communities with single dose B. pullicaecorum 25-3T 
On day seven, the treatment vessels were supplemented with a single dose of B. 
pullicaecorum 25-3T (on average 9 log copies/mL M-SHIME® suspension). Before 
supplementation, there was no difference in average concentrations of total bacteria and B. 
pullicaecorum in lumen and mucus samples of treated vessels compared with control vessels 
(Supplementary Figure 4.2 and Figure 4.2. B1). Three days after treatment the mean 
concentration of B. pullicaecorum was higher (p = 0.005) in lumen of treated vessels 
compared with control vessels (Figure 4.2.B2). This was not the case in mucus samples. If we 
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compare treatment with control concentrations in each individual microbial community there 
were more B. pullicaecorum in mucus samples of treated vessels compared with control in 4 
out of 8 cases (Supplementary Figure 4.3). Ten days after supplementation B. pullicaecorum 
concentration in the treated vessels was similar to those in the control vessels (Figure 4.2.B3). 
Based on 16S rRNA gene amplicon sequencing, we observed a clear increase in 
Butyricicoccus spp. sequences in treated lumen and mucus samples of CD 1, CD 4, CD 5, HV 
1, HV 2 and HV 3 three days after treatment (Supplementary tables 
Supplementary Table 4.1). Seven days after treatment, Butyricicoccus sequences were  
still higher in mucus samples of treated vessels compared to control of CD 4, CD 5, HV 1, 
HV 2 and HV 3.  




Short-Chain Fatty Acid (SCFA) concentrations were determined in lumen samples to 
evaluate the metabolic activity of the different microbial communities in the M-SHIME®. The 
mean concentrations of total SCFA during the startup period (day 3- day 7) ranged from 38.6 
(± 2.8) to 58.5 (± 4.2) mM in the 16 M-SHIME® vessels (Table 4.1). There were inter-
individual differences in the SCFA profile. The relative concentration of 
acetate/propionate/butyrate for example ranged from 50%/20%/20% (CD 3, control) to 
73%/13%/11% (HV1, control). Higher inter-individual differences were observed in case of 
branched chain fatty acids (BCFA) levels ( 1% to 10%). There was no difference in SCFA 
profiles between control and treatment vessels of each corresponding donor microbial 
community. SCFA profiles of CD microbiota were comparable to those of HV microbiota in 
the M-SHIME. On average, single dose of B. pullicaecorum 25-3T did not increase SCFA 
production during a ten days follow-up period (Table 4.1). In two cases (CD 5 and HV 1), a 
clear difference in SCFA profile was observed between treatment and control (Figure 4.3). In 
case of donor CD 5, the relative concentration of acetate started to decrease after 4 days of 
supplementation to 53% (day 14, control level 74%), whereas, the relative concentration of 
butyrate increased to a level of 18% (day 14, control level 8%). In case of donor HV 1, the 
relative concentration of acetate decreased to 53% (day 13, control level 71%) and the relative 
concentration of butyrate increased to 22% (day 13, control level 7%).  
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Figure 4.3 Relative concentration of acetate () and butyrate (●) in mol% (Ration mM acetate or 
butyrate and mM total SCFA) in lumen samples of control (---; open) and treated (—; full) vessels of 
M-SHIME
®
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Table 4.1 Total SCFA concentration (mM) during start-up (day 3 – day 7) and follow-up (day 8 – day 17) period and levels of acetic acid (AA), 
propionic acid (PA), butyric acid (BA) and branched chain fatty acids (BCFA) during start-up period. Data are means with SE. 
  Total SCFA (mM) AA/PA/BA (%) BCFA (%) 
  Start-up Follow-up Start-up Follow-up Start-up Follow-up 
CD 1 C 38.6  (2.8) 39.1 (1.4) 57/15/20 (4/0/2) 45/15/29 (1/0/0) 7 (2) 11 (0) 
 T 42.5  (3.3) 42.6 (2.3) 62/15/17 (3/0/2) 48/15/26 (1/0/0) 5 (2) 11 (0) 
CD 2 C 58.5  (4.2) 51.8 (2.5) 47/22/19 (2/1/0) 58/20/18 (2/1/0) 9 (1) 4 (1) 
 T 56.3  (3.4) 53.1 (2.3) 46/23/20 (1/1/0) 55/21/18 (1/0/0) 10 (0) 7 (1) 
CD 3 C 42.3  (2.0) 43.7 (1.1) 65/17/16 (2/0/1) 67/17/13 (1/0/0) 2 (1) 3 (1) 
 T 38.9  (2.1) 39.6 (2.1) 62/18/16 (2/0/1) 64/18/15 (1/0/0) 3 (1) 3 (1) 
CD 4 C 49.1  (5.2) 48.1 (2.3) 50/20/20 (3/2/1) 50/16/25 (2/0/1) 5 (1) 9 (1) 
 T 56.7  (1.8) 51.0 (2.7) 52/17/22 (2/1/1) 53/16/24 (2/0/1) 4 (1) 7 (1) 
CD 5 C 45.3  (2.1) 41.5 (1.4) 68/14/13 (0/1/0) 73/17/8 (1/0/0) 4 (0) 2 (0) 
 T 43.7  (1.5) 43.7 (2.0) 70/15/12 (1/0/0) 62/16/15 (2/0/1) 2 (0) 6 (1) 
HV 1 C 45.3  (3.2) 41.9 (1.8) 73/13/11 (2/0/1) 72/15/8 (1/0/0) 1 (0) 6 (1) 
 T 44.8  (2.7) 44.1 (2.1) 71/14/12 (0/0/0) 57/16/19 (2/0/1) 2 (0) 8 (0) 
HV 2 C 43.1  (1.9) 39.7 (1.3) 68/13/16 (1/0/1) 58/17/18 (2/0/1) 1 (0) 7 (1) 
 T 44.4  (3.1) 42.7 (2.2) 70/14/15 (0/0/0) 58/17/18 (2/0/1) 1 (0) 7 (1) 
HV 3 C 46.7  (2.9) 40.6 (1.9) 68/14/13 (1/0/1) 60/17/16 (1/0/1) 4 (0) 8 (1) 
 T 42.0  (1.5) 43.1 (1.5) 66/15/17 (1/1/0) 59/14/17 (2/0/1) 1 (0) 8 (0) 
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4.3.4 Non-treated M-SHIME microbiota of responders are different from 
non-responders 
To investigate the basis of differences in butyrate/acetate production, we defined groups 
of “responders” (RS, samples that responded to the inoculation and showed increase in 
butyrate production compared to controls without inoculations, i.e. CD5 and HV1) and “non-
responders” (NR, the rest). We did not find significant differences in alpha-diversity between 
NR and RS samples (Wilcox test p>0.05 in lumen and mucus). However, significant 
differences were observed between RS and NR samples from the control lumen (21.9% 
variation in genus and 15.0% variation in OTU, p=0.002 and 0.004, respectively) and mucus 
(23.6% variation of genus and 24.4% variation of OTU, both p=0.002, Figure 4.4) were 
found, indicating a distinct profile for non-treated RS microbiome.  
We analysed the major genera (those with average abundance >0.5% in the control 
samples, n=24) using Wilcox test and discovered four genera with significant differences 
(p<0.05) between the NR and RS control samples in the lumen and seven in the mucus 
(Figure 4.5). With same approach, 11 OTUs were identified in the lumen and three belong to 
genera identified above (Anaeroglobus, Lachnospiracea and Ruminococcaceae); while in 
mucus 12 OTUs were identified and five belong to genera identified above (Anaeroglobus, 
Cloacibacillus, Citrobacter, Lachnospiracea and Ruminococcaceae). 
In the NR group no significant differences were found between samples after treatment 
and control (all p >0.05), nor in the mucus samples of the RS samples; nevertheless, 
significant differences were found between the lumen samples of the treatment and control in 
the RS group (33.5% variation in genus variation, p=0.035, but not in OTU p=0.221). We 
examined the major genera (defined using same criteria as above, n=21) using Wilcox test 
between the RS control samples and treatment samples, where we found three genera 
exhibiting significant differences between control and treatment (Figure 4.6). A significant 
increase of Anaeroglobus and Sutterella was found in the RS after treatment, while 
Citrobacter decreased, and no significant changes were found in the NR (Figure 4.6). 
Analysis at OTU level identified one OTU confirming the increase Anaeroglobus in RS 





Figure 4.4 Constrained analysis of principle coordinates based on Bray-Curtis distance from genera composition, constrained by sample type (Lumen vs 
Mucus) and response (NR vs RS). CAP1 and CAP2 represent the major axes of separations calculated from ‘capscale’, and NR/RS composes the most 
primary separation of communities (CAP1) while lumen/mucus samples composes secondary separations (CAP2). 
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Figure 4.5 Boxplots of genera that are significantly different between NR and RS control lumen and mucus samples. P-values are from Wilcox test without 




Figure 4.6 Boxplots of genera that are significantly different between treatment and control lumen samples in RS, NR samples were also added to show the 
differences in response to treatment. P-values are from Wilcox test without multiple testing corrections. 
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4.4 Discussion 
The objective of this study was to assess the in vitro colonization preference of 
indigenous B. pullicaecorum from eight individuals and evaluate the colonization ability of a 
B. pullicaecorum isolate 25-3T in the lumen- and mucus-associated microbiome after a single 
supplementation. We further assessed whether a single dose of B. pullicaecorum 25-3T 
resulted in increased butyrate production by the in vitro simulated gut microbiome. Finally, 
the effect of the inoculation of B. pullicaecorum 25-3T on the microbiota composition was 
analyzed.  
B. pullicaecorum was more abundant in mucin- associated microbiota of the M-SHIME 
which is a first indication that it will also associate with the mucus layer in the gut. This 
confirms previous studies where the genus Butyricicoccus was detected in human mucus 
biopsy samples, Nava et al. reported Butyricicoccus at mean relative abundances of 1-2% 
(Frank, et al., 2011, Nava & Stappenbeck, 2011, Durbán, et al., 2012, Harrell, et al., 2012, 
Ng, et al., 2013). This corresponds with the mean relative abundance of B. pullicaecorum in 
the mucin-associated microbiota of 0.85% in our study. Association with the intestinal 
mucosa is a key characteristic in selection of novel probiotic bacteria because it is considered 
important for immune modulation, resistance to pathogen colonization, enhanced mucosal 
healing and prolonged residence time in the gut (Ouwehand, et al., 2002, Atarashi, et al., 
2011). The relative abundance of B. pullicaecorum in lumen M-SHIME samples (0.02 % - 
0.34 %) was comparable with previously reported relative abundances of Butyricicoccus spp. 
in human fecal samples (0.05% - 0.4%) (Claesson, et al., 2012, Schnorr, et al., 2014). We 
conclude that Butyricicoccus has affinity for colonizing the mucus environment.  
Supplementation with a single dose of B. pullicaecorum 25-3T resulted in a temporary 
increase in B. pullicaecorum bacteria in lumen microbiota of all individuals. With the species-
specific qPCR assay we are not able to distinguish the supplemented B. pullicaecorum 25-3T 
strain from the endogenous B. pullicaecorum strains. An overview of strategies to detect and 
develop strain-specific PCR assays for probiotics was recently published (Treven, 2015). The 
identification of strain-specific genomic markers after comparison of the whole genome of 
target strain with related genomes in public databases is a promising strategy we should 
consider in future assays.  
The difference in B. pullicaecorum concentration between treated and non-treated colon 
compartments was gone ten days after treatment. This indicates that B. pullicaecorum 25-3T is 
only able to temporarily colonize the microbiota after a single supplementation. The 
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persistence of traditional probiotics, Lactobacillus and Bifidobacterium species, is also 
generally low (Lawley & Walker, 2013). For example, in a trial with Lactobacillus reuteri, 
the supplemented strain was no longer detected in the majority of participants four days after 
stopping the treatment (Rattanaprasert, et al., 2014). To successfully colonize the gut 
microbiota, the supplemented species has to compete with the established resident microbiota 
for niches and nutrients (Lawley & Walker, 2013). The mucosal niche is thought to be 
saturable and will already contain a specific population (Gibson, et al., 2014), which makes it 
challenging for exogenous strains to colonize that niche. The colonization resistance of the 
resident microbiota towards exogenous strains can be obtained through physical exclusion 
and/or production of antimicrobials, but will also depend on interindividual differences in 
composition of the endogenous microbiome. For example, in a double blinded, placebo-
controlled crossover study with vaginal administration of two probiotic Lactobacillus strains, 
the supplemented strains were only detected in 7 of 12 cases after probiotic treatment (Bisanz, 
et al., 2014). Such studies correspond with our finding of a variable success in B. 
pullicaecorum 25-3T colonization in the eight human-derived microbiota.  
We identified two responder microbiota that displayed a clear increase in butyrate levels 
upon the single supplementation of B. pullicaecorum 25-3T, compared to non-treated 
microbiota. It is noteworthy that responder microbiota already displayed lower butyrate levels 
than non-responder microbiota prior to the treatment. Interestingly, the increase in butyrate 
levels for the responder microbiota was concomitant with a decrease in acetate levels. This 
indicates the presence of cross-feeding which is the metabolic interaction between acetate-
consuming and butyrate-producing microbiota (De Vuyst & Leroy, 2011). It is known that 
many butyrate-producing bacteria, including B. pullicaecorum, follow the butyryl-CoA: 
acetate CoA-transferase pathway (Vital, et al., 2014), which converts intra- and extra-cellular 
acetate and intracellular butyryl-CoA into butyrate and acetyl-CoA (Louis & Flint, 2009).  
Only two out of eight microbiota were responsive to B. pullicaecorum supplementation 
in terms of butyrate production. Studies with murine models reported a general increase in 
butyrate production after treatment with butyrate-producing Clostridium tyrobutyricum, 
Butyrivibrio fibrisolvens or Eubacterium limosum (Okamoto, et al., 2000, Asanuma, et al., 
2001, Ohkawara, et al., 2005, Kanauchi, et al., 2006, Possemiers, et al., 2008, Hudcovic, et 
al., 2012). However, the variability in response was not characterized as biological specimens 
from different animals were pooled. It is not clear in our study whether higher butyrate levels 
in the responder microbiota result from a direct effect – butyrate production by supplemented 
B. pullicaecorum 25-3T – or an indirect effect – stimulation of the butyrate-producing 
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community by supplemented B. pullicaecorum 25-3T. While the SHIME model has been 
successful in demonstrating increased butyrate production upon supplementation of the 
butyrate-producing E. limosum (Possemiers, et al., 2008), the impact on the endogenous 
microbiome needs further characterization. 
The original (non-treated) composition of lumen and mucus microbiota from responders 
and non-responders revealed significant differences. A couple of genera were significantly 
increased or decreased but no clear specific phylogenetic background was identified. With 
respect to the change in RS microbiota upon B. pullicaecorum treatment, Anaeroglobus and 
Sutterella were the two genera that significantly increased and the genus Citrobacter 
decreased compared to the control. Anaeroglobus is a relatively new taxon and is reported to 
have the ability to produce butyrate; the butyrate producing ability of the Sutterella genus is 
less clear (Carlier, et al., 2002). The role of  the genus Sutterella in IBD or other 
gastrointestinal disorders is not clear. There was no difference in its abundance in mucosal 
biopsies of UC or celiac disease patients compared to healthy controls (Mukhopadhya, et al., 
2011, Cheng, et al., 2013). However, in a study with pouchitis and Crohn’s disease-like 
patients, Sutterella was described as one of the genera detected less frequently among patients 
compared to non-inflamed control (Tyler, et al., 2013). Citrobacter bacteria are gram-
negative Enterobacteriaceae that can cause hospital-acquired infections in human (Baron & 
Guentzel, 1996). Non-treated responder microbiota had significant higher proportions of 
Citrobacter bacteria in the lumen and mucus and lower levels of butyrate. This indicates that 
the responders may had a dysbiosed gut microbiota. Interestingly, treatment with B. 
pullicaecorum resulted in a significant decrease of Citrobacter bacteria in responder 
microbiota. Future (co-culture) studies will have to elucidate the mechanism (e.g. substrate 
competition, inhibition) of decrease in Citrobacter bacteria after B. pullicaecorum 
supplementation. Phylogenetically different species in the human gut can perform similar 
(metabolic) functions and this leads to a functional core microbiome instead of a phylogenetic 
core microbiome (Lozupone, et al., 2012). This functional redundancy makes it difficult to 
link the observed differences in composition of the responder microbiota to its function. 
Therefore, it is not yet clear what explains the effect of the treatment with B. pullicaecorum 
25-3T on butyrate production in the two responder microbiota.  
We can conclude that B. pullicaecorum is an efficient colonizer of the mucus 
environment. While a single treatment with B. pullicaecorum 25-3T did not result in a 
persistent colonization, it was effective in increasing B. pullicaecorum levels in mucus in four 
out of eight cases up to 10 days after treatment, and in stimulating butyrate production in two 
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out of eight cases. While the original (non-treated) responder microbiota significantly differed 
from non-responder microbiota and shifts in the responder microbiome were noted upon B. 
pullicaecorum 25-3T administration, the factors for explaining the variability in response 
need to be investigated in studies with more individuals. 
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4.6 Supplementary info 
4.6.1 Supplementary microbiome analysis data 
A minimum of 3,000 reads was obtained for each sample included in the study, and the 
composition resembles that of typical human fecal/gut microbiome. An overview for the 
major phyla (Firmicutes, Bacteroidetes and Proteobacteria) and number of genera in different 
type of samples can found in Supplementary Table 4.2. We examined the relative contribution 
of different variables that could contribute to the variations of the microbiome (Bray-Curtis 
dissimilarities based on genera composition) using “adonis”. Donor individuals have the 
largest effect on the microbiome and explain 32.7% of community variations based on genus 
composition (p=0.001). Type of samples (fecal, mucus and lumen) has second largest effect 
(15.2% variation, p=0.001), and thus different samples were analyzed separately, with a focus 
on lumen and mucus samples. (Supplementary Figure 4.4). The disease status (healthy versus 
CD) has smaller yet significant effect in mucus (12.5% variation, p=0.003) and lumen (11.8% 
variation, p=0.002), but not significant in fecal samples possibly due to the small sample size 
(n=8) (Supplementary Figure 4.5). Control versus treatment and time since treatment do not 
have significant effect on the microbial composition alone or combined (all p>0.05), and no 
significance is found when they are limited to lumen or mucus samples (all p>0.05).  
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4.6.2 Supplementary figures 
 
Supplementary Figure 4.1 Reproducibility of M-SHIME. Fecal sample of two individuals was used to 
inoculate each two identical M-SHIME colon vessels. SCFA concentrations of lumen fractions for 
vessel 1 (○, 
....
) and vessel 2 (●, ---) for CD 5 (A) and HV 3 (B). 
 
Supplementary Figure 4.2 qPCR analysis of mucosal and luminal communities in M-SHIME
®
. 
Concentration of Bacteria (log copies/mL or /g) in lumen and mucus samples of control (C) and 
treatment (T) vessels before treatment, three days after treatment and ten days after treatment. Each 
data point represents an individual M- SHIME
® 
sample. Triangles indicate HV samples and circles 
indicate CD samples. Limit of detection (LOD) is indicated by grey horizontal line. Significant 
differences are indicated by asterisks with ** = p<0.001; *** = p<0.0001  and ns = non-significant.  
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Supplementary Figure 4.3 Log difference of B. pullicaecorum concentration in treatment and control 




Supplementary Figure 4.4 Constrained analysis of principle coordinates of Bray-Curtis distance based on sample type. The major separation is between 
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Supplementary Figure 4.5 Constrained analysis of principle coordinates based on Bray-Curtis distance from genera composition, constrained by sample type 
(Lumen vs Mucus) and health status (HV vs CD). CAP1 and CAP2 represent the major axes of separations calculated from ‘capscale’, and lumen/mucus 
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4.6.3 Supplementary tables 
Supplementary Table 4.1 Number of Butyricicoccus spp. sequences out of 3000 reads (16S 
rRNA gene amplicon sequencing) 
  Butyricicoccus spp. 
  3 days after treatment 7 days after treatment 
  Mucus Lumen Mucus Lumen 
CD 1 C 5 3 3 12 
 T 30 27 3 3 
CD 2 C 0 1 1 2 
 T 2 2 1 0 
CD 3 C 6 6 4 9 
 T 3 9 3 9 
CD 4 C 2 5 11 0 
 T 21 28 6 1 
CD 5 C 0 2 3 1 
 T 106 360 14 1 
HV 1 C 4 6 2 1 
 T 113 321 15 2 
HV 2 C 7 15 7 5 
 T 207 458 17 4 
HV 3 C 6 3 5 1 
 T 124 385 12 1 
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Supplementary Table 4.2 Overview of number of genera and abundances of major phyla (Firmicutes, Bacteroidetes and Proteobacteria) in different type of 
samples. 
  Number of genera Firmicutes Bacteroidetes Proteobacteria 
Sample  F M L F M L F M L F M L 
Day  0 10 14 10 14 0 10 14 10 14 0 10 14 10 14 0 10 14 10 14 
CD 1 C 
41 
39 48 50 46 
15% 
55% 53% 30% 24% 
82% 
12% 16% 50% 54% 
2% 
32% 27% 19% 18% 
 T 53 43 42 43 54% 39% 32% 21% 10% 9% 40% 49% 35% 51% 27% 29% 
CD 2 C 
52 
41 43 47 52 
12% 
34% 34% 26% 33% 
76% 
10% 10% 36% 34% 
12% 
44% 23% 23% 25% 
 T 39 40 51 44 39% 40% 25% 35% 9% 9% 60% 31% 46% 38% 15% 31% 
CD 3 C 
47 
49 40 46 45 
23% 
40% 31% 21% 18% 
76% 
17% 13% 46% 31% 
1% 
42% 40% 33% 36% 
 T 52 58 44 31 38% 31% 15% 11% 16% 12% 51% 35% 37% 35% 33% 32% 
CD 4 C 
58 
49 45 43 42 
55% 
68% 55% 70% 59% 
23% 
8% 16% 17% 31% 
14% 
24% 26% 12% 9% 
 T 49 45 41 38 53% 39% 76% 58% 8% 14% 15% 30% 38% 44% 9% 11% 
CD 5 C 
62 
46 41 53 36 
72% 
48% 30% 51% 52% 
12% 
3% 2% 19% 14% 
9% 
21% 28% 18% 28% 
 T 51 46 50 43 52% 41% 54% 72% 12% 3% 28% 8% 17% 39% 13% 12% 
HV 1 C 
52 
55 53 44 50 
65% 
57% 44% 57% 39% 
18% 
11% 22% 24% 30% 
2% 
30% 31% 19% 30% 
 T 57 44 49 42 54% 42% 54% 37% 12% 10% 21% 23% 16% 14% 8% 7% 
HV 2 C 
44 
45 45 42 40 
55% 
47% 35% 39% 33% 
32% 
12% 8% 26% 16% 
8% 
27% 34% 29% 37% 
 T 43 43 44 40 55% 41% 43% 41% 18% 8% 34% 21% 14% 17% 20% 26% 
HV 3 C 
53 
38 45 46 35 
57% 
55% 56% 34% 64% 
23% 
4% 4% 26% 2% 
5% 
21% 28% 31% 23% 
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The management of the dysbiosed gut microbiota in inflammatory bowel diseases (IBD) is 
gaining more attention as novel target to control this disease. Probiotic treatment with 
butyrate-producing bacteria has therapeutic potential since these bacteria are depleted in the 
microbial community of IBD patients and butyrate has several well-described beneficial 
effects on epithelial barrier function and overall gut health.  
However, studies that assess the effect of supplementation of these bacteria to human 
dysbiosed IBD microbiota on microbe-microbe (e.g. short-chain fatty acid production and 
colonization potential) and host-microbe interactions (e.g. epithelial barrier integrity) are rare. 
In this study, an in vitro approach was used combining microbial and epithelial models to 
study these interactions. Therefore, butyrate-producing bacteria, including three mono-species 
and one multispecies mix, were supplemented to the fecal microbial communities of ten 
Crohn’s disease (CD) patients of which five were in the active, and five in the remission 
disease state. The supplemented fecal samples were then incubated for 65 h in an in vitro 
system simulating the mucus- and lumen-associated microbiota.  
Treatment with F. prausnitzii and a mix of six butyrate-producers resulted in an increased 
butyrate production in both active and remissive CD microbiota. The mix of butyrate-
producers had the highest success rate in terms of increased butyrate production and 
colonization capacity in mucus- and lumen-associated CD microbiota. Microbial supernatant 
of microbiota treated with B. pullicaecorum 25-3T and the mix of six butyrate-producers 
improved epithelial barrier integrity in a Caco-2 cell Transwell assay during differentiation. 
The improved epithelial barrier was not only a result of a higher butyrate concentration 
indicating the presence of another microbial metabolite or bio-active compound, which 
improved intestinal epithelial barrier integrity.  
This study provides proof-of-concept data on different levels for the therapeutic potential of 
butyrate-producing bacteria in CD and supports the future preclinical development of a 
probiotic product containing butyrate-producing species. 
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5.1 Introduction 
Inflammatory bowel diseases (IBD), Crohn’s disease (CD) and ulcerative colitis (UC), 
are characterized by a chronic, relapsing intestinal inflammation. Although the etiology is not 
fully understood, research indicated that an inappropriate immune response in genetically 
susceptible individuals together with the complex interaction between environmental factors, 
intestinal microbiota and the intestinal immune system are involved in the pathogenesis of 
IBD (Danese & Fiocchi, 2006, Zhang & Li, 2014). An influx of luminal antigens into thet gut 
associated lymphoid tissue, as a result of the epithelial barrier dysfunction during 
inflammation, continuously triggers immune cells and results in a chronic inflammation 
(Torres, et al., 2013, Coskun, 2014). Therefore, current IBD therapy is typically focused on 
anti-inflammatory agents and intestinal immune modulating therapies in order to control 
inflammation, restore barrier integrity and finally obtain mucosal healing (Bernstein, 2015). 
Although different types of good and safe therapies are available (e.g. 5-Aminosalicylates, 
corticosteroids, thiopurines and anti-TNF), not all are effective to induce fast and maintain 
remission in the entire IBD population or have side effects. Therefore, researchers proceed 
with the search for novel treatment approaches. The management of the gut microbiome is 
one of the suggested future therapies complementary to the current ones to enhance the 
induction and maintenance of remission in IBD (D'Haens, et al., 2014, Haag & Siegmund, 
2014). In fact, the growing number of human gut microbiome studies demonstrate the 
abnormalities in composition and functionality of gut microbiota in IBD compared to non-
IBD controls. In general, microbial dysbiosis (i.e. imbalance of the microbiota) in IBD is 
characterized by a decrease in diversity and temporal stability of the microbiota (Ott, et al., 
2004, Martinez, et al., 2008, Walker, et al., 2011, Tong, et al., 2013). At phylogenetic level, a 
decrease in Firmicutes and an increase in Proteobacteria taxa is the most consistent outcome 
from IBD microbiome studies (Matsuoka & Kanai, 2015). The decreased abundance of 
Firmicutes bacteria belonging to the families Ruminococcaceae (also referred as clostridial 
cluster IV) and Lachnospiraceae (also referred as clostridial cluster XIVa) is one of the major 
signatures of the microbial dysbiosis in IBD, especially in (active) CD (Kostic, et al., 2014, 
Matsuoka & Kanai, 2015). Both clusters are important functional members of a human gut 
microbiota as most butyrate-producing bacteria from the human gut belong to clostridial 
cluster IV and XIVa. The depletion of these bacterial clusters in IBD can be linked to the 
observed disturbance on functional level, including a lower butyrate-producing capacity of the 
IBD microbiota (Marchesi, et al., 2007). In addition, a metagenomic and proteomics study in 
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ileal CD microbiota demonstrated an underrepresentation of genes for short-chain fatty acid 
(SCFA) production and decrease in metagenomic reads and proteins of important butyrate-
producers Faecalibacterium prausnitzii and Roseburia sp. (Morgan, et al., 2012). 
Butyrate is important to maintain gastrointestinal health and has therapeutic potential in 
IBD, because it serves as the main energy source for colonocytes, enhances epithelial barrier 
integrity and inhibits inflammation (Hamer, et al., 2008). Human studies have been 
performed in UC patients to assess the therapeutic effect of administration of pure butyrate by 
means of butyrate containing tablets or rectal enemas. However, these trials were not always 
successful due to delivery problems, short and discontinuous exposure of butyrate and poor 
compliance of the patients to the treatment (Hamer, et al., 2008). An elegant alternative could 
be the consumption of butyrate-producing bacteria to increase the in situ butyrate production 
in the gut. Therefore, it has been suggested to target microbial dysbiosis by supplementing 
butyrate-producing bacteria to restore homeostasis and health in IBD (Van Immerseel, et al., 
2010). There are a number of in vitro and in vivo studies in different cell lines and rodent 
colitis models demonstrating the therapeutic potential of butyrate and butyrate-producing 
bacteria (with focus on F. prausnitzii) for IBD ((Miquel, et al., 2013) and 1.4.5.1). However, 
there is a lack of studies assessing the effect of supplementation of butyrate-producing 
bacteria to human dysbiosed IBD microbiota on microbial interactions (e.g. SCFA production 
and colonization potential) and host-microbe interactions (e.g. epithelial barrier integrity).  
The aim of this study was to evaluate both microbe-microbe and host-microbe 
interactions in the microbial community of IBD patients after supplementation with butyrate-
producing bacteria. CD patients were selected because there is a stronger shift in their 
butyrate-producing bacterial community compared to UC and healthy individuals . Five CD 
patients with active disease and five in remission were selected to assess the difference 
between disease status in response to treatment with butyrate-producers. We compared four 
types of treatments at same concentration: three times a supplementation with a single 
butyrate-producer and supplementation with a mix of six different butyrate-producers. An in 
vitro system to simulate the lumen- and mucus-associated bacteria was used to follow up the 
response of CD microbiota to the treatment. Colonization of the supplemented butyrate-
producers and SCFA production of the microbiota were analyzed to evaluate microbe-
microbe interactions. A well established in vitro model of the intestinal epithelial barrier of 
Caco-2 cells was treated with samples derived from CD microbiota supplemented with 
butyrate-producers and used to evaluate host-microbe interactions. 
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5.2 Materials and methods 
5.2.1 Bacterial strain, growth conditions and preparation treatment 
Butyrate-producing bacteria Butyricicoccus pullicaecorum 25-3T (LMG 24109T), 
Butyricicoccus pullicaecorum 1.20 (strain isolated from human feces, kindly provided by the 
Department of Pathology, Bacteriology and Avian Diseases of Ghent University), 
Faecalibacterium prausnitzii (DSM 17677), Roseburia hominis (DSM 16839), Roseburia 
inulinivorans (DSM 16841), Anaerostipes caccae (DSM 14662) and Eubacterium hallii 
(DSM 3353) were grown in anaerobic M2GSC medium at pH 6 prepared as described by 
Miyazaki et al. (Miyazaki, et al., 1997) but with 15% (v/v) of clarified rumen fluid instead of 
30% (v/v). M2GSC agar (1.5% m/v) plates were incubated at 37°C in an anaerobic (10% 
CO2, 90% N2) workstation (GP-Campus, Jacomex, TCPS NV, Rotselaar, Belgium) for 20-40 
h. Before use in each experiment, a colony of each butyrate-producing species was transferred 
into 10 mL of anaerobic M2GSC broth and incubated overnight at 37°C. Subsequently, the 
culture was subcultured (1% v/v) once in anaerobic M2GSC broth and incubated for 20h at 
37°C. The cultures were 20 times concentrated by centrifugation (10 min, 1500 g). The 
supernatant was removed and the pellet was suspended in anaerobic nutritional medium (see 
below). Concentration of total and intact bacteria in suspension was determined by means of 
fluorescent staining (SYBR Green/ propidium iodide) and flow cytometry according to Van 
Nevel et al. (Van Nevel, et al., 2013). Staining procedure was adjusted to 4 µM propidium 
iodide and 13 min incubation at 37°C.  
5.2.2 Fecal bacteria from CD patients 
Fecal samples were obtained from 10 CD patients to use for incubation in a fed batch 
system. The study was approved by the Ethics Committee of the University Hospital Ghent 
(permit numbers EC UZG 2006/377 & EC UZG 2012/415), and all volunteers have received 
and signed an informed consent form. None of the patients had received antibiotics or 
probiotics for at least 3 months, and a colonic lavage preparation for colonoscopy at least 1 
month before fecal sample donation. Five patients were in clinical remission and five had 
active disease, determined by presence of endoscopic signs of disease activity. Patient 
metadata including age, gender, disease location, inflammatory markers and medication is 
listed in Supplementary Table 5.1. 
Fresh fecal samples were collected in airtight containers together with one AnaeroGen 
sachet (Oxoid Ltd, Hampshire, UK) to obtain anoxic conditions until start of incubation. Time 
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between fecal sample donation and start of incubation was maximum 4 h. A 20% (m/v) fecal 
suspension was prepared by homogenizing the fecal sample with 0.1 M anaerobic phosphate 
buffer (per L: 8.8g K2HPO4, 6.8g KH2PO4 and 1 g C2H3O2SNa, pH 6.8) in a stomacher for 2 
min. After removing particulate material by centrifugation (2 min. at 500 g), the suspension 
was used as inoculum for incubation.  
5.2.3 Fed batch incubations - Simulation of lumen- and mucus-associated microbiota  
Fecal microbiota were incubated for 65 h in a fed batch system for simulation of colon 
conditions and consisted of 250 mL airtight bottles flushed with N2 (5 min) and filled with 
100 mL nutritional medium and 16 mucin agar-covered microcosms in a polyethylene netting. 
Nutritional medium contained per L: yeast extract (3 g); special pepton (1 g); mucin (2 g); 
arabinogalactan (0.25 g); apple pectin (0.5 g); xylan (0.25 g); starch (1 g) and the medium 
was buffered by addition of KH2PO4 (9.53 g) and Na2HPO4.2H2O (5.34 g) (Sorensen’s 
phosphate buffer, pH 6.47). The mucin-agar beads served as a glycoprotein contact surface 
which resulted in a better simulation of the colon microbiota (Van den Abbeele, et al., 2012, 
Van den Abbeele, et al., 2013). Mucin agar consisted of 5% (w/v) commercial pig gastric 
mucin (Sigma) and 1% (w/v) agar. Bottles were incubated at 37°C in the dark and under slow 
shaking (90 rpm). Twice a day, after 18 h, 26 h, 42 h and 50 h of incubation, 40 % (v/v) of the 
bacterial suspension was replaced by sterile, anaerobic simulation suspension. Simulation 
suspension consisted of 70% (v/v) sterile nutritional medium and 30% (v/v) pancreatic 
simulation fluid (per L: 6 g dehydrated bile extract (Oxgall, Difco) and 0.9 g pancreatin 
(Sigma)). Every day, pH of the microbial suspension was measured to control proper 
functioning of the buffer, the pH ranged from pH 5,88 – 6.62 with median at pH 6.23.  
At time of start-up, fecal microbiota were supplemented to the fed-batch system at a 
final concentration of 1.5 % (w/v) and supplemented with butyrate-producing bacteria. There 
were four different treatments: B. pullicaecorum 25-3T (BP 25-3); B. pullicaecorum 1.20 (BP 
1.20), F. prausnitzii (FP) and a mix of B. pullicaecorum 25-3T, F. prausnitzii, R. hominis, R. 
inulinivorans, A. caccae and E. halli (MIX) and in parallel a control (CON) with only fecal 
microbiota. In each incubation and type of treatment the same concentration of butyrate-
producing bacteria was applied, based on flow cytometry results, of 6.74*10^8 intact 
bacteria/mL fed batch medium or 6.98*10^8 total bacteria/mL fed batch medium. The mix of 
butyrate-producing bacteria was prepared by adding the separate stock suspensions of each 
species. Each treatment and control fed batch incubation for the 10 CD patients was done in 
duplicate (technical replicate).  
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Lumen samples were taken every day, mucin agar samples were taken at the end of 
incubation (65 h). Mucin agar-covered microcosms were washed with sterile PBS to remove 
luminal bacteria. Mucin agar was then removed from the microcosms, homogenized and 
stored immediately at -20°C in aliquots of 0.250 g until further analysis. A fraction of the 
lumen samples was prepared to use for Caco-2 cell experiments (section 5.2.6). Therefore, 
samples were centrifuged for 10 min. at 1500 g, supernatant was collected and filter-sterilized 
over a 0.22 µM PVDF syringe filter (Merck Millipore, Darmstadt, Germany) and immediately 
stored at -80°C in aliquots of 1 mL. 
5.2.4 Short-Chain Fatty Acid (SCFA) analysis 
The SCFA in the luminal samples were extracted with diethyl ether and analyzed using 
a gas chromatograph as described by De Weirdt et al. (De Weirdt, et al., 2010). The 
concentration in mM of acetate, propionate, butyrate, isobutyrate, valerate, isovalerate, 
caproate and isocaproate was determined in each sample. The concentration of acetate, 
propionate, butyrate and total branched SCFA (BCFA) (sum of isobutyrate, isovalerate and 
isocaproate) was expressed as mol% which is the ratio of their concentration (mM) and the 
total SCFA concentration (mM) multiplied by 100 in the sample. 
5.2.5 Microbial community analysis 
5.2.5.1 DNA extraction  
Liquid samples (1 mL fecal suspension and 1 mL lumen) for total DNA extraction were 
centrifuged for 10 min at maximum speed, supernatant was removed and pellet was stored 
immediately at -20°C until further analysis.  
Total DNA was extracted from pellet of liquid samples and 0.250 g mucin agar using a 
phenol-chloroform extraction protocol as previously described (Geirnaert, et al., 2015). After 
finishing the extraction protocol, DNA samples were immediately stored at -20°C until 
further analysis. Quality of DNA samples was analyzed by 1% (w/v) agarose (Life 
technologiesTM, Madrid, Spain) gel electrophoresis.  
5.2.5.2 PCR-DGGE 
To analyze the microbial community in fecal, lumen and mucin-agar samples, PCR was 
performed with group specific primers with GC-clamp to amplify a 16S rRNA gene fragment 
of clostridial cluster IV and clostridial cluster XIVa. Details of primers are listed up in 
Supplementary Table 5.3. PCR amplicons were separated by denaturing gradient gel 
electrophoresis (DGGE) using an Ingeny phorU2X2 DGGE-system (Ingeny, Goes, the 
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Netherlands) for total and clostridial cluster XIVa bacteria and a D-code DGGE system (Bio-
Rad, Nazareth, Belgium) for clostridial cluster IV. Details on each DGGE protocol are 
included in Supplementary Table 5.4. After electrophoresis, gels were stained for 20 min in 
dark in a 33x SYBR Green (Life Technologies, Invitrogen) 1x Tris-Acetate-EDTA buffer 
(Applichem). Stained gels were immediately photographed on a UV-transillumination table 
with camera (OptiGo 600, Isogen) and software ProXima AQ-4 (Isogen Life Sciences, the 
Netherlands). 
Analysis of the fingerprint data was done with BioNumerics software version 5.10 
(Applied Maths, Sint-Martens-Latem, Belgium). Different lanes of each gel were defined, 
background was subtracted, gel was normalized using a home-made marker lane and bands 
were detected (intensity higher than 1%). The range-weighted richness (Rr), indication of the 
richness and genetic diversity, of each fingerprint profile was calculated as earlier described 
(Marzorati, et al., 2008). To monitor the different supplemented butyrate-producing species in 
the fingerprint profiles, band-class analysis was performed. With the BioNumerics 
bandmatching-tool band-classes were identified over all profiles for group-specific DGGE 
profiles of clostridial cluster IV and cluster XIVa as described earlier (Joossens, et al., 2011). 
Each band in the fingerprint profile was designated to a band-class based on their relative 
position within the fingerprint profile. On every gel there were lanes with PCR amplicons of 
each supplemented butyrate-producing species included. The band class of the different 
butyrate-producing species was used to identify band classes in the profile of lumen and 
mucin-agar samples. The relative intensity per band class was exported and used to compare 
relative intensities of the different butyrate-producers between non-treated and treated 
samples. A ‘colonization success’ of the supplemented butyrate-producers was defined if the 
relative intensity in the treated sample was higher as in the non-treated sample. 
5.2.5.3  qPCR 
Group specific 16S rRNA gene qPCR analysis was performed to quantify clostridial 
cluster IV and clostridial cluster XIVa species in DNA extracts of fecal (1000-fold diluted) 
and lumen and mucin-ager samples (10-fold diluted) (Supplementary Table 5.3). All qPCR 
assays were performed on a StepOnePlusTM Real-Time PCR system (Applied Biosystems, 
Carlsbad, CA). The amplification reactions were carried out in triplicate in a volume of 12.5 
µL which contained 10 µL of Power SYBR Green mastermix (Applied Biosystems, Foster 
City, CA USA) and 2.5 µL of DNA template. The cycling program for each protocol was as 
follows: 10 min at 95°C followed by 40 cycles of 15 s at 95°C, 1 min at 50°C and 30 s at 
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72°C. Primer specificity and verification of presence of desired amplicon was determined by 
melting curve analysis and gel electrophoresis. For each qPCR assay, standard curves were 
created by a 10-fold dilution series of plasmid DNA containing the 16S rRNA gene fragment 
of B. pullicaecorum 25-3T (clostridial cluster IV assay) or Roseburia sp. (clostridial cluster 
XIVa assay). PCR efficiency (%) was calculated from the slope of the standard curve of each 
qPCR assay (10(-1/slope) – 1). Assays with an efficiency of 80% - 110% (slope of 3.2 – 3.9) 
were included in data analysis.  
5.2.6 Assessment of epithelial barrier function in response to treatment BP 25-3 and 
MIX: Caco-2 cell experiments 
5.2.6.1 Cell cultures 
The Caco-2 cells were obtained from the American Type Culture Collection (ATCC® 
HTB-37™ATCC; LGC Standards, France). Cell maintenance was carried out in 25 cm2 flasks 
to which 4 mL of Dulbecco’s Modified Eagle Medium (DMEM) with high glucose (4.5 g/L) 
and GlutaMAX™ (Gibco, Langley, OK, USA) (DMEM-HG) was added (Gibco, Life 
Technologies). The DMEM was supplemented with: 10% (v/v) fetal bovine serum (FBS) 
(FBS, Greiner Bio-One, Wemmel, Belgium), 1% non-essential amino acids and 2% 
penicillin/streptomycin (Life Technologies, Merelbeke, Belgium) to obtain complete cell 
growth medium (DMEMc). Medium was replaced every two days until the cell monolayer 
had reached 80% confluence and then the cells were sub-cultured. Briefly, Caco-2 cells were 
detached with a pre-wash with PBS without calcium and magnesium (PBS, Gibco), 
trypsinized for 5-8 min with trypsin solution (2.5 g/L) and EDTA (0.2 g/L) (Gibco) and 
neutralized by the addition of supplemented medium, followed by reseeding at a density of 5 
x 104 cells/cm². The cell morphology was analyzed by phase-contrast microscopy (Motic 
AE31, VWR, Leuven, Belgium) equipped with a camera (Axiocam, Zeiss, VWR). The cells 
were incubated at 37ºC in an atmosphere with 95% relative humidity and a CO2 flow of 10% 
and the cell medium was replaced every 2 days. All the cultures were used between passages 
6 and 10. 
5.2.6.2 Toxicity assay of microbial culture supernatant from incubated CD microbiota on 
Caco-2 epithelial cells.  
To determine the potential cytotoxic effect of the supernatant samples from fed batch 
assays to Caco-2 cells and establish sub-toxic conditions to perform the tests on Transwell 
inserts (section 5.2.6.3), different dilutions of the supernatant samples were checked. 
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Supernatants of fed batch incubation of microbiota from two patients (one active and one in 
remission, CON samples) were diluted 1/5, 1/10, 1/20 and 1/40 (v/v) in DMEM-HG medium. 
In addition, different butyrate concentrations were tested (2 mM, 4 mM, 8 mM and 12 mM). 
Caco-2 cells were seeded in 96 well plates in a density of 7.5 x 104 cells/cm2. After 2 weeks 
of differentiation the cells were treated with 0.2 mL of diluted supernatant samples or butyrate 
suspension.  
Cellular activity, viability and protein content were measured after 24, 48 and 72 h of 
exposure to treatment. The effect on cellular activity was evaluated by using the MTT (3-[4,5-
dimethylthiazol-2-yl]-2,3-diphenyl tetrazolium bromide) assay (Sigma) (Laparra, et al., 
2005), a yellow solution which is converted to blue formazan crystals by mitochondrial 
activity. MTT solution was added at a final concentration of 0.5 mg/mL in cell culture 
medium, and the cell cultures were incubated at 37 °C for 2 h. Afterwards, the medium was 
removed and the formazan crystals were suspended in 200 µL DMSO, and measured using a 
spectrophotometer (Benchmark Plus Microplate Reader, Bio-Rad, Hercules, CA, USA) at a 
wavelength of 530 nm. Unspiked control cells were used throughout each assay. The SRB 
assay (sulforhodamine B) was used for the measurement of cellular protein content, as 
described earlier (Vichai & Kirtikara, 2006). Briefly, cells were fixed by adding 
trichloroacetic acid (final concentration 25%) during 1 h, washed with tap water, treated with 
SRB stain for 30 min, washed again with 1% glacial acetic acid to remove the excess of stain, 
and then suspended in Tris-buffer, and measured at 490 nm. Membrane integrity was 
monitored by the trypan blue exclusion assay (Hernandez-Zavala, et al., 2005). Cells were 
harvested using trypsin–EDTA solution (2.5 g/L trypsin, 0.2 g/L EDTA), collected and mixed 
with an equal volume of PBS containing 0.4% (w/v) trypan blue dye, and then 
microscopically counted with a Bürker counting chamber. Six replicates were made for each 
treatment for MTT, SRB and membrane permeability test. Cytotoxicity was expressed as 
percentage of value for the untreated control cells. 
5.2.6.3 Effect of microbial culture supernatant from CD microbiota treated butyrate-
producers on the epithelial barrier function.  
Cell differentiation and the posterior tests were carried out in double chamber wells 
(Corning® HTS Transwell®-24 well, pore size 0.4 µm; Costar Corp., NY, USA) equipped 
with a porous support on which the Caco-2 cells form a monolayer separating the apical and 
basal compartment. The cells were seeded at a density of 7.5 x 104 cells/cm² and maintained 
with DMEMc until confluency (1 week). The volumes used for apical and basolateral 
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compartments were 0.2 and 1 mL respectively. One week after seeding, the DMEMc was 
removed and cells were washed twice with DMEM. The supernatants of fed batch systems 
from 6 CD patients (3 in remission, 3 with active disease) treated or not with butyrate-
producing bacteria (BP 25-3 or MIX) were diluted 1/10 in DMEM-HG and adjusted to pH 7.2 
with NaOH (0.5 M). An overview with characteristics (pH, ammonium and SCFA 
concentrations) of the undiluted supernatant samples used in this assay is given in 
Supplementary Table 5.2. Next, 0.2 mL of filtered supernatant was added to the apical 
chambers. Different treatments from each patient were evaluated independently at least in 
triplicate. One mL of DMEM-HG supplemented with 20 % of FBS was added to the 
basolateral compartment. Every two days until day 19 after seeding, apical and basolateral 
medium were replaced and the cell monolayer integrity was evaluated.  
5.2.6.4 Measurement of epithelial barrier function: transepithelial electrical resistance 
(TEER) and apparent permeability (Papp) of paracellular marker 
The monolayer integrity was assessed by measuring the transepithelial electrical 
resistance (TEER) and the apparent permeability (Papp) of the paracellular transport marker 
lucifer yellow (LY, Sigma-Aldrich, Belgium). An automated TEER Measuring System with a 
REMS auto-sampler (World Precision Instruments, Germany) was used for the TEER 
measurements. During the growth period (1 week after seeding), the cell monolayer status 
was evaluated every two days. The cell monolayer was considered to be confluent when 
stable values of ≥ 350 Ω cm2 were obtained and only monolayers in this condition were used. 
Apparent permeability coefficient (Papp) of LY, which is mainly transported through the 
paracellular route, was used to assess the integrity of the epithelial cell monolayer. Papp of 
LY was measured by adding the marker (100 µM) to the apical compartment of the wells. 
After 15, 30, 60 and 120 min, 100 µL of medium was removed from the basolateral 
compartment and replaced with an equal volume of fresh medium (DMEM-HG with 20% 
FBS). LY fluorescence was measured at an excitation/emission wavelength of 485/520 nm in 
96 black plates (Greiner), using a microplate fluorescence reader (Spectramax Gemini XS 
Microplate Reader, Molecular devices, Orleans, USA). A calibration curve (0, 5, 10, 25, 50 
and 100 µM) for LY quantification was run in duplicate in each reading. The apparent 
permeability coefficients (Papp coefficients) were calculated from equation 1:  




dC/dt  is the is the slope of the cumulative concentration (µM) of LY in the 
basolateral chamber over time (sec) 
Vr  is the acceptor compartment volume (basal 1 mL) 
A is the surface area occupied by the cell monolayer (0.33 cm2) 
Co  is the initial concentration in the donor compartment (100 µM) 
Only monolayers with Papp values < 0.1 x 10-6 cm/s at the end of the assay were included in 
data-analysis.  
TEER and Papp results of epithelial cells treated with BP 25-3 and MIX samples were 
normalized to the results of cells treated with corresponding CON sample (fecal microbiota, 
but no probiotic-butyrate-producer added) and expressed as %. 
5.2.7 Statistical analysis 
All statistical analysis were performed in SPSS Statistics 21 software (SPSS Inc., 
Chigaco, USA). Significance level was set at 0.05. Normality of the data set was tested with 
the Kolmogorov-Smirnov test. In case of normality, mean values of two different groups were 
compared with an independent samples t-test. Significant differences between different 
treatment on SCFA levels were tested with One Way Anova in case of normality. 
Homogeneity of variances was tested with the Modified Levene test. Depending on the 
outcome of the Levene test, Bonferroni or Dunett T3 were used as post hoc tests to determine 
p-values. In case of non-normal distributions, differences were tested with non-parametric 
Mann-Whitney U test. 
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5.3 RESULTS 
5.3.1 Microbiota of CD patients with active versus remissive disease 
Fecal samples of five patients with active CD and five patients with quiescent CD were 
studied and incubated for 65h. Although there were no significant differences (p > 0.05) due 
to high inter-individual variability and small number of individuals, there was a tendency to a 
less diverse butyrate-producing microbiota in active CD compared to quiescent CD. For 
example, the mean Rr of both clostridial clusters in fecal samples tended to be lower in case 
active CD: for clostridial cluster IV mean Rr was 10.5 (active) and 15.2 (remission) (p = 0.31) 
and for cluster XIVa 2.5 (active) and 7.3 (remission) (p = 0.09) (Figure 5.1A). In addition, the 
average concentration of clostridial cluster XIVa was significant lower (p = 0.02) in fecal 
samples of active CD (8.1 log copies/mL fecal suspension) compared to fecal samples of 
quiescent CD (10.7 log copies/mL fecal suspension) (Figure 5.1B). After 65 h of incubation 
in fed batch system to simulate lumen- and mucus-associated bacteria, the average 
concentration of clostridial cluster XIVa in non-treated samples tended to be lower in both 
lumen (p = 0.08) and mucus (p = 0.07) samples of active CD (Figure 5.1D). 
During incubation SCFA production was monitored and results after 18h and 65h are 
shown in Figure 5.1E. Although there are no significant differences at the 0.05 level between 
active and remission samples, there was a tendency to lower butyrate levels in active CD after 
18h (p = 0.07) and 65h (p = 0.17) of incubation. Furthermore, the tall box plots in case of 




Figure 5.1 Microbial parameters of non-treated microbiota from CD patients with active disease (A; 
red) (n=5) versus in remission (R; blue) (n=5). Range-weighted richness (Rr) (panel A) and 
concentration (panel B) of clostridial cluster IV and clostridial cluster XIVa species in fecal samples. 
Concentration of clostridial cluster IV (panel C) and clostridial XIVa (panel D) of lumen and mucus 
samples of non-treated microbiota after 65h of incubation. Black lines within data plot represent mean 
values. SCFA production after 18h and 65h of incubation (panel E): Boxplot of relative SCFA 
concentration (filled boxes) and absolute SCFA concentration (downward diagonal pattern). Black 
lines within boxplot represent median values and whiskers indicate minimum and maximum value. 
Significant differences on 0.05 level between average value of active and remission samples are 
indicated with an asterisk.  
Microbiota of Crohn’s disease patients treated with butyrate-producing bacteria 
101 
5.3.2 Treatment with butyrate-producing bacteria results in higher butyrate 
production 
The fecal microbiota of CD patients were supplemented with four different types of treatment 
containing the same number, but different species of butyrate-producing bacteria. Levels of 
SCFAs acetate, propionate and butyrate were compared between treated and non-treated 
microbiota after 18h, 42h and 65h of incubation (Figure 5.2). 
Overall, there was a decrease in acetate and an increase in butyrate levels in treated 
microbiota. This was especially the case for treatments FP and MIX which resulted 18h after 
treatment in an average increase of butyrate of 11% (active CD) and 5% (quiescent CD). 
Treatment with BP resulted only in case of active CD in higher butyrate levels: 18h after 
treatment (BP 25-3 and BP 1.20) and 42h after treatment (BP 1.20). Towards the end of 
incubation, the difference in SCFA levels between non-treated and treated microbiota became 
smaller.  
The different type of treatments resulted in different changes in SCFA levels. The MIX 
resulted in significant higher butyrate levels and lower acetate levels compared to BP 
treatment in microbiota of quiescent CD (18h and 42h) and active CD (42h, BP25-3, 
butyrate). Also, treatment with FP resulted in significant higher butyrate levels compared to 
BP treatment in case of microbiota of CD in remission (42h).  
5.3.3 Mix of butyrate producers results in highest colonization success 
To assess the effect of supplementation of butyrate-producing bacteria on the mucus- and 
lumen associated microbiota of the five active and five remissive CD patients, we quantified 
and analyzed the microbial fingerprint of clostridial cluster IV and clostridial cluster XIVa by 
group-specific qPCR and DGGE. In 40% of treated samples, the concentration of clostridial 
cluster IV and XIVa was increased compared to control (Supplementary Table 5.5). Although 
these data suggest that in the other 60% nothing changed in both clostridial clusters, DGGE 
profiles of most treated samples showed differences with control profiles. We introduced the 
parameter colonization success  (explained in 5.2.5.2 page 93) to qualitatively describe the 
fingerprint data (Figure 5.3). In all ten incubations of CD microbiota, at least one of the 
butyrate-producing species of the MIX colonized the mucus- and lumen- associated 
microbiota. Treatment with F. prausnitzii resulted in a higher colonization success in lumen 
(7/10) compared to mucus (5/10). There was a difference in colonization success in mucus-
associated microbiota between both B. pullicaecorum strains, the 1.20 strain colonized in 
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seven and the 25-3 strain in four out of ten cases. Their colonization success in lumen was the 
same, three out of ten.  
Treatment with a MIX of butyrate-producing bacteria resulted in all cases in a colonization 
success. However, it was not always the same or same number or same combination of 
species which colonized the microbiota (Figure 5.4). In mucus-associated microbiota E. hallii 
was the most successful colonizer (8/10) followed by F. prausnitzii (4/10) and B. 
pullicaecorum and Roseburia spp. (3/10). In lumen-associated microbiota F. prausnitzii was 
the most successful colonizer (8/10) followed by B. pullicaecorum and Roseburia spp. (5/10). 
Overall, A. caccae had the lowest colonization success as it was only present in two mucus-
associated samples.  
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Figure 5.2 Treatment with butyrate-producers results in higher butyrate production. ∆ Mol% 
represents the difference in SCFA levels (acetate, propionate and butyrate) between samples treated 
with butyrate-producers and corresponding non-treated samples. Average values and SEM are plotted 
for samples of active CD (A) and CD in remission (R) after 18h, 42h and 65h of treatment. Treatments 
are indicated with letter codes: BP 25-3: B. pullicaecorum 25-3; BP 1-20: B. pullicaecorum 1.20; FP: 
F. prausnitzii; MIX: mix of B. pullicaecorum 25-3, F. prausnitzii, R. intestinalis, R. hominis, E. hallii, 
A. caccae. Significant differences at 0.05 level between treatments are indicated with different letter 
codes, the averages of bars with the same letter in their letter code are not significant different from 




Figure 5.3 Colonization success of different treatments in mucus and lumen samples at end of 
incubation. Based on group-specific DGGE profiles by comparing the relative intensity of the band 
classes of the different butyrate-producing species used in treatments between non-treated and treated 
samples. We defined a colonization success of the supplemented butyrate-producers if the relative 
intensity in the treated sample was higher as in the non-treated sample. In case of the MIX, there was 
a colonization success defined if the relative intensity of the band class of at least one species was 
higher in treated sample. 
 
 
Figure 5.4 Overview of the colonization successes of the different members of the MIX in mucus- and 
lumen-associated of microbiota of active CD (A, n=5) or CD in remission (R, n=5) at the end of 
incubation. For each sample the number and type (color code) of butyrate-producer which colonized 
the microbiota is given. Initials of different butyrate-producers in the MIX: FP: F. prausnitzii; BP: B. 
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5.3.4 Both B. pullicaecorum 25-3T and a mix of butyrate producers improve epithelial 
barrier integrity in a Caco-2 model 
The preliminary toxicity assay with 1/5, 1/10, 1/20 and 1/40 (v/v) dilutions of microbial 
supernatant of CD samples incubated for 42h in fed batch system showed no cytotoxicity for 
1/10 to 1/40 dilutions (Supplementary Figure 5.1). Therefore, in the following Caco-2 cell 
experiments 1/10 (v/v) dilutions of fed batch supernatant was used.   
Caco-2 epithelial cells were grown for 7 days and treated during 11 days of 
differentiation with supernatant of fed batch system with microbiota of CD patients treated or 
not (no probiotic) with a mix of butyrate-producers (MIX) or with B. pullicaecorum 25-3T  
(BP 25-3). Butyrate has a positive effect on epithelial barrier function and therefore the 
samples of the treatment MIX were included as these resulted in the highest increase in 
butyrate levels. Samples of treatment BP25-3 were included as controls for supplementation 
of butyrate-producers since BP25-3 did not resulted in higher butyrate levels. The epithelial 
barrier function was evaluated by TEER measurement and LY transport. High TEER values 
and low LY Papp values are indicative of a good tight junction formation and therefore a 
proper intestinal barrier function. 
Caco-2 monolayers treated with supernatant of microbiota of active and remissive CD 
treated with BP 25-3 and the MIX showed a higher epithelial barrier integrity compared to 
non-treated microbiota (Figure 5.5). Taken all six assays together, the effect on TEER was 
higher after 4 days of differentiation and the effect on Papp of LY was higher after 9 days of 
differentiation. The TEER% of Caco-2 cells treated with supernatants from BP 25-3 varied 
from 107 – 166% (median 129%) and from 97 – 115% (median 108%) after 4 days and 9 
days of differentiation, respectively. The TEER% of MIX varied from 113 – 176% (median 
123%) and from 91 – 120% (median 104%) after 4 days and 9 days of differentiation, 
respectively. The Papp LY% of BP 25-3 varied from 65 – 84% (median 77%) and from 25 – 
62% (median 41%) after 4 days and 9 days of differentiation, respectively. The Papp LY% of 
MIX varied from 56 – 86% (median 62%) and from 39 – 84% (median 55%) after 4 days and 
9 days of differentiation, respectively. We observed inter-individual differences in response 
to treatment but no difference in treatment response between microbiota of active and 
remissive CD (p > 0.05). There was also no difference on the 0.05 significance level between 





Figure 5.5 Epithelial barrier integrity at day 4 and day 9 of differentiation of Caco-2 epithelial cells 
treated with 1/10 (v/v) microbial supernatant of incubated CD microbiota which were treated or not 
(no probiotic) with B. pullicaecorum 25-3
T
 (BP25-3) or a mix of six butyrate-producers (MIX). Data 
of BP25-3 and MIX are expressed as % of the ‘no probiotic’. Average TEER (light grey bar plots) 
and Papp LY (dark grey bar plots) values with Stdev  are shown (n ≥3) of the six assays (3 active (A), 
3 remissive (R) patients) performed. Significant differences with corresponding ‘no probiotic’ sample 
are indicated with an asterisk. Concentration of butyrate [BA] (mM) in the microbial supernatant is 
indicated below each graph. 





To assess the epithelial barrier improving effect of butyrate, an extra Caco-2 cell assay 
was performed where supernatant samples spiked with butyrate (all spiked samples contained 
2 mM butyrate) were compared to non-spiked samples. Butyrate spiking of supernatant of 
microbiota not treated with butyrate-producing bacteria resulted in an improved epithelial 
barrier (Figure 5.6). There was a statistically significant decrease of LY transport (Papp) 
(both on day 4 and day 9) and an increase in TEER on day 4 of differentiation. In contrast, 
butyrate spiking of supernatant of microbiota treated with butyrate-producing bacteria (BP 
25-3 and MIX) did not result in an improved epithelial barrier compared to non-spiked 
samples. In addition, butyrate-spiked control supernatant resulted in a similar or even lower 






Figure 5.6 Effect of butyrate-spiking on epithelial barrier integrity. Epithelial barrier integrity at day 4 and day 9 of differentiation of Caco-2 epithelial cells 
treated with 1/10 (v/v) microbial supernatant of incubated CD microbiota which were treated or not (no probiotic) with B. pullicaecorum 25-3
T
 (BP25-3) or a 
mix of six butyrate-producers (MIX). In addition, 1/10 (v/v) diluted supernatant samples were spiked with butyrate (final concentration of 2 mM) (boxes with 
downward diagonal pattern). Data of spiked ‘no probiotic’, BP25-3 and MIX are expressed as % of the non-spiked ‘no probiotic’. Average TEER (left panel) 
and Papp LY (right panel) values with stdev are shown (n≥3) of the two assays (active patient 5, A5, and patient in remission 4, R4) . Significant differences 
with corresponding ‘no probiotic’ sample are indicated with an asterisk. 
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5.4 Discussion 
The aim of this study was to demonstrate the positive effects of supplementing 
butyrate-producing bacteria to a dysbiosed microbial community by assessing the microbe-
microbe and host-microbe interactions with in vitro models . With these results we wanted to 
support the rationale to use butyrate-producing bacteria as a probiotics to target microbial 
dysbiosis in IBD. Patients with CD (active and remission) were selected as there is a major 
shift in their butyrate-producing gut microbial community, especially in active CD. 
Supplementation of butyrate-producing bacteria to fecal microbiota of five active and 
five remissive CD patients resulted in an increase in butyrate and a decrease in acetate levels 
during the 65h incubation after treatment. The decrease in acetate can be explained by 
metabolic cross-feeding between acetate-producing and butyrate-producing bacteria. Most 
butyrate-producers rely on exogenous acetate during their butyrate-production (Louis & Flint, 
2009). Although the number of supplemented butyrate-producers in the four different 
treatments was the same, only FP and MIX resulted in an increased butyrate production 
which was still detectable at the end of incubation. This indicated that F. prausnitzii A2-165 
and one or more members of the mix of butyrate-producers were able to compete more 
successful than B. pullicaecorum with the other microbiota for the available substrates 
resulting in butyrate-production. For example, one of the carbon sources in the simulation 
medium was apple pectin and it was shown that F. prausnitzii A2-165 is able to utilize it as 
sole energy source and produce butyrate from it (Lopez-Siles, et al., 2012). The capacity of 
fermenting apple pectin is not a common feature among butyrate-producing Firmicutes 
bacteria, as so far, there are only two other pectin-utilizing Firmicutes species identified 
(Eubacterium eligens and Lachnospira pectinoschiza) (Flint, et al., 2012). In a fermentation 
study by Moens and co-workers. with fructose, oligofructose or long-chain inulin as sole 
carbon source, it was shown that B. pullicaecorum 25-3T  could only degrade and produce 
butyrate from fructose indicating it relies on other species to degrade complex substrates to 
simple sugars. In contrast, F. prausnitzii A2-165 was able to also degrade complex substrates, 
oligofructose and inulin, resulting in butyrate production (Moens, et al., 2014). As substrate 
degradation is very species specific, the use of a mix of different butyrate-producers increases 
the chance that at least one of the members is able to compete with the resident microbiota 
for available substrates resulting in colonization, growth and butyrate production.  
The supernatant of CD microbiota supplemented with B. pullicaecorum 25-3T or a mix 
of six butyrate-producers improved the epithelial barrier integrity in a Caco-2 Transwell 
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model demonstrated by increased TEER and decreased paracellular flux of LY. Of the in 
vitro models, Caco-2 cells are one of the most widely used to study the epithelial barrier 
function as these cells are able to develop tight junctions and apical-basolateral polarity 
during differentiation. Both TEER and LY-flux are measures for the monolayer integrity and 
formation and function of tight junction (TJ) structures between the Caco-2 cells. However, 
LY-flux was more sensitive as the differences in Papp LY with non-treated samples were 
much higher compared to TEER differences. Certain microbial compounds or metabolites in 
the BP25-3 and MIX treated microbial supernatants could have an influence on the epithelial 
barrier integrity. As a matter of fact, the role of microbial butyrate in improving epithelial 
barrier function is well known and demonstrated in a number of in vitro and in vivo studies 
(Plöger, et al., 2012). At concentrations at the same level of our butyrate-spiking assay (2 
mM), butyrate promoted expression of tight junction proteins and facilitated their assembly 
by acceleration of the relocation of ZO-1 and occludin which resulted in an increased barrier 
integrity (Peng, et al., 2007, Peng, et al., 2009). This explains the observed increase in 
epithelial barrier integrity after spiking of the supernatants of microbiota not treated with 
butyrate producers. However, butyrate-spiking of BP25-3 and MIX supernatants did not 
result in an additional improvement of epithelial barrier integrity. Moreover, butyrate and 
SCFA concentrations in supernatants of microbiota treated with B. pullicaecorum 25-3T were 
not higher as in supernatants of non-treated microbiota. So butyrate is not the only microbial 
factor that can explain the improved epithelial barrier.  
The epithelial barrier regulating function of B. pullicaecorum 25-3T was already 
demonstrated with its culture supernatant in two previous studies. It was also able to preserve 
epithelial barrier function and down-regulate IL-8 production in TNFα and IFNγ stimulated 
Caco-2 cells (Eeckhaut, et al., 2012). In a follow-up study it was demonstrated that in the 
mucosa of active UC patients the concentration of Butyricicoccus spp. negatively correlates 
with claudin-1 expression (Devriese, et al., 2014). Although most TJ proteins are decreased 
in IBD, TJ protein claudin-1 is increased in inflamed areas in IBD (Weber, et al., 2008). 
Therefore it is hypothesized that B. pullicaecorum 25-3T can regulated the TJ structures 
leading to a proper epithelial barrier integrity. It has been described that other microbial 
metabolites, as indole 3-propionic acid (Venkatesh, et al., 2014) or 10-Hydroxy-cis-12-
octadecenoic acid (Miyamoto, et al., 2015) are involved in epithelial barrier function 
regulation and tight junction expression. So, to elucidate the mechanism of host and B. 
pullicaecorum 25-3T interactions further studies are necessary. 
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 The used Caco-2 cell Transwell assay is the standard model for studying epithelial 
barrier function since these cells develop functional tight junction complexes in a higher 
degree compared to other monolayer of cell lines (e.g. HT29-MTX) (Lea, 2015). However, in 
most assays treatment is applied for a short period (24h) to differentiated cells after 
disruption of barrier function. In our set-up, we evaluated the effect our treatment on pre-
differentiated cells (7 days after seeding) during the development of epithelial barrier 
integrity (11 days). This is a unique approach which has, as far as we know, only been 
presented by Van Rymenant et al. (2014) (Van Rymenant, et al., 2014). They have 
demonstrated significant differences in TEER development and polyphenol metabolism and 
transport when Caco-2 cells were pretreated with a 1/20 dilution of filter sterilized SHIME 
suspension for 14 days, compared to a single exposure of non-pretreated cells.  
Physiologically, intestinal epithelial cells undergo differentiation, which transforms the cells 
from an immature (undifferentiated) state to a mature (differentiated) state. This event occurs 
as the cells move upward from the crypt to the villus region and is associated with changes on 
the expression of a variety of genes, including those involved in tight junction formation, in 
vivo and in vitro (Suzuki, 2013). During this process, the cells are in contact with bacterial 
metabolites, that can modulate the development of the cells. The exposure of Caco-2 cells to 
bacterial metabolites during the time of differentiation resembles in a more realistic way the 
complex environment at intestinal level.  
Similarly, in this study microbial supernatant and not living bacteria were applied with 
the rationale that in vivo, direct contact between intestinal epithelial cells and microbiota is 
minimal since the epithelium is covered by a mucus layer. Even in CD, not a thinner, as in 
UC patients, but a thicker mucus layer with altered structure is present (Boltin, et al., 2013). 
Also, our set-up differentiated from others by the indirect treatment effect of probiotic 
candidates. Previous published in vitro studies evaluated probiotic candidates by applying 
(culture supernatant of) the probiotic candidate to epithelial cells (Ohland & MacNaughton, 
2010). However, in this study the probiotic candidates were supplemented to microbiota of 
CD patients, allowing microbe-microbe interactions during incubation, and then this complex 
microbial supernatant was used to treat Caco-2 cells. By this, the epithelial cells were 
provided with the microbial metabolites and compounds of a more realistic probiotic 
treatment. 
Supplementation of butyrate-producing bacteria to CD microbiota resulted in changes 
in the microbial fingerprint of mucus- and lumen-associated microbiota at the end of 
incubation. Overall, a mix of six butyrate-producers had the highest colonization success rate 
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since at least one species colonized all CD microbiota and in some cases three species 
colonized. The type and combination of colonizing species varied among the different CD 
microbiota which indicates that the mix can adapt to the endogenous microbial community. 
Several other studies provided evidence that multispecies probiotic formulations are more 
effective than monostrain probiotics, e.g in preventing antibiotic-associated dysbiosis in 
children (Zoppi, et al., 2001, Timmerman, et al., 2004). However, the underlying mechanism 
of the better performance of the multispecies mix of butyrate-producers is complex and 
further research is needed to reveal possible synergistic interactions between members of the 
mix.  
To conclude, this study demonstrated that supplementation of microbiota of CD 
patients with butyrate-producing bacteria results in a higher butyrate production. A 
multispecies mix of butyrate-producers had the highest success rate in terms of increased 
butyrate production and colonization capacity in mucus- and lumen-associated CD 
microbiota. In addition, we have demonstrated the capacity of butyrate-producing bacteria 
and especially of B. pullicaecorum 25-3T to improve epithelial barrier integrity which was not 
only a consequence of their butyrate production. Future studies will have to elucidate the 
mechanisms of action and identify the metabolite/s or bio-active compound/s which improves 
intestinal epithelial barrier integrity. The capacity of improving epithelial barrier integrity 
may have important therapeutic consequences for CD as a disrupted intestinal barrier 
function is associated with development of the disease. 
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5.6 Supplementary info 
Supplementary Table 5.1 Metadata of Crohn's disease patients used for fecal sample collection. 
WBC: White Blood Cell count in fecal suspension. CRP: C-Reactive Protein levels blood. 
Label Gender Age 







A 1 F 36 Colonic 21.164 - Immunosuppressive drug 
A 2 F 57 Ileocolonic - - Mesalamine 
A 3 F 28 Ileocolonic - 15,9 Immunosuppressive drug 
A 4 
F 13 Ileocolonic 115.506 30,8 
Nutritional therapy, 
Immunosuppressive 
A 5 M 14 Pancolitic 511.341 26,9 none 
R 1 




M 20 - 4.503 - 
Immunosuppressive 
drug; Mesalamine 
R 3 F 26 Ileal 3.364 - none 
R 4 F 43 - 5.720 - none 
R 5 F 64 - 3.598 - Immunosuppressive drug 
 
Supplementary Table 5.2 Characteristics of undiluted supernatant samples of fed batch system of CD 
microbiota incubated for 42h and used in Caco-2 cell assays.( - : sample not analyzed). 












CON 6.45 310 49.4 29.4 9.2 8.5 
BP 25-3 6.27 269 40.4 23.2 7.9 7.9 
MIX 6.31 296 40.5 23.2 6.9 10.0 
A 4 
CON 6.23 191 14.3 11.0 3.2 0.0 
BP 25-3 6.31 194 18.0 12.5 5.1 0.3 
MIX 6.29 210 18.2 11.1 3.7 3.2 
A 5 
CON 6.17 342 38.2 23.0 8.3 5.4 
BP 25-3 6.19 349 42.3 26.4 8.7 5.6 
MIX 6.28 336 32.2 16.9 7.2 7.1 
R 2 
CON 6.20 329 41.1 29.6 6.5 4.7 
BP 25-3 6.08 297 42.4 30.9 7.0 4.3 
MIX 6.16 316 40.5 26.6 7.0 6.6 
R3 
CON - - 38.2 23.1 7.3 5.7 
BP 25-3 6.37 - 41.2 24.9 8.1 6.0 
MIX 6.33 - 41.4 23.8 8.0 8.0 
R4 
CON 6.13 274 38.0 22.8 8.7 6.3 
BP 25-3 6.26 292 35.0 21.6 8.2 5.1 
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Clept-f 
qPCR 
GCA CAA GCA GTG GAG T (Tm 49) 
50 239 bp 
(Matsuki, et 













AAA TGA CGG TAC CTG ACT AA 






GGGCACGGGGGG CTT TGA GTT TCA 





AAA TGA CGG TAC CTG ACT AA (Tm 51) 
50 440 bp 
(Matsuki, et 
al., 2004) g-Ccoc-r 
CTT TGA GTT TCA TTC TTG CGA A (Tm 
58) 
 
Supplementary Table 5.4 DGGE conditions.  
Protocol Polyacrylamide % (w/v) Gradient
1 
DGGE system Run conditions 
Total bacteria 8% 45% - 60% PhorU Ingeny 120 V – 60°C – 16h 
Clostridial cluster IV 8% 30% - 52,5 % DCode Bio-Rad 200 V – 60°C – 4h 
Clostridial cluster XIVa 6% 38% - 60% PhorU Ingeny 120 V – 60°C – 16h 
1 Denaturating gradient: 100% is 7 M urea and 40% formamide  
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Supplementary Table 5.5 Concentration of Clostridial cluster IV and cluster XIVa in log copies/mL in lumen- and mucus-associated microbiota of five active 
CD (A) and five remissive CD (R) samples 65h after start incubation and treatment. Values are averages of technical replicates (n=3) ± standard deviation. 
Light grey boxes indicate a higher concentration in treated sample compared to non-treated control; dark grey boxes indicate a difference with control of at 
least 1 log unit. 
 
Control 5.53 ± 0.00 4.93 ± 0.04 4.01 ± 0.47 7.04 ± 0.07 6.72 ± 0.03 6.40 ± 0.06 6.46 ± 0.00 7.43 ± 0.01 7.84 ± 0.03
BP 25-3 5.73 ± 0.04 3.88 ± 0.00 5.33 ± 0.01 4.32 ± 0.21 7.09 ± 0.00 6.95 ± 0.04 7.09 ± 0.05 6.24 ± 0.40 7.82 ± 0.09 8.08 ± 0.05
BP 1.20 5.98 ± 0.03 5.84 ± 0.04 4.97 ± 0.23 3.90 ± 0.00 6.50 ± 0.12 6.61 ± 0.03 6.82 ± 0.06 5.82 ± 0.38 7.44 ± 0.07 8.02 ± 0.01
FP 5.99 ± 0.07 4.69 ± 0.30 5.67 ± 0.02 7.02 ± 0.00 6.24 ± 0.04 8.13 ± 0.04 6.55 ± 0.02 7.26 ± 0.03 7.54 ± 0.03
MIX 5.65 ± 0.40 5.99 ± 0.00 3.91 ± 0.22 4.01 ± 0.30 6.90 ± 0.12 6.91 ± 0.01 7.41 ± 0.02 6.06 ± 0.06 7.82 ± 0.04 7.69 ± 0.06
Control 4.02 ± 0.08 4.28 ± 0.10 3.96 ± 0.46 4.21 ± 0.02 9.03 ± 0.10 8.64 ± 0.08 8.24 ± 0.09 7.29 ± 0.00 8.46 ± 0.04 8.47 ± 0.07
BP 25-3 3.51 ± 0.19 3.56 ± 0.08 4.05 ± 0.10 5.14 ± 0.07 9.14 ± 0.02 8.54 ± 0.05 8.46 ± 0.04 7.71 ± 0.04 8.55 ± 0.03 8.50 ± 0.10
BP 1.20 4.45 ± 0.12 3.79 ± 0.53 3.41 ± 0.11 5.81 ± 0.06 8.74 ± 0.02 8.33 ± 0.05 8.41 ± 0.03 7.60 ± 0.04 8.47 ± 0.04 8.49 ± 0.07
FP 4.30 ± 0.13 3.67 ± 0.12 4.80 ± 0.03 4.67 ± 0.27 9.26 ± 0.02 7.43 ± 0.09 8.32 ± 0.04 7.24 ± 0.07 8.40 ± 0.02 7.53 ± 0.08
MIX 4.02 ± 0.04 5.07 ± 0.00 3.86 ± 0.05 4.98 ± 0.08 9.19 ± 0.01 8.60 ± 0.05 8.67 ± 0.03 7.35 ± 0.02 8.43 ± 0.02 7.93 ± 0.19
Control 7.40 ± 0.09 6.60 ± 0.00 6.35 ± 0.14 6.2337 ± 0.01 6.98 ± 0.09 7.11 ± 0.08 6.78 ± 0.02 7.045 ± 0.06 8.84 ± 0.03 8.63 ± 0.05
BP 25-3 7.23 ± 0.01 6.08 ± 0.05 6.56 ± 0.02 6.70 ± 0.06 7.22 ± 0.26 7.25 ± 0.06 6.75 ± 0.00 6.815 ± 0.07 8.86 ± 0.03 8.39 ± 0.05
BP 1.20 7.18 ± 0.04 6.37 ± 0.03 6.45 ± 0.06 6.5261 ± 0.02 7.20 ± 0.03 6.57 ± 0.00 8.05 ± 0.02 7.20 ± 0.04 8.58 ± 0.05 7.59 ± 0.02
FP 7.50 ± 0.07 6.91 ± 0.06 6.93 ± 0.28 6.8166 ± 0.01 7.03 ± 0.06 7.19 ± 0.01 8.05 ± 0.02 7.475 ± 0.06 8.84 ± 0.05 8.84 ± 0.05
MIX 7.21 ± 0.03 6.94 ± 0.06 6.47 ± 0.04 6.3177 ± 0.04 7.30 ± 0.03 7.06 ± 0.04 7.97 ± 0.04 8.988 ± 0.04 8.67 ± 0.08 8.67 ± 0.08
Control 9.05 ± 0.04 8.584 ± 0.01 9.17 ± 0.00 8.8612 ± 0.04 8.52 ± 0.01 9.66 ± 0.07 9.38 ± 0.01 8.466 ± 0.05 8.99 ± 0.02 7.91 ± 0.05
BP 25-3 9.12 ± 0.05 8.156 ± 0.02 9.12 ± 0.03 9.5862 ± 0.05 8.64 ± 0.04 9.28 ± 0.14 9.30 ± 0.02 8.279 ± 0.02 8.88 ± 0.06 8.37 ± 0.05
BP 1.20 9.01 ± 0.04 8.706 ± 0.03 9.06 ± 0.01 10.54 ± 0.16 8.51 ± 0.07 8.09 ± 0.3 9.17 ± 0.04 8.362 ± 0.02 8.54 ± 0.04
FP 9.06 ± 0.06 8.458 ± 0.00 9.33 ± 0.01 10.02 ± 0.09 8.55 ± 0.01 8.51 ± 0.05 9.17 ± 0.04 8.088 ± 0.02 8.67 ± 0.02 8.67 ± 0.02
MIX 9.08 ± 0.04 9.022 ± 0.06 9.28 ± 0.02 9.2055 ± 0.04 8.63 ± 0.04 7.86 ± 0.03 8.81 ± 0.01 8.42 ± 0.01 8.42 ± 0.01
Lumen Mucus Lumen Mucus
A1 A2 A3 A4 A5
















Supplementary Figure 5.1 Cytotoxicity assay for different dilutions of microbial culture supernatant from incubated CD microbiota (A5: active patient 
5 and R5: remissive patient 5) and for butyrate. Average MTT and SRB results ± standard deviation. Cytotoxicity is expressed as percentage to the MTT- and 











6.1 Relevance of performed research 
The microbial dysbiosis is part of the pathogenesis in IBD and therefore, modulation of 
the gut microbiota in IBD with probiotics is one of the strategies to counterbalance the 
microbial dysbiosis and to support current therapy. Current probiotic formulations, 
containing predominantly lactate-producing bacteria, showed a low (UC) or no (CD) efficacy 
in inducing and maintaining remission in IBD. It is hypothesized that administration of 
butyrate-producing bacteria to IBD patients will have a higher success rate as these species 
are an important functional group within the healthy human gut. Moreover, microbial 
dysbiosis in the gut of IBD patients, and especially in CD patients, is characterized by a 
decrease in diversity and abundance of butyrate-producing bacteria. As introduced in chapter 
1, butyrate-producing bacteria can be useful as probiotics to support current IBD therapy, 
because butyrate has anti-inflammatory functions and has the capacity to strengthen the 
intestinal barrier. In addition, butyrate-producing bacteria can restore gut homeostasis by 
increased butyrate concentrations in situ, additional anti-inflammatory and barrier fortifying 
effects and modulation of microbial diversity and composition. A well-known butyrate-
producer with potential for application in IBD is Faecalibacterium prausnitzii. This species 
was found to have additional anti-inflammatory properties, independent of butyrate 
production, (Sokol, et al., 2008, Quévrain, et al., 2015).  
In this thesis, we investigated the probiotic potential of Butyricicoccus pullicaecorum 
25-3T. This is a butyrate-producing species, isolated from the caecal content of a broiler 
chicken, and is considered as an interesting candidate for probiotic therapy in intestinal 
disorders like IBD due to its anti-inflammatory and epithelial barrier strengthening 
properties. In a rodent colitis model it showed a protective effect against chemically induced 
colitis as good as - or even better as (macroscopic and histologic criteria) - treatment with F. 
prausnitzii (Eeckhaut, et al., 2012). However, before setting up clinical trials with B. 
pullicaecorum 25-3T in healthy individuals (phase I trial) and IBD patients (phase II trial), 
more knowledge of its behavior under gastrointestinal conditions is required. For this reason, 
the aim of this PhD research was to characterize and evaluate with in vitro techniques the 
potency of butyrate-producing bacteria, and especially B. pullicaecorum 25-3T, to modulate 
the microbiome and epithelial barrier in inflammatory bowel disease (see 1.5 for detailed 
objectives). The main research outcomes of each chapter are summarized in Figure 6.1 and 
their contribution to the general research topic will be discussed below. 




Figure 6.1  Overview of the main research outcomes. UGIT: upper gastrointestinal conditions. VBNC: viable but non cultivable.CAP: cellulose acetate 
phthalate. HPMC: hydroxypropyl methylcellulose. 
B. pullicaecorum 25-31 
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6.2 Future of probiotic therapy in Crohn’s disease 
6.2.1 High inter-individual variability (in response to probiotic therapy) is a challenge 
to demonstrate probiotic efficacy  
Most clinical trials with probiotics in IBD and especially in CD have failed to prove 
their efficacy. This may be due to the probiotic species used in the trial or the experimental 
set-up (dose, formulation, design of the trial, measured end points, small number of 
participants), but can also be caused by the heterogeneity of patient responses (Shanahan & 
Quigley, 2014). In chapter 4 and 5 of this work, such differences in response to 
supplementation with butyrate-producers were observed in our in vitro model. As inter-
individual differences in microbial composition and functionality are preserved in our in vitro 
model, the observed differences in response to treatment were due to the unique microbial 
composition of the different fecal inocula (Van den Abbeele, et al., 2013). Understanding the 
reasons for inter-individual responses to probiotic therapy and how to control for them, will 
be important in future development of probiotics for IBD.  
The complexity of IBD etiology and pathogenesis - as explained in chapter 1 - results 
in a very heterogeneous group of IBD patients with resulting variable responses to (microbial) 
therapies. Clinical trials that did show probiotic efficacy were performed in well-defined 
subgroups of patients. For example, efficacy of the probiotic mix VSL#3 in prevention of 
relapse was demonstrated in two randomized-placebo-controlled trials in pouch-UC patients 
which were in remission after antibiotic treatment (Gionchetti, et al., 2000, Mimura, et al., 
2004). Fecal samples of IBD patients used in this study (chapter 4 and 5) were all from CD 
patients but the location of the inflammation (ileitis or ileocolitis) and their medical therapy 
varied. Due to the low number of patients in each subgroup it was not possible to see 
differences between subgroups in response to treatment with butyrate-producers. Defining 
subgroups in future clinical trials based on IBD phenotype, genotype, type of medication and 
biomarkers for disease activity may improve the evaluation of probiotics for IBD. 
Also the complexity of the human microbiome and its variability among individuals 
can explain the inter-individual response to microbial therapy. The two responder microbiota 
(defined as increased butyrate production after treatment with B. pullicaecorum 25-3T) in the 
M-SHIME study (chapter 4) had a distinct microbial composition from non-responder 
microbiota. Furthermore, the colonization success of the different butyrate-producers used in 
chapter 5 varied between the microbiota derived from the 10 CD patients. The gut microbial 
community of an individual will determine if an exogenous probiotic species can fulfill its 
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function and may establish in the gut. In a recent study in UC patients, response to probiotic 
treatment for maintaining remission was associated with the fecal microbial composition 
before start of the treatment. Molecular fingerprint analysis of the fecal microbiota divided 
UC patients in three clusters and the response to probiotic treatment was higher in one 
specific cluster (Yoshimatsu, et al., 2015). These findings suggest that before the start of a 
probiotic intervention trial it can be of interest to screen the microbiota of participants in order 
to predict their response.  
This requires first a definition of the microbiome subgroups that have a higher 
potential to respond to probiotic treatment. In 2011 it was suggested that the human gut 
microbiome fall into three distinct ‘enterotypes’ (Arumugam, et al., 2011). The concept of 
these discrete microbiome types could be useful as a predictive tool in probiotic research. For 
example, evaluate if a certain enterotype can be associated with response to a certain probiotic 
treatment. However, most human microbiome studies were not able to detect the three 
enterotypes and support continuous gradients of dominant taxa rather than discrete 
enterotypes (Jeffery, et al., 2012). It was also demonstrated that an individual’s enterotype is 
highly variable (Knights, et al., 2014). In addition, the enterotype concept was introduced 
based on the analysis of the microbiome associated to fecal samples of healthy individuals 
and two IBD patients, each belonging to a different enterotype (Arumugam, et al., 2011). 
Follow up studies demonstrated that the enterotype concept is less effective to be used as 
disease biomarker for IBD (Knights, et al., 2014). Furthermore, due to the functional 
redundancy - as explained in chapter 1 - it is more relevant to define microbiome subgroups 
based on functionality instead of composition. In this regard, it will be important to know the 
exact mechanism of action of the probiotic to define which subgroup of patients can benefit 
from the therapy. For example, if the application of butyrate-producing bacteria with 
beneficial properties for host health will be most effective in patients with low diversity and 
abundance of butyrate-producing microbiota. 
6.2.2 No future for fecal microbial transplantation as microbial therapy in IBD? 
Fecal microbial transplantation (FMT), i.e. removal of resident gut microbiota and 
replacement with fecal microbial suspension from a healthy donor, is an effective therapy 
for recurrent Clostridium difficile infection (CDI) with a success rate of ~ 90% (van Nood, 
et al., 2013). FMT was also suggested as a microbial therapy for IBD. Up to now, 19 studies 
with IBD patients (9 cohort studies, 8 case studies, 2 randomized trials) are published in 
which the dysbiotic microbiota was replaced with one derived from a healthy individual, and 
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the aim was to achieve clinical remission (Colman & Rubin, 2014, Rossen, et al., 2015). A 
meta-analysis of these studies showed an induction of short-term clinical remission in only 
45% of the patients (Colman & Rubin, 2014). None of the published studies of FMT in IBD 
could demonstrate a long-term improvement of the disease. Moreover, we should take into 
account the publication bias as these case studies only report positive outcomes. Overall, it 
seems that FMT is not an effective microbial therapy for IBD.  
This can be explained by different factors. First of all, IBD has a more complicated 
etiology and a heterogeneous pathology as compared to CDI. In addition, the disturbed host-
microbe interactions and immune-modulating therapy will result in variable response to a 
complex microbial treatment like FMT. Second, FMT involves a supplementation with an 
uncharacterized fecal sample and there is a risk of transferring pathogens. Although FMT 
is generally well tolerated, adverse side-effects after FMT in IBD (transient fever, C-reactive 
protein elevation) were reported (Colman & Rubin, 2014) while long-term safety was not 
yet assessed. In addition, mouse studies demonstrated the possibility of transferring 
undesired disease phenotypes with FMT, such as obesity, metabolic syndrome, and fatty 
liver (Hansen & Sartor, 2015). Next, FMT in its current application is not convenient for 
patients with severe gut inflammation. The fecal suspension is delivered into the gut via a 
nasogastric tube or rectal enema. While for CDI, a single session is sufficient to cause long-
term recovery, in IBD multiple FMT sessions are needed to induce short-term clinical 
remission (Colman & Rubin, 2014). Finally, the efficacy of FMT is dependent on the 
composition and functionality of the donor sample. Donors with a higher proportion of 
Lachnospiraceae bacteria resulted in a higher success rate of FMT in IBD (Moayyedi, et al., 
2015). In addition, recipients which responded to FMT (induction of short-term clinical 
remission) had an increase in butyrate-producing bacteria post-FMT (Angelberger, et al., 
2013, Libertucci, et al., 2014, Rossen, et al., 2015). These findings support the hypothesis of 
this PhD research that butyrate-producing bacteria are promising probiotics for IBD. 
Altogether, future microbial therapy in IBD requires a safe, well-characterized, standard 
procedure with a known mechanism. These requirements can better be fulfilled by using a 
defined (mix of) probiotic species with known functionality than by using uncharacterized 
fecal samples. For example, the use of recombinant bacteria as vectors to in situ deliver 
therapeutic molecules is such a novel probiotic strategy that extents the current use of 
commensals and probiotics (Martin, et al., 2013).  Genetically modified Lactococcus lactis 
strains that secrete antibodies against the pro-inflammatory cytokine TNF-α (Vandenbroucke, 
et al., 2009) or secrete anti-inflammatory cytokine IL-10 (Steidler, et al., 2000) are studied as 
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probiotic for CD.  The latter strain showed already clinical benefit in a small clinical trial with 
10 CD patients (Braat, et al., 2006).  
6.2.3 Multi-species probiotic formulations are valuable alternatives for FMT 
A multi-species mix is more effective than mono-species probiotic for several reasons 
(Timmerman, et al., 2004, Chapman, et al., 2011): 
In order to successfully colonize the gut and be metabolically active after supplementation, 
probiotic bacteria have to compete with the resident microbiota for niches and nutrients. 
Their ability to degrade available substrate and to compete for it with the resident microbiota 
is species specific. The use of a multi-species probiotic mix would increase the chance that 
at least one species succeeds in colonizing the gut. On the one hand, a mix containing 
species with similar (metabolic) microbial functions may have a higher potential to activate 
or stimulate this microbial function in the gut. This was demonstrated in chapter 5, where 
the multi-species mix with butyrate-producers had the highest success rate in terms of 
increasing butyrate levels and colonization of the CD-derived microbiota compared to three 
mono-species treatments. On the other hand, when species of the probiotic mix possess 
different beneficial properties, the supplementation of a mix may result in a wider spectrum 
of action. For example, treatment with B. pullicaecorum 25-3T resulted in improved gut 
barrier integrity whereas treatment with the multi-species mix containing B. pullicaecorum 
25-3T resulted in both an increase in butyrate production and an improved barrier integrity 
(chapter 5). The additional effects of multi-species probiotics is also supported by studies 
showing a higher pathogen-inhibiting effect by multi-species treatments compared to their 
single-species components in equal concentrations of biomass (Chapman, et al., 2012). 
Moreover, synergistic effects within a mix of strains may lead to even higher efficacy as 
compared to mono-species probiotics. For example, mixtures containing both acetate- and 
butyrate-producing species may enhance butyrate production due to metabolic cross-feeding 
(as described in chapter 1). Synergistic effects were also observed in a mix of 17 Clostridia 
strains that stimulate the induction of colonic Treg cells. Mono-colonization of germ free 
mice with one of each of the 17 members of the mix or subsets of the 17-mix did not result 
in stimulation of Treg cells (Atarashi, et al., 2013). 
Different strategies are possible in developing a multi-species probiotic mix. First, one 
can apply a mix with species with comparable functionality (e.g. butyrate-producing bacteria) 
or a mix with species that comprises all important functions of the human microbiota. The 
latter is also known as ‘Microbial Ecosystem Therapeutics’ and was already applied as 
CHAPTER 6 
124 
alternative for FMT in CDI therapy in two patients (Petrof, et al., 2013). The use of this 
artificial microbial ecosystem was successful in inducing recovery of CDI in both cases. 
Second, prebiotics and other supplements can be added to the probiotic mix (= synbiotic) in 
order to protect the probiotics from harsh environments during formulation, storage and 
passage of the upper gastrointestinal tract and to enhance their metabolic activity in the gut. 
For example, a formulation to protect the oxygen-sensitive F. prausnitzii was developed with 
cysteine and riboflavin as antioxidants, inulin as cryoprotectant and corn starch and wheat 
bran as bulking agents (Khan, et al., 2014). Some bacteria are specialist primary degraders of 
certain substrates. For example, Ruminococcus bromii was identified as a key stone species in 
degradation of resistant starch (Ze, et al., 2012) and F. prausnitzii is able to utilize pectin 
(Lopez-Siles, et al., 2012). Addition of specific substrates to a probiotic mix containing their 
primary degraders may enhance the efficacy of the synbiotic product. 
6.2.4 B. pullicaecorum 25-3T a valuable candidate to include in a probiotic multi-
species mix for IBD 
Butyrate-producing clostridial cluster IV and cluster XIVa species are proposed as 
future probiotic strains for IBD (Van Immerseel, et al., 2010). In this thesis, we focused on 
the cluster IV species B. pullicaecorum 25-3T and investigated its potential as a probiotic in 
IBD. The abundance of the genus Butyricicoccus in human fecal samples is low compared to 
that of the major butyrate-producing genus within cluster IV, Faecalibacterium. For example, 
the relative abundance in the eight different fecal samples used in chapter 4 varied from 0.03 
to 0.77% for Butyricicoccus spp. and from 4 to 19% for Faecalibacterium spp. Nevertheless, 
low-abundance species also perform different functions that can contribute to host health 
(Arumugam, et al., 2011). The type strain, B. pullicaecorum 25-3T, has several properties, 
which makes it suitable for probiotic use. 
B. pullicaecorum 25-3T is a non-traditional probiotic species as it has a non-human 
origin, it is not present in fermented foods for human consumption (like lactic acid bacteria) 
and it is the first strain of the genus Butyricicoccus proposed for probiotic use. Therefore, it is 
important to determine its safety status before administrating it to humans. From standard oral 
toxicity tests in rats and analysis of its complete genome it could be concluded that B. 
pullicaecorum 25-3T is a non-pathogenic strain as there were no induction of adverse effects 
and no virulence factors present (Steppe, et al., 2014). During a placebo-controlled cross-over 
randomized intervention study, a daily intake of B. pullicaecorum 25-3T - by oral intake of 
capsules developed in chapter 3 - for four weeks was well tolerated in 30 healthy individuals 
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and did not induce adverse effects (Boesmans, et al., 2015). However, Steppe et al. 
discovered antimicrobial resistance genes against fluoroquinolones, vancomycin, tetracycline 
and beta-lactam antibiotics in the genome of B. pullicaecorum 25-3T. Minimum inhibitory 
concentration assays demonstrated that B. pullicaecorum 25-3T is susceptible to low 
concentrations of these antibiotics but is resistant to kanamycin, gentamicin, erythromycin 
and streptomycin. Antibiotic resistance or presence of resistance genes were also detected in 
common used probiotic Lactobacillus and Bifidobacterium species (Gueimonde, et al., 2013) 
and in F. prausnitzii isolates (Foditsch, et al., 2014). Future studies should assess the in vivo 
risk of antibiotic resistance transfer by B. pullicaecorum. Overall, we can conclude that B. 
pullicaecorum 25-3T is safe for human consumption. 
In chapter 2 we demonstrated that B. pullicaecorum 25-3T is intrinsically tolerant to the 
harsh conditions of the stomach and small intestine. In response to low pH conditions (pH 2 
and pH 3) B. pullicaecorum 25-3T enters the so-called VBNC state and resuscitate fast after 
removal of the pH stress. Moreover, a CAP enteric coated HPMC capsule was successful in 
protecting freeze-dried B. pullicaecorum 25-3T bacteria from pH stress (chapter 3). Studies 
describing the tolerance of (probiotic formulations containing) other butyrate-producing 
bacteria at low pH conditions (pH 2-3) followed by small intestine conditions (0.3% bile 
salts), are – to our knowledge – non-existent. Separate tolerance assays were performed for F. 
prausnitzii isolates to mild acidic conditions and to bile salts and resulted in an average 
growth inhibition of 60% at pH 5.75 and 95 % in presence of 0.25% (w/v) bile salts (Lopez-
Siles, et al., 2012). The recent development of a stable formulation of F. prausnitzii by Khan 
and colleagues (Khan, et al., 2014) together with the knowledge of chapter 3 and 4 may 
enhance the future development of an efficient probiotic formulation with butyrate-producing 
species like F. prausnitzii and B. pullicaecorum.  
Although B. pullicaecorum 25-3T is a strict anaerobe, it may be able to survive 
moderate oxygen concentrations in its environment in presence of riboflavin, with a similar 
mechanism to that previously described for F. prausnitzii. Khan et al. demonstrated that F. 
prausnitzii protects itself from an oxidative environment through molecular oxygen reduction 
via an extracellular electron shuttle (Khan, et al., 2012). F. prausnitzii reduces riboflavin (RF) 
to dihydroriboflavin (RFH2) which in its turn reduces O2 to H2O. In our recent study we could 
demonstrate that B. pullicaecorum 25-3T is also able to reduce RF, but with a much slower 
kinetics than F. prausnitzii A2-165 (k cat,RF = (8.1 ± 0.8) x 10
3 s-1 for B. pullicaecorum 
compared to k cat,RF = (5.3 ± 1.3) x 10
5 s-1 for F. prausnitzii) (Prévoteau, et al., 2015). The 
ability of F. prausnitzii and B. pullicaecorum to handle moderate oxygen concentrations 
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enhances their potential to colonize the microaerophilic mucus layer in the gut. In addition, 
this mechanism can be used to increase the number of viable cells in their probiotic 
formulation by adding riboflavin or other redox mediators (Khan, et al., 2014). 
Overall, B. pullicaecorum 25-3T can survive different stress conditions (acid, bile and 
oxygen). In chapter two and three we demonstrated the VBNC state as a survival mechanism. 
However, it is possible that B. pullicaecorum uses other strategies to cope with harsh 
environmental conditions. Steppe et al. sequenced and annotated the genome of both B. 
pullicaecorum strains (25-3T and 1.20) (Steppe, et al., 2014). Sporulation genes in both 
genomes were detected such as the sporulator master regulator Spo0A and other genes 
responsible for different steps of the sporulation process (Galperin, et al., 2012, Steppe, 
2015). In theory it is possible that B. pullicaecorum sporulates to survive harsh environmental 
conditions. However, it is not known yet if the sporulation genes are active or how to induce 
sporulation in B. pullicaecorum. 
Despite their high butyrate production potential in monoculture incubations, the 
butyrogenic capacity of B. pullicaecorum 25-3T in presence of a colon microbial community 
was low and highly variable (chapter 3 – 5). The metabolic end product of a species depends 
on its environmental conditions and interactions with the rest of the community (Fischbach & 
Sonnenburg, 2011). Hence, it is possible that B. pullicaecorum was less efficient in competing 
with the other colon bacteria for the available substrates for its butyrate-production or that it 
switched its metabolism to acetate production as seen after upper gastrointestinal conditions 
in chapter 2. Further studies will have to elucidate the exact contribution of B. pullicaecorum 
to butyrate production by the colon microbiota and how it could be stimulated. This first 
requires the development of an analytical tool to monitor the butyrate production of B. 
pullicaecorum within a microbial community. A possibility can be the quantification of the 
expression of its butyryl-CoA: acetate CoA transferase gene. 
Butyricicoccus bacteria have the affinity to colonize the colonic mucus environment. 
Mucus-colonizing (butyrate-producing) bacteria and their metabolites may have a higher 
impact on host health and physiology due to their closer contact with the gut epithelium. 
Butyricococcus spp. were detected in human colon biopsy samples at mean relative 
abundances of 1-2% (Nava & Stappenbeck, 2011). Concordantly, B. pullicaecorum bacteria 
were more dominant in the mucin-associated microbiota of our M-SHIME model compared 
to the luminal microbiota (chapter 4). Other butyrate-producing genera of both clostridial 
cluster IV (Faecalibacterium) and cluster XIVa (Roseburia and Anaerostipes) have also been 
detected in human colon biopsies (Nava & Stappenbeck, 2011). In addition, previous M-
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SHIME studies detected more butyrate-producers, in particular cluster XIVa species, in 
mucin-associated microbiota compared to lumen microbiota (Vermeiren, et al., 2012, Van 
den Abbeele, et al., 2013, Vigsnaes, et al., 2013).  
B. pullicaecorum 25-3T has the capacity to improve the epithelial barrier integrity. 
Previously, this was demonstrated in an in vitro model of the gut epithelium (Eeckhaut, et al., 
2012) with the supernatant of a B pullicaecorum monoculture. In this study, this effect was 
also demonstrated in vitro with the supernatants of CD microbiota that had been 
supplemented with B. pullicaecorum 25-3T (Chapter 5). Our results indicated that the 
improved barrier integrity was independent from the levels of butyrate in the microbial 
supernatant. Future studies will have to confirm this observation in vivo, and further in vitro 
studies are needed to elucidate the underlying mechanism. Improvement of epithelial barrier 
integrity is also described for other probiotic species (Lactobacillus spp., Bifidobacterium 
spp., E. coli Nissle) and the butyrate-producer F. prausnitzii (Andrade, et al., Bermudez-
Brito, et al., 2012, Laval, et al., 2014). This probiotic characteristic is important in the light of 
IBD-therapy as a disturbed epithelial barrier function is associated with the onset of the 
chronic disease. 
6.3  In vitro studies are essential in the preclinical phase to evaluate a 
probiotic therapy 
Evaluation of a probiotic candidate prior to clinical intervention trials is normally done 
with a combination of in vitro and in vivo (animal) experiments (Papadimitriou, et al., 2015). 
Each approach has its own strengths and limitations but both are necessary as they deliver 
complimentary results. In vivo studies are needed to confirm the mechanisms revealed in in 
vitro experiments. Likewise, in vitro technologies are needed to understand and evaluate in 
vivo observations. During this research we used in vitro models for gastrointestinal processes 
to study butyrate-producing bacteria and evaluate their usefulness as probiotics for IBD. 
6.3.1 Prediction of probiotic viability after stomach and small intestine passage 
For screening of different candidates and development of probiotic formulations, in 
vitro simulations are useful to evaluate the survival of probiotics from the harsh conditions of 
the stomach and small intestine. In this PhD research, the intrinsic tolerance of B. 
pullicaecorum 25-3T (chapter 2) and the protective effect of an enteric coating (chapter 3) 
under these conditions were assessed in static batch incubations with a 2h gastric phase and a 
4h small intestine phase. Static batch tests are simple, reproducible and make it possible to 
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screen a high number of products in a relatively short period of time. Parameters of the in 
vitro simulation (pH, enzyme and bile concentration and transit times) were based on the 
available reports of in vivo observations. However, these parameters vary among individuals 
and depend on external factors (e.g. diet, medication, etc…). In vivo stomach pH is dynamic 
(low under fasted state and high under fed state) and depends on the buffering capacity of the 
food (Kalantzi, et al., 2006). In vivo enzyme and bile concentrations vary along the small 
intestine (high in duodenum, low in ileum) and depend on nutritional status (fed or fasted) 
(Versantvoort & Rompelberg, 2004).  
In this PhD, stomach pH was fixed at pH 2 and enzyme and bile concentrations of the 
small intestine simulation were fixed at an intermediate in vivo concentration. These can be 
considered as a ‘worst case’ scenario, so it is expected that in vivo B. pullicaecorum survival 
will be higher as the observed in vitro survival.  
A more realistic but complex simulation of the survival can be performed using 
dynamic digestion models like an adapted SHIME set-up (Marzorati, et al., 2015) or the TNO 
Gastro-Intestinal Model (TIM-1) (Minekus, et al., 1995), which includes dynamic change of 
pH, gradual secretion of digestive fluids, absorption of water and nutrients and peristaltic 
movements. Although the dynamic digestion models are more realistic, static digestion 
simulations remain important in food and probiotic research. Recently, a group of 
international experts has proposed a consensus, standard protocol for static digestion 
simulation (Minekus, et al., 2014). The implementation of this standard protocol in future 
probiotic research will make it possible to compare probiotic survival data among different 
studies. 
6.3.2 Assessment of interaction with complex colon microbiota 
After passage through the stomach, duodenum and jejunum, probiotics reach the ileum 
and colon where they interact with the endogenous microbial community and take part in the 
microbial metabolism. In vitro models of the colon microbial community are useful to assess 
the effect of probiotic treatment on the endogenous microbial community and its metabolism, 
and to evaluate the colonization and functional potential of the probiotic species. Although 
these in vitro models lack a host response (immune system and metabolite absorption) they 
are operated to mimic the physiological conditions of the colon and are well suited for 
mechanistic studies (Marzorati, et al., 2014). They offer the possibility to control and vary 
different parameters (pH, substrate composition, transit time), to take samples at regular time 
points without cessation of the experiment and to collect reproducible functional microbial 
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data. In the SHIME-model, screening of microbial communities derived from different 
individuals makes it possible to assess the responders/non-responders ratio to a specific 
probiotic treatment (Van den Abbeele, et al., 2010, Van den Abbeele, et al., 2013). 
There is a range of different in vitro models available to simulate the colon microbial 
processes, going from static batch set-ups and semi-continuous fed-batch systems to complex 
multi-compartmental dynamic, continuous models (Venema & van den Abbeele, 2013). The 
in vitro models used in this research study were a semi-continuous system (fed-batch; chapter 
5) and a continuous model (M-SHIME; chapter 4). These in vitro systems were sufficient to 
simulate both lumen- and mucin-associated microbiota, preserve inter-individual differences 
in microbial composition and function, and monitor the effect of a single dose of butyrate-
producers on both short (65h, chapter 5) and longer term (10 days, chapter 4).  
The (M-) SHIME was demonstrated to be able to maintain a human-like microbial 
composition and functionality after inoculation with fecal microbiota (Van den Abbeele, et 
al., 2010, Van den Abbeele, et al., 2013). Nevertheless, the human fecal microbiota is 
gradually adapting to the in vitro system, which can partially be explained by the absence of 
host response. For IBD simulations in the SHIME, it can be expected that the absence of 
inflammatory processes and altered intestinal conditions (pH, transit time, oxygen) is 
inducing a stronger shift from in vivo to in vitro, which leads to the eventual disappearance of 
the specific diseased microbiome composition during a long-term simulation. Therefore, the 
microbiota of active CD patients were only studied for a short incubation period (65 h, 
chapter 5) and this is comparable with earlier in vitro assays performed with UC microbiota 
of patients with active disease (Rose, et al., 2010, Vermeiren, et al., 2012, Vigsnaes, et al., 
2013). Including stress factors associated with active IBD during future in vitro simulations 
may help to maintain the dysbiosed microbial community. 
6.3.3 Assessment of interaction with host epithelium 
Probiotic bacteria and their metabolites can improve the epithelial barrier function and 
inhibit pro-inflammatory processes at the gut epithelium. Different in vitro tools are available 
to study these processes in simplified intestinal epithelial models and to elucidate the 
mechanism of action of probiotic treatment (Marzorati, et al., 2014). Most of these models 
use the immortalized cancer-derived cell lines Caco-2 or HT29-MTX, as these express 
morphological and functional characteristics of the intestinal mucosa (Lea, 2015). 
In chapter 5, we used a trans-epithelial Caco-2 monolayer model to evaluate the 
impact of microbial supernatant on the epithelial barrier integrity during differentiation of the 
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epithelial cells. An improved epithelial integrity was observed upon supplementation of 
supernatant derived from B. pullicaecorum 25-3T–treated microbiota or a mix of butyrate-
producing bacteria. It was hypothesized that B. pullicaecorum 25-3T stimulated the expression 
of tight junction proteins resulting in an improved epithelial barrier. This should be confirmed 
in future epithelial cell experiments by monitoring the tight junction formation. This can be 
done with immunofluorescence microscopy assessing tight junction organization in the 
epithelial cell layers followed with computerized image analysis (Terryn, et al., 2013).  
An alternative approach to replace the used 2-D monolayer epithelial cell model can be 
a 3-D cell culture model consisting of aggregates of intestinal epithelial cells grown on 
microcarrier beads (Barrila, et al., 2010). The enhanced formation and better physiological 
organization of tight junctions is one of the advantages of this organotypic model over a 
monolayer model to study the effect of B. pullicaecorum. In addition, there is a high mucin 
production by the HT-29 epithelial cells in this model which opens perspectives to study more 
into detail the observed mucin-associating properties of B. pullicaecorum (chapter 4) (Höner 
zu Bentrup, et al., 2006). The 3-D model allows also high-throughput screening and delivers 
very reproducible results (Höner zu Bentrup, et al., 2006, De Weirdt, et al., 2012). 
To protect the intestinal epithelial cells from the cytotoxic effect of direct contact with a 
complex microbial sample, supernatant of the fed-batch system was used in the transepithelial 
cell model in chapter 5. Recently, a novel in vitro model which allows studying complex 
microbial communities in combination with intestinal epithelial cells was developed. The 
host-microbe interaction (HMI) module consists of a microbial and a host compartment 
separated by a semi-permeable membrane (Marzorati, et al., 2014). The semi-permeable 
membrane is coated with a mucin-agar layer that allows for formation of a mucosal biofilm. It 
is possible to couple the HMI-module to the (M-)SHIME and create a controlled flow of 
bacterial suspension through the microbial compartment which can interact with the host 
compartment containing intestinal epithelial cells. This novel HMI module can be used to 
further investigate the in vitro potential of B. pullicaecorum 25-3T to maintain remission in 
IBD. For example, microbiota of IBD patients in remission can be simulated and treated with 
B. pullicaecorum as described in chapter 4. Next, the host-microbe interactions can be studied 
by coupling the HMI module to the M-SHIME vessels. It was previously shown that the 
supernatant of a B. pullicaecorum 25-3T monoculture prevented increases in IL-8 secretion in 
a Caco-2 cell model after stimulation with TNFα and IFNγ (Eeckhaut, et al., 2012). 
Therefore, inflammation can be induced in the host compartment of the HMI module by 
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adding pro-inflammatory cytokines (e.g. TNFα and IFNγ) to assess if the anti-inflammatory 
effect of B. pullicaecorum 25-3T is also expressed in a complex microbial environment. 
 
6.4 Concluding remarks  
Modulation of the dysbiosed gut microbiota in IBD is gaining more attention as a novel 
strategy to control the disease and to support current therapy. Application of current 
probiotics and the practice of fecal microbial transplantation in IBD have shown a low 
efficacy in controlling the disease and maintaining remission. Future microbial treatments 
should include carefully selected probiotic species with known mechanism of action. Butyrate 
has therapeutic potential in IBD but its delivery to the site of inflammation is difficult. It is 
hypothesized that probiotic treatment with butyrate-producing bacteria may in situ increase 
butyrate levels in the gut. Therefore, the focus of this PhD research was on butyrate-
producing bacteria, and especially on B. pullicaecorum 25-3T, as future probiotic candidates 
for IBD. By using an in vitro intestinal technology platform we provided more insights in the 
potential of applying B. pullicaecorum 25-3T as probiotic for IBD.  
- We demonstrated the intrinsic tolerance of B. pullicaecorum 25-3T to stomach and 
small intestine conditions and its ability to enter the VBNC state as stress 
response to acid conditions. 
- We developed capsules for oral intake that successfully delivered viable and 
active B. pullicaecorum bacteria to the colon.  
- The in vitro colon simulations performed with microbiota of different individuals 
showed a variable and low butyrogenic capacity of B. pullicaecorum 25-3T.  
- A mix of butyrate-producing bacteria including B. pullicaecorum had a higher and 
less variable butyrogenic effect.  
- Treatment with B. pullicaecorum 25-3T increased epithelial barrier integrity 
showing its probiotic potential.  
Hence, not only butyrate levels and disease activity should be the end points of future in 
vivo validation studies. Future in vivo validation of a probiotic product (containing B. 
pullicaecorum) as complementary treatment to the current IBD therapy requires follow-up of 





The human gastrointestinal tract contains up to 100 trillion microbes which live in 
symbiosis with their host and contribute to its health and gut homeostasis. An imbalance in 
structural and functional properties of the gut microbiota that can disrupt host-microbe 
homeostasis – defined as microbial dysbiosis – and is associated with disorders such as 
inflammatory bowel diseases (IBD). Crohn’s disease (CD) and ulcerative colitis (UC) are the 
major IBD pathologies and are characterized by a severe chronic, relapsing intestinal 
inflammation. An inappropriate immune response in genetically susceptible individuals 
together with the complex interaction between environmental factors, intestinal microbiota 
and the intestinal immune system are involved in the onset of IBD. Current therapy in IBD 
aims to restore the immune homeostasis and focusses predominantly on the host response. 
Correcting both facets of the pathogenesis (host and microbiota) may increase efficacy of IBD 
therapy. Therefore, modulation of the dysbiosed gut microbiota in IBD is gaining more 
attention as a strategy to control the disease and to support current therapy. However, 
application of current lactic-acid producing probiotics and the practice of fecal microbial 
transplantation in IBD have shown a low efficacy in controlling the disease and maintaining 
remission. Future microbial treatments should include carefully selected probiotic species 
with known mechanism of action. Butyrate, a microbial metabolite, has therapeutic potential 
in IBD but its delivery to the site of inflammation is difficult. It is hypothesized that probiotic 
treatment with butyrate-producing bacteria may in situ increase butyrate levels in the gut. 
Moreover, microbial dysbiosis in the gut of IBD patients, and especially in CD patients, is 
characterized by a decrease in diversity and abundance of butyrate-producing bacteria.  
Before administrating butyrate-producing bacteria to IBD patients, more knowledge of 
their behavior under gastrointestinal conditions is required to evaluate their efficacy of 
probiotics for IBD. In this PhD research, we investigated with in vitro intestinal technology 
the probiotic potential of Butyricicoccus pullicaecorum 25-3T. This is a butyrate-producing 
species, isolated from the caecal content of a broiler chicken, and is considered as an 
interesting candidate for probiotic therapy in intestinal disorders like IBD due to its anti-
inflammatory and epithelial barrier strengthening properties.  
In the first part of this research, static batch incubations simulating gastric and small 
intestine conditions were performed to evaluate (1) the intrinsic tolerance of B. pullicaecorum 
and (2) enteric coated capsules containing freeze-dried B. pullicaecorum to protect the 




so-called VBNC - viable but not cultivable – state in response to the acid stress (pH 2 and pH 
3) during gastric conditions. Cultivability was rapidly restored during subsequent small 
intestine conditions. B. pullicaecorum produced short chain fatty acids after upper 
gastrointestinal conditions and so was still metabolically active, but there was a shift from 
butyrate to acetate production. We demonstrated that HPMC capsules containing freeze-dried 
B. pullicaecorum bacteria were a stable formulation to preserve oxygen-sensitive butyrate-
producing bacteria. Enteric coating of the capsules protected the bacteria from acid stress 
during gastric conditions and delivered more cultivable bacteria into the colon as compared to 
uncoated capsules. Butyrate production by B. pullicaecorum during subsequent colon 
incubation was highly variable, especially in presence of a colon microbial community. 
Enteric coated capsules however resulted in higher butyrate production in sterile colon 
suspension compared to uncoated capsules. 
The second part of this research focused on the behavior of B. pullicaecorum 25-3T and other 
butyrate-producing bacteria under colon conditions and in the presence of endogenous 
microbiota of different individuals. The M-SHIME® was used to assess the colonization 
potential of B. pullicaecorum 25-3T and to analyze the impact of a single dose on butyrate 
production by the microbiota of three healthy volunteers and five CD patients in remission. B. 
pullicaecorum was more abundant in the mucin-associated microbiota compared to the lumen 
microbiota of the M-SHIME. While a single treatment with B. pullicaecorum 25-3T did not 
result in a persistent colonization, it was effective in increasing B. pullicaecorum levels in 
mucus in four out of eight cases up to 10 days after treatment, and in stimulating butyrate 
production in two out of eight cases. While the original (non-treated) responder microbiota 
significantly differed from non-responder microbiota and shifts in the responder microbiome 
were noted upon B. pullicaecorum 25-3T administration, the factors for explaining the 
variability in response need to be investigated in studies with more individuals. In a final 
study, the microbe-microbe (short-chain fatty acid production and colonization potential) and 
host-microbe interactions (epithelial barrier function) in CD microbiota were studied after 
supplementation with butyrate-producing bacteria. An in vitro approach was used combining 
microbial and epithelial models to study these interactions. Three mono-species and one 
multispecies mix of butyrate-producing bacteria were supplemented to the fecal microbiota of 
10 CD patients. Treatment with F. prausnitzii and a mix of six butyrate-producers resulted in 
an increased butyrate production in both active and remissive CD microbiota. The mix of 
butyrate-producers had the highest success rate in terms of increased butyrate production and 
colonization capacity in mucus- and lumen-associated CD microbiota. Microbial supernatant 
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of microbiota treated with B. pullicaecorum 25-3T and the mix improved epithelial barrier 
integrity in a Caco-2 cell Transwell assay during differentiation. The improved epithelial 
barrier was not only a result of a higher butyrate concentration indicating the presence of 
another microbial metabolite or bio-active compound which improved intestinal epithelial 
barrier integrity. Future research is necessary to identify this unknown microbial compound 
and to elucidate its exact functioning. 
This PhD research demonstrated the potential of butyrate-producing bacteria as future 
probiotics for IBD to modulate the microbiota and improve epithelial barrier integrity. A 
stable formulation for oral intake was developed to deliver these oxygen-sensitive bacteria 
into the colon. While a single dose of B. pullicaecorum 25-3T resulted not in a persistent 
colonization and its butyrogenic effect was highly variable, resulted in an improve barrier 
integrity demonstrating its probiotic potential. Supplementation of CD microbiota with a mix 
of butyrate-producing bacteria, including B. pullicaecorum 25-3T, resulted in an increased 
butyrate production and an improved epithelial integrity. Future in vivo validation of this kind 
of probiotic mix containing B. pullicaecorum is required as next step of its application in IBD 








Het menselijk gastro-intestinaal stelsel bevat tot 100 biljoen bacteriën die in symbiose 
samenleven met hun gastheer en bijdragen tot zijn gezondheid en de gastheer-bacterie 
homeostase in de darm. Wanneer de samenstelling en functies van de darmbacteriën uit 
evenwicht zijn, kan de gastheer-bacterie homeostase verstoord worden. Dit fenomeen wordt 
gedefinieerd als een dysbiose van de darmbacteriën en is geassocieerd met aandoeningen 
zoals inflammatoire darmziekten (IBD). De ziekte van Crohn en colitis ulcerosa (CU) zijn de 
belangrijkste chronische aandoeningen binnen IBD en gaan gepaard met ernstige en 
recurrente ontstekingen binnen het gastro-intestinaal stelsel. Een eenduidige oorzaak voor het 
ontstaan en in stand houden van IBD is nog niet gekend. Er wordt aangenomen dat bij 
personen met een genetische aanleg voor de ziekte een ontregelde immuunreactie samen met 
de complexe interactie tussen omgevingsfactoren, de darmbacteriën en het immuunsysteem in 
de darm een rol spelen bij het ontstaan van de ziekte. De huidige therapie bij IBD heeft als 
doel de homeostase ter hoogte van het immuunsysteem te herstellen en focust zich 
voornamelijk op de gastheer en niet op de verstoorde darmbacteriën. De werkzaamheid van 
de therapie in IBD zou kunnen vergroot worden door beide facetten van de ziekte (gastheer en 
darmbacteriën) te corrigeren. Daarom wordt het principe van het moduleren van de dysbiose 
van de darmbacteriën in IBD naar voor geschoven als strategie voor het controleren van de 
ziekte en ter ondersteuning van de huidige therapieën. De huidige probiotica met 
melkzuurbacteriën en de stoelgangtransplantatie bij IBD patiënten geven echter tot nu toe 
teleurstellende resultaten op voor het controleren van de ziekte en het behouden van remissie 
(= periode zonder actieve ontsteking en symptomen). Toekomstige microbiële behandelingen 
moeten probiotische stammen bevatten die zorgvuldig geselecteerd werden en waarvan hun 
werking gekarakteriseerd is. Boterzuur, een omzettingsproduct van bepaalde darmbacteriën, 
bezit therapeutisch potentieel in IBD, maar toediening op de plaats van ontsteking is moeilijk. 
Daarom wordt verondersteld dat het toedienen van probiotica bestaande uit 
boterzuurproducerende bacteriën de in situ concentratie aan boterzuur in de darm kan 
verhogen. Daarenboven werd vastgesteld dat de dysbiose van de darmbacteriën in IBD 
patiënten, en vooral in Crohn patiënten, is gekenmerkt door een daling in de diversiteit en 
aantal aan boterzuurproducerende bacteriën.  
 
Vooraleer boterzuurproducerende bacteriën kunnen toegediend worden aan IBD 




intestinaal stelsel om zo hun werkzaamheid als probiotica voor IBD te evalueren. Tijdens dit 
doctoraatsonderzoek werd met in vitro technologie voor het gastro-intestinaal stelsel 
onderzocht wat het probiotisch potentieel is van Butyricicoccus pullicaecorum 25-3T. Dit is 
een boterzuurproducerende bacterie die geïsoleerd werd uit de blinde darm van een kip en die 
beschouwd wordt als een interessante probiotische kandidaat voor intestinale aandoeningen 
zoals IBD. In vitro en dier-proeven toonden namelijk aan dat deze stam anti-inflammatoire 
eigenschappen bezit en de darmbarrière kan versterken.  
 
In het eerste deel van dit onderzoek werd tijdens statische batch experimenten de maag 
en dunne darm condities gesimuleerd. Hiermee werd de intrinsieke tolerantie van B. 
pullicaecorum tegenover maag en dunne darm condities opgevolgd. Vervolgens werd het 
potentieel van een enterische coating op capsules met B. pullicaecorum geëvalueerd voor het 
beschermen van de bacteriën tegen de zure maagcondities en het aanleveren van levende 
bacteriën in de darm.  
Bij zure condities (pH 2 en pH 3) tijdens de maag simulatie gingen B. pullicaecorum 
bacteriën in een VBNC (viabel maar niet cultiveerbare) toestand. De bacteriën werden terug 
cultiveerbaar tijdens de dunne darm simulatie. B. pullicaecorum bacteriën waren nog steeds 
metabolisch actief na maag- en dunne darm condities aangezien er kortketen vetzuren werden 
geproduceerd. Er was echter een verschuiving van boterzuur naar azijnzuur productie.   
We konden aantonen dat HPMC capsules met gevriesdroogde B. pullicaecorum 
bacteriën een manier is om zuurstofgevoelige boterzuurproducerende bacteriën stabiel te 
bewaren. Het coaten van de capsules met een enterisch polymeer gaf in vergelijking met niet 
gecoate capsules een betere bescherming van de bacteriën tegen de zuurstress tijdens 
maagcondities en resulteerde in meer cultiveerbare bacteriën na maag- en dunne darm 
simulatie. Vervolgens werden B. pullicaecorum bacteriën uit gecoate en niet gecoate capsules 
verder geïncubeerd en werd de boterzuurproductie opgevolgd tijdens simulatie van de colon 
condities, zowel in af- als aanwezigheid van andere colonbacteriën. In aanwezigheid van 
andere colonbacteriën, was de stijging in boterzuurproductie door toevoeging van  B. 
pullicaecorum erg variabel. In afwezigheid van ander colonbacteriën was er een hogere 
boterzuurproductie door B. pullicaecorum bacteriën uit gecoate capsules in vergelijking met 
niet gecoate capsules.  
In het tweede deel van dit onderzoek lag de focus op het onderzoeken van het gedrag 
van B. pullicaecorum 25-3T en andere boterzuurproducerende bacteriën onder coloncondities 
en in aanwezigheid van de microbiota van verschillende individuen. De M-SHIME®, een in 
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vitro model voor de humane colon microbiota, werd gebruikt om the kolonisatiepotentieel van 
B. pullicaecorum 25-3T te evalueren en de impact op boterzuurproductie van één dosis B. 
pullicaecorum. Hierbij werd gestart met de microbiota van vijf Crohn patiënten in remissie en 
drie gezonde vrijwilligers. B. pullicaecorum was meer aanwezig in de mucine-geassocieerde 
microbiota in vergelijking met de lumen microbiota van de M-SHIME. Terwijl de 
behandeling met één dosis B. pullicaecorum 25-3T niet resulteerde in een persistente 
kolonisatie, was het wel effectief in het verhogen van de B. pullicaecorum niveaus in de 
mucine-geassocieerde microbiota in vier van de acht gevallen, tot tien dagen na de 
behandeling. Verder werd na behandeling de boterzuurproductie gestimuleerd in twee van de 
acht gevallen. De originele, niet behandelde, microbiota van de twee responders (verhoogde 
boterzuurproductie) verschilden significant van de niet-responder microbiota en er werden 
verschillende verschuivingen waargenomen in het responder microbiome na B. pullicaecorum 
25-3T toediening. Het is noodzakelijk dit in de toekomst in meerdere individuen te bestuderen 
om zo de verschillende factoren te identificeren die de variabiliteit in respons op B. 
pullicaecorum behandeling kunnen verklaren. 
In een finale studie werden de microbe-microbe (kortketen vetzuur productie en 
kolonisatie potentieel) en gastheer-microbe (darmbarrière functie) interacties bestudeerd in de 
colon microbiota van Crohn patiënten na toevoeging van boterzuurproducerende bacteriën. 
Hiervoor werd een in vitro methode gebruikt waarbij microbiële en epitheliale modellen 
werden gecombineerd om beide types van interacties te kunnen bestuderen. Drie mono-
species en een multi-species mix van boterzuurproducerende bacteriën werden toegevoegd 
aan de fecale microbiota van tien Crohn patienten (vijf met actieve ziekte, vijf in remissie). 
Behandeling met Faecalibacterium prausnitzii  en een mix van zes boterzuurproducerende 
bacteriën resulteerde in een stijging in boterzuurniveau  in de microbiota van zowel Crohn 
patiënten met actieve ziekte als in remissie. De mix van boterzuurproducerende bacteriën had 
verder ook de meeste slaagkans in het verhogen van het boterzuurniveau en het koloniseren 
van de mucine- en lumen- geassocieerde Crohn microbiota. Microbieel supernatans van de 
Crohn microbiota behandeld met B. pullicaecorum 25-3T of met een mix aan 
boterzuurproducerende bacteriën bevorderde de epitheliale barrière van Caco-2 
darmepitheelcellen tijdens hun differentiatie. De betere darmbarrière was niet enkel het 
resultaat van boterzuur in de gebruikte stalen en doet vermoeden dat een ander microbiële 
component aanwezig was die de epitheliale barrière functie kan verhogen. Verder onderzoek 




Tijdens dit doctoraatsonderzoek werd het potentieel aangetoond van 
boterzuurproducerende bacteriën als toekomstige probiotica voor IBD patiënten in het 
moduleren van de microbiota en het verhogen van de epitheliale darmbarrière. Er werden 
orale capsules ontwikkeld die geschikt zijn voor het bewaren en aanleveren van deze 
zuurstofgevoelige bacteriën tot in de darm. Terwijl één dosis aan B. pullicaecorum 25-3T niet 
resulteerde in een persistente kolonisatie van de colon microbiota en het butyrogeen effect erg 
variabel was, resulteerde B. pullicaecorum wel in een beter epitheliale barrière wat zijn 
probiotisch potentieel aantoont.  Het toedienen van een mix van boterzuurproducerende 
bacteriën, waaronder B. pullicaecorum 25-3T, resulteerde in een verhoogde 
boterzuurproductie en een betere epitheliale darmbarrière. Een verdere in vivo validatie van 
dit type van probiotische mix met B. pullicaecorum is noodzakelijk als volgende stap in de 
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Hoera! Ik ben aan de laatste to do gekomen van m’n soms eindeloos lijkende takenlijst 
van de afgelopen vier doctoraatsjaren. Het afwerken van deze lijst zou nooit gelukt zijn 
zonder de hulp, het advies, de schouderklopjes en onvoorwaardelijke steun van velen. Daarom 
dit apart hoofdstukje om jullie extra te bedanken. 
First, I would like to thank the members of the jury for their effort, constructive remarks 
and discussion during the pre-defense. It resulted in an improved version of my PhD and it is 
an honor to defend for such a group of specialists. 
Zonder promotor geen doctoraat en ik had het geluk om er op twee te kunnen 
vertrouwen.  
Tom, bedankt voor de kans die je me vier jaar geleden hebt gegeven om op het SBO project 
met m’n droomonderwerp te mogen starten (gelukkig wist ik toen nog niet wat een anaerobe 
kast was). Het onderzoek liep in het begin niet altijd even vlot en de resultaten waren soms 
voor mij verrassend, voor jouw eerder interessant.  Jouw advies en bemoedigende kijk hebben 
er voor gezorgd dat het tijdens het laatste anderhalf jaar in een stroomversnelling is geraakt en 
ik vandaag mijn laatste woorden typ. Bedankt voor de kansen en het vertrouwen om m’n werk 
te mogen presenteren op verschillende congressen, dit was steeds een inspirerende ervaring. 
Zonder jouw duwtje in de rug begon ik waarschijnlijk volgende maand ook niet aan het 
Zwitsers avontuur. De in vitro/darm/microbiële ecologie-wereld is gelukkig niet zo groot dus 
hopelijk komen we elkaar in de toekomst nog eens tegen, ik kijk er alvast naar uit!  
Nico, zes jaar geleden had ik nooit gedacht dat het opnemen van het keuzevak 
‘Moleculaire Microbiële technieken’, waarin een case studie zat over de darmbacteriën bij 
IBD, zou resulteren in een doctoraat. Bedankt voor de aanzet, de vele tips en tricks gaande 
van DGGE,  qPCR, flow cytometry tot FISH. Maar vooral bedankt voor de inspirerende 
discussies, samen met Tom, rondom microbiële ecologie in de SHIME. 
Verder wil ik ook al de collega’s van het SBO-butyraat-project bedanken voor de 
samenwerking en projectvergaderingen. Prof. Van Immerseel en Prof. Ducatelle, bedankt 
voor de kans om te kunnen meewerken aan het Butyricicoccus onderzoek. Prof. De Vos, Prof. 
Laukens en Elien Glorieus van UZ Gent, bedankt voor de hulp bij het recruteren van Crohn 
patienten. Sarah, bedankt de vele Butyricicoccus discussies. Jun, Gwen and Prof. Raes, 
thanks a lot for your help and input with the Illumina data processing. 
Een speciaal woord van dank gaat naar Dr. Eeckhaut, in mijn ogen dé mama van 
Butyricicoccus.  Venessa, je kan niet geloven hoe jouw energie, gedrevenheid en 
enthousiasme voor ons onderzoek me bleef motiveren – zelfs als de anaerobe kast/technicus 
het nogmaals liet afweten of Butyricicoccus niet mee wou werken. Na een bezoek aan jou in 
het labo kwam ik telkens terug met veel inspiratie en goede moed. Blijf jouw passie 
verderzetten en ik wens je alle succes toe in jouw verdere onderzoekscarrière! 
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Graag wil ik het bestuur en de leden van de Crohn- en colitis ulcerosa vereniging 
bedanken voor hun steun onder de vorm van de onderzoeksprijs en de kansen die ik kreeg 
deel te nemen aan interessante bijeenkomsten onder meer in het Europees parlement. Jullie 
doen fantastisch werk! 
Dit werk was er niet gekomen zonder de hulp van de vele studenten die ik heb mogen 
begeleiden tijdens hun LabMET thesisperiode. Bo, Marlene, Alix, Floor, Maxim, Kathleen, 
Magali en Sam, jullie waren één voor één top studenten en ik kijk met veel voldoening terug 
op de fijne samenwerking. Bo & Alix jullie waren de pioniers tijdens de moeilijke opstart van 
het Butyricicoccus verhaal, maar jullie inzet resulteerde in mooi werk die ik kon opnemen in 
twee publicaties, bedankt! Marlene & Floor, your topic was not included in this PhD, but I’m 
pleased that I could transfer the research - vibe and I wish you both a lot of success with your 
PhD! Maxim, het rupsenverhaal is er niet in geraakt, maar bedankt voor de hulp bij de 
Butyricicoccus-PCR. Magali, bedankt voor jouw enthousiasme en vele SHIME en moleculair 
werk voor het FEMS paper! Sam, zonder jouw enorme hulp en geduld tijdens m’n laatste 
experimenten was dit doctoraat nooit zo mooi geworden, bedankt! 
Bedankt aan alle SHIME/HAM cluster leden voor hun advies, inspirerende clusters en 
leuke sfeer: Joan (Dankzij jouw goede begeleiding ben ik na m’n thesis toch nog op LabMET 
gebleven) - Pieter (Bedankt om me de kneepjes van het M-SHIME-vak te leren) - Rosemarie 
(Bedankt voor de steun, tips en constructieve feed back tijdens heel m’n doctoraat, maar 
vooral bedankt voor de vriendschap!) - Massimo (Thanks for the help with the capsule chapter 
and reading of my discussion) - Emma & Hugo (Thanks for the input during the experimental 
HAM and MRM clusters) - Kim, Floor & Eline (Wat was ik blij dat ik niet meer het jongste 
SHIME lid was, bedankt voor de fijne samenwerking tijdens de practica, praktische hulp en 
warme vriendschap) - Wendy (Bedankt om met tijdens het schrijven te helpen herinneren aan 
m’n persoonlijke deadlines en de ontspannende zwempauzes) - Charlotte (Bedankt voor de 
fijne samenwerking en om me de wondere wereld van het celwerk te leren kennen) - Marta 
(Thanks a lot for your enthousiasm, nice collaboration and big help with the last chapter and 
caco-2 work!). 
Bedankt aan alle LabMET – ATP leden (onze kleine, maar krachtige motor van het 
labo) om alles in goede banen te leiden. Christine, bedankt voor de enorme hulp bij de 
financiële verslaggeving van het SBO, maar ook voor de steun tijdens de hele rit. Regine, 
bedankt voor de vele en snelle praktische regelingen.  Greet, Siska, Renée, Mike en Sarah, 
bedankt voor de hulp bij de bestellingen, maar ook voor de leuke lunch- en koffiepauzes. Tim, 
onvoorstelbaar hoeveel paardenkracht uit jou komt, bedankt voor alle werkgerelateerde zaken 
(van DNA tot de mooie cover) maar vooral voor de vriendschap. Jana, over jou zou ik een 
hele paragraaf kunnen schrijven om je te bedanken voor alle praktische en morele steun, maar 
ik ga het toch kort houden: Bedankt om vier jaar geleden te solliciteren bij LabMET, het heeft 
mij een vriendschap voor het leven opgeleverd.  
 
 
Ik had het ‘geluk’ om tijdens m’n doctoraat naast m’n bacteriën ook nog de anaerobe 
kast bijzonder goed te leren kennen. Hierbij wil ik de LabMET gasverantwoordelijken 
bedanken die me dikwijls uit de nood hebben geholpen en in bijzonder Joachim, Francis en 
Robin. Verder ook nog dank aan Gilles van InBio voor het vervangen van vele gasflessen en 
steun tijdens de vele anaerobe-kast-kuren. Korneel, bedankt voor het vrijmaken van het ERC- 
budget voor de aankoop van twee nieuwe exemplaren. 
Antonin & Jan, thanks for the interesting collaboration with the RDE and F. prausnitzii! 
FM & Emilie, bedankt voor de samenwerking tijdens het cryopreservatie verhaal! 
To all my office mates, thanks for the nice office activities from bowling, climbing or a 
boat trip to having a cappuccino with a layer of soap. Aan het ‘vast meubilair’ van de bureau 
ook nog een speciale dank voor de steun en vriendschap tijdens de afgelopen vier jaar. Jan, Jo 
en Marlies, bedankt voor de vele duwtjes in de rug. Rosemarie, wat ga ik het missen om m’n 
bureaustoel te draaien om met jou eens te overleggen. Eline, ook over jou kan ik een hele 
paragraaf schrijven om je te bedanken, maar ik ga het ook kort houden: Bedankt om twee jaar 
terug te gaan voor een doctoraat bij LabMET! 
To all the other LabMET colleagues thanks a lot for the nice lunch and coffee breaks 
(Pieter, Jana, Sylvia, Synthia, Emilie, Sam, Francis, Floor, Benjamin, Kim, Nicole, …), the 
superb winter weekends (Kim, Sofie, Benjamin, FM, Eleni, Cristina, …), after work meetings 
in the Koepuur (…) and after-LabMET-friendship (Karen, Eva, Linde). 
Er was gelukkig ook nog tijd voor een leven naast het labo en hiervoor wil ik ook nog 
enkele mensen bedanken. 
Delphine, Ellen, Eveline & Liesbet, Meisjes van Adegem, bedankt voor de mooie en 
lange vriendschap al sinds de kleuterklas. Ook al zijn sommigen uitgeweken naar Zelzate, 
Waarschoot of het verre Singapore, ik ben er van overtuigd dat we op onze oude dag nog 
steeds elkaar op de hoogte zullen houden van elkaars en andermans leven bij koffie en taart! 
Bedankt Evi, Lisa en Judith, ik kijk met veel plezier terug op onze tijd op Ten Doorn in Eeklo, 
onze interactieve groepswerkjes, eerste fuifjes in de Artevelde en de jarenlange vriendschap 
sinds 3E.  
Van Adegem naar Gent was in kilometers niet zo’n grote stap, maar voor m’n 
persoonlijk leven wel. Ik wil hierbij iedereen bedanken die bijgedragen heeft tot m’n 
fantastische 9 jaar in Gent:  
- Lieve & Roland voor de goede zorgen in de Zandpoortstraat en interesse in m’n 
studies en doctoraat. 
- Boerekotvrienden van het eerste uur en latere vrienden van de milieuronde voor de 
vele Gentse uitjes en avonden waarop ik m’n doctoraatszorgen kon delen of 
vergeten. 
- De bende van de Toffe van Gent om me als enige niet-West-Vlaamse te aanvaarden 
(m’n woordenschat is flink rijker geworden). Ik heb na onze studententijd heel erg 
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genoten van de vele ontspannende/(twee)maandelijkse verrassingsactiviteiten met 
als kers op de taart ons jaarlijks vroegtijdige Kerst- en oudejaarsavond viering tijdens 
het tweede weekend van december.  
- Charlotte, Tine & Hanne voor de kook-, zwem- en caféavondjes waarop we onze 
werkverhalen konden ventileren. 
- Marian, Eveline en Sophie voor de ontspannende (Walrus) lunch pauzes en zo even 
de Unief te vergeten.  
- Eva voor de trouwe vriendschap sinds IAAS en de vele oppeppende berichtjes, 
kaartjes en verwenpakket uit Mechelen tijdens de laatste maanden van m’n 
schrijfperiode! 
- Ellen en Elien voor de vriendschap en compagnie tijdens de vele Gentse after-work 
uitjes en de mooie reizen in de zomer. 
- Liesbeth & Steven voor de steun vanuit Wingene en de vele Gentse bezoekjes. 
- Stefanie voor de enorme steun en ontspannende uitjes tijdens de afgelopen 4 jaar, er 
zullen er nog vele volgen. Jouw gedrevenheid, succes en ambitie werkt op mij heel 
inspirerend en motiverend.  
- … 
Tenslotte ben ik aangekomen aan de drie personen die me mijn hele leven 
onvoorwaardelijk steunen en waar ik tot rust bij kan komen. Ma en Pa en broer, ik weet niet 
hoe ik jullie kan bedanken voor de kansen, steun, zorg en liefde die ik van jullie kreeg en nog 
steeds krijg. Broer, bedankt voor de bemoedigende woorden tijdens de laatste fase, ik 
verwacht jou zeker een paar keer op bezoek in Zurich! Ma en Pa, het was soms voor jullie 
moeilijk om te begrijpen waarom ik zoveel en op de meest rare tijdstippen naar het labo moest 
en jullie vroegen zich dikwijls af of er ooit een einde zou komen aan ‘het doctoraat’. Waar het 
kon, sprongen jullie bij, zo ook bij het à la minute ophalen over heel Oost-en West-
Vlaanderen van witte potjes met cruciale stalen, zodat ik ondertussen kon verder voorbereiden 
in het labo. Kortom, ik kan me geen betere broer en paar ouders voorstellen, bedankt!  
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